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ABSTRACT 
Precise regulation of cholesterol levels is necessary for survival of individual cells and 
the normal functioning of multicellular organisms.  Many of the genes important in these 
processes are regulated at a transcriptional level by the sterol regulatory element binding 
proteins (SREBPs) and liver X receptors (LXRs).  This thesis describes the identification 
by microarray technology of novel genes in cholesterol metabolism and the 
characterization of two of these genes.  Microarray analysis of the livers of mice fed a 
low versus high cholesterol diet identified 37 down-regulated and 32 up-regulated genes. 
Confirmation of these genes and analysis in transgenic and pharmacologically treated 
mice identified three novel putative SREBP target genes and three novel putative LXR 
target genes.  One of the down-regulated genes, Proprotein convertase subtilisin kexin 9 
(Pcsk9) was cloned from mouse liver.  Pcsk9 was found to be synthesized as a pro-form 
in the endoplasmic reticulum (ER) and expressed as a processed form in the trans-Golgi 
network.  In mice, Pcsk9 was found to be expressed mainly in the liver.  Overexpression 
of Pcsk9 in vivo demonstrated that Pcsk9 post-transcriptionally down-regulates low 
density lipoprotein receptor (LDLR) levels leading to elevated plasma LDL cholesterol. 
Furthermore, it was determined that Pcsk9 induces the degradation of the LDLR by a 
non-proteasomal mechanism in a post-ER compartment.  One of the up-regulated genes, 
A disintegrin and metalloprotease 11 (Adam11) was cloned from mouse liver and a novel 
isoform with an alternative C-terminal tail was characterized.  Adam11 was determined 
to be a cell surface protein expressed in multiple tissue types.  Finally, preliminary 
functional studies with Adam11 indicate a potential role in LXR transcriptional activity 
and/or apolipoprotein B metabolism.   
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CHAPTER 1:  INTRODUCTION 
The Significance of Cholesterol 
Cholesterol is necessary for life but is harmful when in excess 
Cholesterol is a 27-carbon, amphipathic molecule composed of a rigid, planar 
four-ring steroid nucleus, a polar hydroxyl group, and an alkyl side chain.  Nature has 
devoted nearly 100 genes to its biosynthesis, transport, metabolism, and regulation 
(Tabas, 2002a).  Cells obtain cholesterol by endogenous synthesis from acetyl-CoA using 
over 30 enzymes and cofactors (Vance and Van den Bosch, 2000) and via uptake from 
plasma lipoproteins (Havel and Kane, 2001).  Cholesterol is necessary for normal 
membrane function by providing membrane permeability, contributing to membrane 
rigidity, and inducing membrane packing into rafts which provide a scaffold for various 
signaling pathways (Tabas, 2002a).  Cholesterol may also be covalently attached to other 
proteins, such as sonic hedgehog, a protein essential for proper development (Tabas, 
2002a).  On an organismal level, cholesterol is the precursor for bile acids, which are 
necessary for solubilization and absorption of dietary fats and fat-soluble vitamins 
(Russell and Setchell, 1992).  Cholesterol is also the precursor for pregnenolone and 
hence the steroid hormones progesterone, estrogen, testosterone, cortisol, and 
aldosterone; thus cholesterol is necessary for reproductive biology, stress response, and 
salt and volume homeostasis (Tabas, 2002a)  Finally, cholesterol is a precursor for 
vitamin D3 (cholecalciferol), which is essential for calcium homeostasis (Tabas, 2002a).     
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 Despite the necessity of cholesterol, excess cholesterol is cytotoxic (Tabas, 
2002b); therefore, cells have elaborate control mechanisms to maintain normal 
cholesterol concentrations.  Excess cholesterol represses endogenous cholesterol 
biosynthesis, induces esterification by the enzyme acyl-coenzyme A:cholesterol 
acyltransferase (ACAT), and is effluxed out of the cell (Tabas, 2002b).  However, these 
control mechanisms can ultimately fail, and the most devastating consequence in modern 
times is the resultant development of atherosclerosis.  The atherosclerotic plaque is 
formed when excess plasma cholesterol carried in lipoproteins is deposited in the 
subendothelial space of arteries, setting off a cascade of inflammatory responses and 
apoptosis (Hansson, 2005).  The atheroma progresses to contain lipid-laden macrophage 
derived foam cells, extracellular lipid, and inflammatory cells surrounded by a smooth 
muscle cell derived fibrous cap.  These plaques may eventually rupture leading to acute 
thrombotic vascular occlusion and infarction of the tissues supplied; thus, this 
pathogenetic process is the cause of myocardial infarction in the heart and embolic stroke 
in the brain, the first and third leading causes of death in 2002 (Anderson and Smith, 
2005).  In addition, cholesterol excess can lead to cholesterol gallstones, liver 
dysfunction, cholesterol crystal emboli, and dermatological abnormalities (Tabas, 2002a). 
 
Lipoproteins carry cholesterol in the blood 
 Cholesterol and cholesteryl esters are carried in plasma solubilized with proteins 
called apolipoproteins and triglyceride into particles called lipoproteins (Havel and Kane, 
2001) (Figure 1.1).  Triglyceride rich chylomicrons are secreted from the intestine and 
contain apolipoprotein B-48 (apoB48), and triglyceride-rich very low density lipoproteins  
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Figure 1.1. Overview of lipoprotein metabolism.  Dietary cholesterol, in the form of cholesteryl esters 
(CE), and triglycerides (TG) in the small intestine are packaged into large apoB-48 containing 
chylomicrons and secreted.  In the plasma compartment, chylomicrons acquire apoE and apoC; they are 
converted into chylomicron remnants via lipoprotein lipase (LPL) and are taken up by the liver.  The 
liver produces apoB100 containing, triglyceride-rich VLDL.  Through the action of LPL and hepatic 
lipase (HL), VLDL is converted into IDL and LDL.  LDL can be taken up into the liver and in the 
periphery via the binding of apoB100 to the LDLR.  Peripheral cells efflux cholesterol to nascent apoAI 
containing HDL particles which are converted to HDL by LCAT.  Cholesterol ester in HDL is 
transferred between HDL and apoB containing lipoproteins by cholesterol ester transfer protein (CETP); 
HDL can also be taken up the liver via SRBI.
 
(VLDL) are secreted from the liver and contain apoB100.  Within the plasma 
compartment, chylomicrons are converted into chylomicron remnants for uptake into the 
liver.  VLDL, which also contains apoE and apoC, is converted into smaller, slightly 
higher density VLDL remnant (or intermediate density lipoprotein, IDL) particles via the 
action of lipoprotein lipase; these particles also contain apoB, apoE, and apoC (Havel and 
Kane, 2001).  Subsequently, IDL particles are converted into higher density low density 
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lipoprotein (LDL) particles via the action of hepatic lipase and lipoprotein lipase and the 
loss of apoE and apoC.  Finally, high density lipoproteins (HDL) are produced via efflux 
of cholesterol from peripheral cells.  LDL and HDL can be taken up by the liver via the 
LDL receptor (LDLR) and scavenger receptor BI (SRBI), respectively.   
 
Genes that determine cholesterol levels 
 It is well-established that elevated total and, particularly, LDL-cholesterol levels, 
are a risk factor for atherosclerotic heart disease (Glass and Witztum, 2001).  Many genes 
are known to be involved in determining LDL cholesterol levels.  Liver expressed genes 
are particularly important because the liver is the major organ responsible for the 
production and degradation of apoB-containing lipoproteins (Davis and Hui, 2001), 
specifically, and it plays a critical role in maintaining proper cholesterol homeostasis in 
general (Figure 1.2).  The liver receives cholesterol from the diet via chylomicron 
remnants derived from the intestine and it synthesizes cholesterol de novo.  The liver then 
uses this cholesterol for all of the important processes described above; therefore, the 
liver harbors many enzymes, transporters, transcription factors, and signaling molecules 
necessary for cholesterol homeostasis.  Many of these genes are known, including the 
LDLR and apoB; however, many more genes exist.  Furthermore, there is variation 
among different people in the response of LDL cholesterol levels to changes in dietary 
cholesterol levels, ranging from a negative to a positive response (Hopkins, 1992; 
Sehayek et al., 1998b), and hence there is much interest in identifying the genetic 
determinants that underlie this individual variation in response to diet (Ordovas, 2001).  
Some of the genes proposed to play a role in regulating individual dietary responsiveness 
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to high cholesterol diets include apoA-IV, apoE, apoB, and cholesterol ester transfer 
protein (CETP) (Ordovas, 2001), but many more genes likely exist. 
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Figure 1.2. The liver is a central organ of cholesterol homeostasis.  The liver receives cholesterol 
from three main sources.  Cholesterol from the diet is delivered to the liver via uptake of chylomicron 
remnants.  The liver synthesizes cholesterol from acetyl-CoA in a multi-enzyme pathway.  Finally, the 
liver takes up cholesterol from LDL and HDL in the plasma via cell surface proteins.  The liver then uses 
this cholesterol pool for many important processes.  The liver synthesizes bile acids from cholesterol and 
excretes these along with cholesterol into the bile.  The liver exports cholesterol in the form of VLDL for 
delivery to other tissues.  Finally, the liver esterifies excess cholesterol for storage.   
 
 
Low Density Lipoprotein Metabolism 
 This section will provide background to some of the important players in 
determining LDL cholesterol levels, with focus on the production of apoB-containing 
lipoproteins by the liver and their subsequent metabolism by the LDLRs.  The importance 
of variations in the genes involved in these pathways, namely the LDLR and apoB, will 
be highlighted by describing familial human diseases resulting from mutations in these 
 7
genes.  Due to the focus of this thesis, this section will focus on the biology of apoB and 
the LDLR; the other apolipoproteins found on apoB-containing lipoproteins, namely 
apoE and apoC will be mentioned only briefly at the end of the section. 
 
Production of apoB containing lipoproteins 
 The secretion of apoB-containing chylomicrons and VLDL from the intestine and 
liver, respectively, is a complex process (Figure 1.3).  ApoB100 is produced from a 
14,000 nucleotide mRNA in the liver (Davidson and Shelness, 2000).  Additionally, the 
intestines of mice and humans and the liver of mice contain an RNA binding protein and 
cytidine deaminase called apobec-1 that converts a cytidine to a uracil in the apoB 
mRNA, creating a premature stop codon and resulting in the production of a shorter form 
called apoB48.  Regardless of the form produced, the highly lipophilic nature of apoB 
necessitates cotranslational addition of lipid to the nascent apoB molecule within the 
rough endoplasmic reticulum (ER) , which is accomplished by microsomal triglyceride 
transfer protein (MTP) (Shelness and Sellers, 2001).  As the apoB mRNA is being 
translated on ER associated ribosomes into the ER lumen, lipid is recruited to a cavity 
formed by the nascent apoB and MTP forming a spherical emulsion particle with a 
neutral lipid core and apoB on the surface.  This small particle is released into the ER 
lumen where it meets apoB-free triglyceride and phospholipid particles that were formed 
in the smooth ER.  These particles fuse to form mature VLDL and are then secreted 
(Shelness and Sellers, 2001).  The location of the final assembly of VLDL is still unclear, 
although the vesicular tubular complex and the Golgi have been proposed (Fisher and 
Ginsberg, 2002).   
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Figure 1.3. apoB-VLDL production and apoB degradation pathways.  apoB mRNA is translated on 
ER associated ribosomes.  Through the action of MTP, phospholipid and triglyceride are added to the 
nascent apoB particle cotranslationally to form immature particles.  These particles acquire additional
triglyceride and exit the ER where they meet apoB-free particles from the smooth ER.  These particles 
assemble into mature VLDL, possibly in the Golgi, and are secreted.  In the absence of sufficient lipid or 
MTP, and due to other metabolic signals, apoB is degraded by one of three pathways.  First, apoB may 
be co-translationally polyubiquitinated and targeted for degradation in the cytoplasm by the proteasome 
in the ER associated degradation pathway (ERAD).  Second, apoB may be degraded by an unknown 
protease, possibly in the Golgi by a non-proteasomal, non-lysosomal mechanism (PERPP).  Third, apoB 
may be degraded subsequent to reuptake.    
 
 The secretion of VLDL is dependent on the the presence of MTP and the 
availability of sufficient apoB protein, phospholipids and free cholesterol for the surface 
of the particle and sufficient triglyceride and cholesterol esters for the neutral lipid core 
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(Avramoglu and Adeli, 2004).  VLDL production and by extension apoB secretion from 
cells is increased when any component is in excess, for example, excess fatty acid 
increases VLDL secretion presumably via the SREBPs (Kang and Davis, 2000; Davis 
and Hui, 2001).  In contrast, VLDL production and apoB secretion are inhibited when 
any of the components are lacking via degradation of apoB.  apoB degradation in 
response to lipid deficiency and other signals is accomplished by three main mechanisms: 
1) reuptake of apoB by endocytosis, 2) ER associated degradation (ERAD), and 3) post-
ER presecretory proteolysis (PERPP) (Fisher et al., 2001).  The ERAD pathway for apoB 
degradation involves co-translational polyubiquitination of apoB while it is associated 
with the translocon in the ER, and then subsequent proteasomal degradation in the 
cytosol (Avramoglu and Adeli, 2004).  The PERPP pathway for apoB degradation 
involves proteolysis of apoB by an unknown protease(s) in a post-ER compartment, 
possibly the Golgi, but not the proteasome or lysosome (Fisher et al., 2001; Pan et al., 
2004).    
  
Catabolism of apoB containing lipoproteins by the LDL receptor (LDLR) 
The Low density lipoprotein receptor (LDLR):  The concept of a liver receptor with an 
ability to bind and mediate uptake of LDL was born out of studies of the fibroblasts from 
human patients defective in this process (Brown and Goldstein, 1974; Goldstein and 
Brown, 1974).  These patients, with the disease familial hypercholesterolemia, were 
shown to have consequently high levels of LDL in the blood and premature 
atherosclerosis (Brown and Goldstein, 1986; Goldstein et al., 2001).  This cell surface 
LDL binding activity was shown to be a single protein of approximately 164kDa, called 
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the LDL receptor (LDLR), after isolation and purification from bovine adrenal cortex 
(Schneider et al., 1982).  The LDLR was shown to undergo synthesis in the secretory 
pathway, leading first to the formation of a precursor LDLR of 120kDa (Tolleshaug et 
al., 1982) containing an N-linked high mannose oligosaccharide and O-linked N-
acetylgalactosamine (GalNAc) residues (Cummings et al., 1983).  Processing in the 
secretory pathway was shown to lead to the production of the mature LDLR due to 
addition of sialic acid and galactose residues to the O-linked GalNAc residues resulting 
in aberrant migration in SDS-PAGE gels at 160kDa (Cummings et al., 1983) (Figure 
1.4).  Cloning of the bovine and human LDLR demonstrated that the LDLR contains a 
signal peptide which targets the protein to the secretory pathway, a ligand binding 
domain, an epidermal growth factor (EGF) precursor homology domain, an O-linked 
sugar binding region, a transmembrane region, and a short cytoplasmic tail (Brown and 
Goldstein, 1986) (Figure 1.4).  The LDLR is a type I membrane protein with the majority 
of the protein protruding into the extracellular space (Defesche, 2004; Gent and 
Braakman, 2004).  The N-terminal ligand binding domain is made up of seven identical 
cysteine-rich repeats that mediate binding of the LDLR to apoB100 and apoE.  The EGF 
precursor homology domain contains three EGF-like repeats with a YWTD (tyrosine, 
tryptophan, threonine, aspartic acid) domain between the second and third repeat; this 
domain functions in ligand binding, ligand release and receptor recycling.  The O-linked 
sugar binding region functions to stretch out the ligand binding portion of the LDLR and 
protects it from proteolytic cleavage.  Finally, the C-terminal domain is critical for 
basolateral sorting of the LDLR within hepatocytes, localization of the LDLR to clathrin-
coated pits on the cell surface, and for receptor-mediated endocytosis of the LDLR.   
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Figure 1.4. Life cycle of the LDLR.  The LDLR is a multidomain
protein (right) consisting of a ligand binding domain, an EGF 
precursor homology domain, an O-linked sugar domain, a 
transmembrane domain and a C-terminus.  The LDLR is 
synthesized in the ER as a 120kDa precursor.  Glycosylation and 
maturation of sugar residues in the ER and Golgi result in the 
formation of the 160kDa mature LDLR.  The LDLR traffics to the 
cell surface where it resides in clathrin coated pits via its interaction 
with ARH.  The LDLR binds LDL via an interaction with apoB.  
The LDLR with or without cargo undergoes clathrin mediated 
endocytosis into the early endosome.  The drop in pH leads to 
dissociation of LDL.  The LDL traffics into the lysosome and the
LDLR recycles to the cell surface approximately 100 times.
ARH
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 LDLR folding is remarkably efficient and has been proposed to require either 
generalized ER chaperones or private, protein-specific chaperones (Gent and Braakman, 
2004).  Other members of the LDLR family, such as LDLR related protein 1 (LRP1), 
require the 39-kDa receptor associated protein (RAP), for proper folding (Bu and 
Schwartz, 1998).  Although RAP may assist in LDLR folding in some tissues (Li et al., 
2002), the absence of a defect in hepatic LDLR folding in RAP knockouts (Willnow et 
al., 1996) indicates that if a specialized chaperone is required for LDLR folding, it is not 
RAP.  Another candidate LDLR chaperone is mesoderm development (Mesd), which 
promotes the maturation of the EGF modules in LRP5/6 (Gent and Braakman, 2004).   
Receptor-mediated endocytosis by the LDLR:  The LDLR associates with clathrin coated 
areas of the plasma membrane via an interaction of the NPxY motif in its C-terminal 
domain with the autosomal recessive hypercholesterolemia (ARH) protein, a modular 
adaptor protein which binds the LDLR cytoplasmic tail, clathrin and another member of 
the endocytic machinery, β2-adaptin subunit of AP-2 (He et al., 2002) (Figure 1.4).  The 
LDLR-ARH-clathrin complex undergoes endocytosis into clathrin-coated pits in the 
presence or absence of cargo into the endocytic recycling compartment (Brown and 
Goldstein, 1986).  This compartment is acidified to form early endosomes, wherein the 
low pH triggers the release of the LDLR cargo which is subsequently degraded in the 
lysosome (Beglova and Blacklow, 2005).  The LDLR is trafficked into a recycling 
vesicle and returned to the cell surface; each LDLR molecule recycles multiple times 
before being degraded. 
The LDLR and other proteins function together in the catabolism of apoB-containing 
lipoproteins.  The LDLR functions in the uptake of LDL by extrahepatic tissues and 
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importantly in the liver via the interaction of the LDLR with apoB (Havel and Kane, 
2001).  The LDLR also takes up VLDL remnants via an interaction with apoE and apoB; 
additionally other proteins such as LRP1 and cell surface proteoglycans mediate uptake 
of these particles into the liver (van Berkel et al., 1995).  The role of the LDLR is clearly 
shown in LDLR knockout mice which have slightly increased VLDL and markedly 
increased LDL levels (Ishibashi et al., 1993); these mice develop atherosclerosis when 
placed on a Western-type diet (Breslow, 1996).  In addition, it is important to consider 
the metabolism of apoB48 containing chylomicrons produced by the intestine.  
Chylomicrons are converted to chylomicron remnants by the action of lipoprotein lipase 
and the acquisition of apoE and apoC in the circulation; these remnants are then taken up 
by the liver in a complex apoE-dependent process (Havel and Kane, 2001) which in part 
involves the LDLR and LRP1.  The importance of liver-mediated chylomicron remnant 
uptake is unequivocally demonstrated by the extremely high levels of these particles in 
the circulation of the apoE deficient mouse, one of the main mouse models of 
atherosclerosis (Plump and Breslow, 1995).  Finally, apoC plays a role in decreasing the 
catabolism of apoB-containing VLDL and chylomicrons remnants by inhibiting 
lipoprotein lipase and apoE binding to the LDLR (Shachter, 2001)   
 
Familial forms of hypercholesterolemia 
 Monogenic disorders can result in hypercholesterolemia, specifically elevated 
total and LDL cholesterol levels, due to mutations in the main players in LDL 
metabolism, and the study of these disorders has been critical to the understanding of 
many of the biological pathways described above.   
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Table 1.1. Genetic forms of hypercholesterolemia (type II hyperlipoproteinemia)
 
Familial hypercholesterolemia (FH):  Familial hypercholesterolemia (FH, OMIM 
143890) is an autosomal dominant disorder caused by mutations in the LDLR gene 
resulting in defective LDL uptake by the liver (Goldstein et al., 2001; Rader et al., 2003).  
Heterozygotes have 2 to 3-fold elevations in total cholesterol (350-550 mg/dL) and 
homozygotes have 4 to 5-fold elevations in total cholesterol (650-1000 mg/dL); the 
elevations are due to increases in LDL cholesterol.  These patients exhibit cholesterol 
deposition in tissues resulting in premature atherosclerosis, skin and tendon xanthomas, 
and arcus corneae.  The heterozygote frequency is approximately 1 in 500 and the 
homozygote frequency approximately 1 in 1x106; however, certain populations have 
much higher frequencies.  For example, the prevalence of heterozygous FH among 
Afrikaners and Ashkenazi Jews from South Africa is between 1 in 60 and 1 in 100; in 
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Christian Lebanese, the frequency is 1 in 85 and among French Canadians, 1 in 270 
(Austin et al., 2004).   
 Over 800 mutations in the LDLR that cause FH are listed in the LDLR mutation 
database (http://www.ucl.ac.uk/fh/), and these can be separated into six classes of 
mutations (Brown and Goldstein, 1986; Goldstein et al., 2001; Defesche, 2004).  Class 1, 
null, mutations result in an absence of immunodetectable LDLR protein; mutations 
described include deletions, nonsense mutations, frameshift mutations, splicing 
mutations, and promoter mutations that prevent transcription.  Class 2, transport (or 
synthesis/processing) defective, mutations result in the synthesis of the 120kDa precursor 
LDLR but no transport through the secretory pathway and conversion to the mature form 
of the LDLR; these misfolded proteins are degraded before reaching the cell surface. 
These mutations are missense or short deletions usually in the EGF precursor homology 
domain.  Class 3, binding defective, mutations result in a normally synthesized and 
processed LDLR that reaches the cell surface but cannot bind LDL; these are usually 
deletions or insertions with the ligand binding domain.  Class 4, internalization defective, 
mutations result in a normally synthesized and processed LDLR that reaches the cell 
surface and can bind LDL but is not properly localized to clathrin coated pits and hence 
does not undergo endocytosis.  These mutations include missense mutations in the 
cytoplasmic tail (specifically the NPxY site) and deletions of the cytoplasmic tail.  Class 
5, recycling defective, mutations result in a normally synthesized and processed LDLR 
that reaches the cell surface, binds LDL and is internalized but is defectively trapped 
within endosomes and rapidly degraded.  These mutations include deletions in the EGF 
precursor homology domain.  Finally, a new class of mutations, Class 6, has been 
 16
proposed due to the identification of a LDLR mutation that results in the synthesis of a 
LDLR that is mis-targeted to the apical membrane. 
Familial defective apolipoprotein B-100:  Familial defective apoB100 (ADH type B or 
FDB, OMIM 144010) is an autosomal dominant disorder with similar clinical 
characteristics (premature atherosclerosis, xanthomas) as FH (Innerarity et al., 1990; 
Rader et al., 2003).  Heterozygotes have approximately 1.5 to 2-fold elevations in LDL 
cholesterol levels and homozygotes have approximately 3-fold elevations, similar to FH 
heterozygotes.  This disease is rarer than FH, with a heterozygote frequency of 
approximately 1 in 1000 and a homozygote frequency of 1 in 4x106.  These patients have 
normal LDLRs and normal appearing LDL and apoB, but the LDL exhibits deficient 
binding to the LDLR due to specific mutations in apoB.  Only three mutations have been 
described, R3500Q (most common), R3500W, and R3531C.  Although these mutations 
are not found in the receptor binding domain of apoB, they cause altered conformation of 
the receptor-binding mutation (Boren et al., 2001) 
Autosomal recessive hypercholesterolemia:  Autosomal recessive hypercholesterolemia 
(ARH, OMIM 603813) is an autosomal recessive disorder with similar clinical 
characteristics as FH (Cohen et al., 2003; Rader et al., 2003).  Homozygotes have 4 to 5-
fold elevations in LDL cholesterol levels, similar to FH homozygotes.  This disease is 
exceedingly rare, with a frequency of less than 1 in 5x106.  These patients also have 
normal LDLRs, but, similar to patients with Class 4 internalization defective LDLR 
mutations, they have defective LDLR endocytosis due to mutations in the ARH protein.   
Other forms of monogenic hypercholesterolemia:  It has been proposed that 
approximately 15% of cases of inherited autosomal dominant hypercholesterolemia are 
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not explained by mutations in the LDLR or apoB (Defesche, 2004).  These patients are 
indistinguishable from FH and FDB patients, with total cholesterol greater than 300mg/dl 
and LDL cholesterol greater than 200mg/dl.  One example described in a small number 
of families is a disorder recently named ADH3, FH3, or Hchola3 (OMIM 603776) 
(Haddad et al., 1999; Varret et al., 1999).  Varret (Varret et al., 1999) described in detail 
one such French family (HC2) and three Spanish families and showed linkage of the 
phenotype to chromosome 1p34.1-p32 (between 65-74 cM, Marshfield map).  Haddad 
(Haddad et al., 1999) and later Hunt (Hunt et al., 2000) described another such family in 
Utah (Kindred 1173), and showed linkage to chromosome 1p32 (between 73-89 cM).  
Finally, Canizales-Quinteros (Canizales-Quinteros et al., 2003) described a Mexican 
family (CGZ) with ADH linked to chromosome 1p32 (between 76-82cM) and an 
independently segregating hyperalphalipoproteinemia trait.   Hchola3 has been associated 
with mutations in Pcsk9, the gene cloned in these studies and described in Chapters 3 and 
4; therefore, the Pcsk9 mutations will be described in Chapter 6 (page 158) in the context 
of the data on Pcsk9 described in this work and by others.  
 
Summary of Section:  In summary, many genes are involved in determining the levels 
of LDL cholesterol in the blood, including apoB, the protein component of LDL, and the 
LDLR, the liver receptor that mediates uptake of LDL.  The importance of these genes is 
demonstrated by the hypercholesterolemia and premature atherosclerosis that results from 
their defects in humans and mice.  However, many other genes, some unknown, play a 
role in regulating plasma LDL cholesterol levels. 
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Cholesterol Regulation of Gene Expression:  SREBP Transcription Factors 
 Many of the genes important in the regulation of LDL cholesterol levels and 
plasma and cell cholesterol levels in general are regulated by cholesterol at a 
transcriptional level.  Many of these transcriptional effects are mediated by the SREBP 
and the LXR transcription factors, and these pathways will be described in more detail in 
the next two sections.  This section will describe the SREBPs, which are crucially 
important in the regulation of genes involved in cholesterol, fatty acid, triglyceride and 
phospholipid synthesis (Brown and Goldstein, 1999; Horton et al., 2002; Eberle et al., 
2004). 
 
Three Sterol Regulatory Element Binding Proteins (SREBPs) 
 The SREBP transcription factors are synthesized within the ER and contain an N-
terminal basic helix-loop-helix (bHLH) leucine zipper transactivation domain that 
projects into the cytosol, two hydrophobic membrane spanning regions separated by a 30 
amino acid loop within the ER lumen,  and a C-terminal regulatory domain that projects 
into the cytosol (Eberle et al., 2004).  The mammalian genome contains two genes which 
direct the synthesis of three different SREBP transcription factors, SREBP-1a, SREBP-
1c, and SREBP-2 (Table 1.2).  The SREBP-1 gene, which encodes SREBP-1a and 
SREBP-1c, is found on human chromosome 17p11.2; whereas the SREBP-2 gene is 
found on human chromosome 22q13 (Eberle et al., 2004).  The SREBP-1a and SREBP-
1c proteins differ only in their N-terminus due to the use of alternative first exons; 
SREBP-1a has a longer N-terminal transactivation domain then SREBP-1c, making it a 
more potent transcription factor (Horton et al., 2002).  The SREBP-1 and SREBP-2 
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proteins are approximately 47% homologous (Eberle et al., 2004).  The SREBP-1a, -1c, 
and -2 transcription factors act differentially on different gene promoters (see below). 
Table 1.2. Properties of the three SREBP transcription factors 
 SREBP-1a 
(BP-1a) 
SREBP-1c 
(BP-1c) 
SREBP-2 
(BP-2) 
Gene 17p11.2 
 
17p11.2 22q13 
Structure Longer N-terminal 
transactivation domain 
 
Shorter N-terminal 
transactivation domain 
n/a 
Expression Predominant BP-1 isoform 
in cultured cells 
Predominant BP-1 isoform 
in human and mouse 
tissues 
 
Expressed in most tissues 
and cells 
Transgenic 
phenotype 
↑ liver triglyceride 
↑ fatty acid synthesis 
↑ liver cholesterol 
↑ cholesterol synthesis 
 
↑ liver triglyceride 
↑ fatty acid synthesis 
↑ liver cholesterol 
↑ cholesterol synthesis 
Target genes All SREBP targets Lipogenic genes  
(i.e. FAS, Acac) 
Cholesterologenic genes 
(i.e. Hmgcr, LDLR) 
 
 The SREBP transcription factors are synthesized within the ER and bound to the 
ER membrane owing to the presence of the two transmembrane domains and to their 
interaction with the SREBP cleavage activating protein (SCAP) (McPherson and 
Gauthier, 2004).  In order to activate gene transcription, these factors must undergo a 
two-step proteolytic cleavage in the Golgi apparatus to release the N-terminal 
transactivation domain (Figure 1.5) (Sakai et al., 1996; Brown and Goldstein, 1997).  The 
first step in activating the SREBPs is interaction of the SREBP-SCAP complex in the ER 
with COPII proteins Sec23/24 and incorporation into COPII dependent vesicles for 
transport from the ER to the Golgi (DeBose-Boyd et al., 1999; Espenshade et al., 2002).  
In the Golgi, the subtilisin serine protease, site 1 protease (S1P, Pcsk8, SKI-1, Mbtps-1), 
cleaves the SREBP in the middle of the luminal loop, dissociating the N-terminal 
transactivation and C-terminal regulatory domains (Duncan et al., 1997; Sakai et al., 
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1998; Horton et al., 2002).  Then, the atypical metalloprotease, site 2 protease (S2P, 
Mbtps-2), cleaves the SREBP within the transmembrane domain, releasing the N-
terminal transactivation domain from the Golgi membrane (Rawson et al., 1997; Duncan 
et al., 1998; Horton et al., 2002).  Finally, the N-terminal transactivation domain of 
SREBPs is translocated to the nucleus via the interaction of its nuclear localization signal 
with importin (Nagoshi et al., 1999; Eberle et al., 2004).   
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Figure 1.5. Proteolytic activation of the SREBP transcription factors.  (A) The SREBP transcription 
factors are synthesized as transmembrane precursors in the ER membrane.  The C-terminal regulatory 
domain of the SREBP complexes with SCAP. (B) Interaction of SCAP with the COPII complex allows 
the formation of COPII vesicles for transport of the SREBP-SCAP complex out of the ER.  (C) In the 
Golgi, the site 1 protease (S1P) cleaves the intraluminal loop of the SREBP and the site 2 protease (S2P) 
cleaves intramembraneously to release the N-terminal bHLH transcriptional activation domain.  (D) 
Interaction of the SREBP with importin leads to nuclear localization, binding to target gene promoters
via an SRE binding site and activation of target genes. 
 
SREBPs regulate genes involved in fatty acid and cholesterol synthesis 
 As stated above, there are three SREBP transcription factors in mammalian cells.  
SREBP-1c is usually the predominant SREBP-1 isoform in human and mouse tissues, 
except in the spleen; whereas SREBP-1a predominates in cultured cells (McPherson and 
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Gauthier, 2004); SREBP-2 is also expressed in most tissues.  Understanding of the 
distinct roles of these three transcription factors initially came from the elegant analysis 
of transgenic mice constitutively overexpressing the N-terminal transactivation domain of 
the SREBPs, leading to unregulated overexpression of the transcription factor in the 
nucleus of cells.  Overexpression of SREBP-2 led to an 2-fold increase in liver 
cholesterol content due to a 28-fold increase cholesterol biosynthesis, with a smaller 
increase in liver triglyceride content and only a 4-fold increase in fatty acid biosynthesis 
(Horton et al., 1998a).  This was explained by a selective increase in the mRNA levels of 
the enzymes of cholesterol biosynthesis (Horton et al., 1998a; Sakakura et al., 2001), with 
little or no change in genes of fatty acid synthesis.  In contrast, overexpression of 
SREBP-1c led to a 4-fold increase in liver triglyceride content (Shimano et al., 1997b) 
due to a 4-fold increase in fatty acid synthesis (Horton et al., 1998a) with no affect on 
cholesterol content or cholesterol biosynthesis.  Similarly, this was explained by a 
selective increase in the mRNA levels of genes in fatty acid synthesis (Shimano et al., 
1997b; Shimomura et al., 1998).  Possibly due to the more potent transactivation domain 
of SREBP-1a, overexpression of SREBP-1a led to increases in both liver cholesterol and 
triglyceride content, increases in cholesterol and fatty acid biosynthesis, and increases in 
genes of cholesterol and fatty acid synthesis pathways (Shimano et al., 1996; Horton et 
al., 1998a).  SREBP-1a/c (Shimano et al., 1997a) and SREBP-1c specific (Liang et al., 
2002) knockout mice demonstrate the opposite phenotype as the transgenic mice with 
respect to basal expression of genes of fatty acid synthesis.  These results led to the 
general idea that in intact animals, SREBP-1c is important for regulating the genes of 
fatty acid synthesis (lipogenic genes), such as acetyl-CoA synthetase, acetyl CoA 
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carboxylase, and fatty acid synthase; whereas, SREBP-2 is important for regulating the 
genes of cholesterol biosynthesis (cholesterogenic genes), such as HMG-CoA synthase, 
HMG-CoA reductase, among others (Table 1.2) (Horton et al., 2002).  Other genes 
besides cholesterol and fatty acid biosynthetic enzymes have been shown to be regulated 
by SREBPs, including genes involved in the generation of NADPH such as malic 
enzyme, genes in triglyceride synthesis, including glycerol-3-phosphate acyltransferase, 
and the LDLR which is involved in cholesterol uptake into the liver (Horton et al., 2002). 
 
Regulation of SREBP transcription factors  
 The activity of the SREBP transcription factors are controlled at the levels of 
transcription of the SREBP genes, proteolysis within the secretory pathway, and other 
post-translational modifications.   
Regulation of SREBP activity at the level of proteolysis.  The well-studied mechanism 
of regulating SREBP activity is at the level of proteolysis.  This is accomplished through 
regulation of the budding of SCAP from the ER (Nohturfft et al., 2000), and hence access 
of the S1P and S2P to the SREBP in the Golgi (Figure 1.6).  When cellular sterol levels 
are low, the SCAP-SREBP complex moves from the ER to the Golgi where the S1P and 
S2P cleave the SREBP and allow translocation of the N-terminal transactivation domain 
to the nucleus (McPherson and Gauthier, 2004).  High cellular sterol levels are sensed 
through binding of cholesterol to the sterol sensing domain within the membrane domain 
of SCAP (Radhakrishnan et al., 2004), leading to a conformational change in SCAP 
(Brown et al., 2002), and binding to the ER resident protein insulin induced gene 1 
(Insig-1) (Yang et al., 2002).  This retains the SREBP-SCAP complex in the ER and 
 23
prevents activation of regulated genes when cellular sterol levels are high, such as 
through feeding a high cholesterol diet (Shimomura et al., 1997).  The importance of this 
process is highlighted by transgenic mice that express a SCAP mutant that prevents 
SCAP binding to Insig regardless of cellular sterol levels and leads to constitutive nuclear 
expression of SREBP-1 and SREBP-2 and activation of target genes (Korn et al., 1998; 
Yabe et al., 2002).   
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Figure 1.6. Regulation of SREBP proteolytic activation by cellular sterol levels.   (A) Under low 
sterol conditions, the SREBP-SCAP complex does not interact with Insig and instead interacts with the 
COPII complex.  This leads to transport to the Golgi where the SREBP is proteolytically activated (see 
Figure 1.5).  Transport of the SREBP to the nucleus activates target genes.  (B) The sterol sensing domain 
of SCAP detects high sterols and undergoes a conformational change that leads to interaction with the ER 
resident protein Insig.  Binding to Insig leads to retention of the SREBP-SCAP complex in the ER.  Thus, 
proteolytic activation in the Golgi cannot take place and target genes are not activated.
 
Control of SREBP activity at the level of SREBP transcription.  At the level of 
transcription, SREBP-2 appears to be self-regulated at an SREBP response element 
(SRE) site in its promoter and via an interaction of SREBP-2 with NF-Y (Sato et al., 
1996), allowing a feed-forward regulation of SREBP-2 levels.  Other mechanisms of 
transcriptional activation of SREBP-2 have not been reported (Eberle et al., 2004).  In 
contrast, SREBP-1 mRNA levels are highly regulated at a transcriptional level via the 
LXR transcription factors.  It was shown that SREBP-1c is a LXR target gene by the 
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demonstration that SREBP-1c mRNA levels were reduced in LXRα knockouts (Peet et 
al., 1998) and induced by LXR ligands (Repa et al., 2000a; Yoshikawa et al., 2001).  
Since the LXR transcription factors activate genes in the liver necessary for cholesterol 
efflux when oxysterol levels are high (see below), it is thought that LXR may activate 
SREBP-1c in order to produce fatty acids to buffer an associated increase in free 
cholesterol (Eberle et al., 2004).  The importance of LXR activation of SREBP-1c has 
been shown in the link between SREBP-1c activation to insulin and fatty acid levels.  It 
has been shown that feeding a high carbohydrate diet after a period of fasting up-
regulates SREBP-1c mRNA levels (Horton et al., 1998b).  As this is a hallmark of  
insulin action, Foretz and colleagues showed that insulin itself up-regulates SREBP-1c 
mRNA levels (Foretz et al., 1999).  This effect has been shown to be mediated by LXREs 
in the SREBP-1c promoter (Chen et al., 2004).  In contrast, polyunsaturated fatty acids 
decrease SREBP-1c mRNA levels by antagonizing ligand binding and hence activation 
of the LXRs (Yoshikawa et al., 2002).   
Control of SREBP activity at the level of protein modification.  The SREBPs may also 
be regulated by other mechanisms.  First, the levels of nuclear SREBPs are increased by 
proteasome inhibitors, leading to increased expression of target genes (Hirano et al., 
2001).  This is due to normal rapid turnover of the SREBPs by polyubiquitination and 
degradation by the proteasome.  This pathway depends on GSK phosphorylation of the 
SREBP, binding of the ubiquitin E3 ligase specificity factor F-box and WD-40 domain 
protein 7 (Fbw7), and subsequent ubiquitination and degradation by the proteasome 
(Sundqvist et al., 2005).  In fact, siRNA-mediated knockdown of Fbw7 leads to 
stabilization of SREBPs and an increase in target genes.   Second, it has been found that 
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the nuclear forms of SREBPs are modified by the small ubiquitin-related modifier 
(SUMO-1), leading to decreased transcriptional activity of the SREBPs through a non-
degradative mechanism (Hirano et al., 2003).   
 
Summary of Section:  In summary, dietary cholesterol decreases the amount of nuclear 
SREBP-1 and SREBP-2 in the liver and thus inhibits the expression of the SREBP target 
genes.  These genes play a role in cholesterol biosynthesis and liver cholesterol uptake 
(SREBP-2) and lipogenesis (SREBP-1c). 
 
Cholesterol Regulation of Gene Expression:  LXR Transcription Factors 
 The LXRs are transcription factors that regulate genes involved in many 
processes including reverse cholesterol transport, dietary cholesterol absorption, bile acid 
metabolism and in lipid biosynthesis.  The LXRs thus play a role in maintaining whole 
body cholesterol homeostasis and impact on the development of atherosclerosis 
(Schoonjans et al., 2000; Repa and Mangelsdorf, 2002; Steffensen and Gustafsson, 2004). 
 
LXRs are nuclear hormone receptor transcription factors 
 Liver X receptors LXR-α (also known as NR1H3) and LXR-β (also known as 
NR1H2) are members of the nuclear hormone receptor superfamily of transcription 
factors (Repa and Mangelsdorf, 2002).  Nuclear hormone receptors include the steroid 
hormone receptors and non-steroidal receptors (Chawla et al., 2001).  The steroid 
hormone receptors act as homodimers and bind such ligands as glucocorticoids, 
mineralocorticoids, estrogen, androgens, and progesterone to activate relevant gene 
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transcription.  In contrast, the non-steroidal receptors function as heterodimers with the 
retinoid X receptor (RXR), and many are lipid sensors.  These include the oxysterol 
activated LXRs, the fatty acid activated peroxisome proliferator activated receptors 
(PPARs), the bile acid activated farnesoid X receptor (FXR), and the xenobiotic activated 
pregnane X receptor (PXR) (Chawla et al., 2001).  Nuclear hormone receptors recognize 
a wide variety of ligands; however, they all contain a similar domain structure.  These 
proteins are made up of a N-terminal ligand-independent transcriptional activation 
function (AF-1), a highly conserved zinc-finger DNA-binding domain (DBD), a hinge 
region, and a C-terminal domain containing the ligand binding region, dimerization 
interface and ligand-dependent activation function (AF-2) (Chawla et al., 2001; Edwards 
et al., 2002).  The DNA binding domain directs the binding of the nuclear hormone 
receptor to specific DNA sequences, called hormone response elements (HREs).  
 
LXRs are activated by endogenous oxysterols  
 In general, the non-steroidal nuclear hormone receptors bind to DNA at the 
hormone response element as heterodimers with RXR and in association with co-
represssors.  Upon binding of their small lipophilic ligand to the ligand binding domain, 
the receptor undergoes a conformational change leading to the release of co-repressors 
and the binding of co-activators, allowing increased transcription (Edwards et al., 2002).  
In the case of LXR, LXR/RXR heterodimers can be activated by RXR ligands, such as 9-
cis retinoic acid, and LXR ligands which include oxysterols (Janowski et al., 1996) and 
synthetic ligands.  The endogenous oxysterol ligands of LXR include 24,25(S)-
epoxycholesterol, which is a by-product of cholesterol biosynthesis in such tissues as the 
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liver and builds up in the liver after cholesterol feeding, 22(R)-hydroxycholesterol which 
is found in the gonads and adrenals, 24(S)-hydroxycholesterol which is found in the 
brain, and 27-hydroxycholesterol in the macrophage (Schoonjans et al., 2000; Chawla et 
al., 2001).  All of these compounds have been found to activate LXRs at physiological 
concentrations (Lehmann et al., 1997; Janowski et al., 1999; Fu et al., 2001).  Synthetic 
ligands of LXR include TO901317 (Schultz et al., 2000). 
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Figure 1.7. LXRs activate transcription of target genes in the presence of oxysterol ligands.  (A) 
LXRs heterodimerize with RXR and bind to LXRE sites in the promoters of target genes.  In the absence 
of ligand, the LXR-RXR heterodimer binds co-repressors and target genes are turned off.  (B) In the 
presence of ligand, such as endogenous oxysterols and synthetic ligands, the LXR-RXR heterodimer 
releases co-repressors, binds co-activators and activates transcription of target genes. 
 
 
LXRs play an important role in reverse cholesterol transport 
 LXRα expression is restricted to the liver, kidney, intestine, adipose, spleen and 
macrophage; whereas LXRβ is ubiquitously expressed (Schoonjans et al., 2000; 
Steffensen and Gustafsson, 2004).  A definitive role for LXRα in cholesterol metabolism 
came from the analysis of LXRα knockouts.  While normal mice increase hepatic 
cholesterol levels by 2-3 fold after a week of a high cholesterol diet, LXRα knockouts 
increase hepatic cholesterol levels by nearly 25-fold, largely due to an inability to up-
regulate the bile acid synthetic enzyme, cholesterol 7α hydroxylase (Cyp7a1) (Peet et al., 
1998).  This phenotype is not seen in LXRβ knockout mice, indicating that LXRα is the 
relevant isoform for the control of Cyp7a1 up-regulation in response to a high cholesterol 
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diet (Alberti et al., 2001).  Many other LXR target genes have been identified through the 
use of LXR knockout animals and natural and synthetic oxysterol LXR ligands in tandem 
with studies identifying LXREs in promoters, introns and distal enhancer elements.   
 Many of the identified LXR target genes function in the general process of 
reverse cholesterol transport (RCT) by which cholesterol is effluxed to high density 
lipoprotein (HDL) from non-hepatic tissues and returned to the liver and steroidogenic 
organs for use in the synthesis of lipoproteins, bile acids, vitamin D and steroid hormones 
(Figure 1.8) (von Eckardstein et al., 2001; Repa and Mangelsdorf, 2002).  This pathway 
is of pharmacological and clinical interest as aberrations in RCT can lead to the 
deposition of cholesterol within arterial walls and the development of arteriosclerosis, 
and the role of HDL in RCT is a major contributor to its anti-atherogenic properties 
(Sviridov and Nestel, 2002).  In the first step of RCT, the LXR target gene ATP binding 
cassette a1 (Abca1) effluxes cholesterol to pre-βHDL and free apoAI from peripheral 
tissues (Costet et al., 2000; Repa et al., 2000b; Schwartz et al., 2000); Abcg1 is another 
LXR target gene that can efflux cholesterol (Kennedy et al., 2001; Steffensen and 
Gustafsson, 2004).  HDL is then transported back to the liver where the cholesterol esters 
are taken up through the action of the LXR target gene SRBI (Silver et al., 2001; Malerod 
et al., 2002).  Another LXR target gene, lipoprotein lipase, has been shown to promote 
this process (Zhang et al., 2001a).  In an alternative route, cholesterol esters may be 
transferred from HDL to LDL through the action of the LXR target gene CETP (Luo and 
Tall, 2000; Steffensen and Gustafsson, 2004), and taken up by the LDL receptor.  Once 
in the liver, cholesterol is converted to bile acids by the LXR target Cyp7a1 or effluxed 
into the bile via the LXR target genes Abcg5 and Abcg8 (Yu et al., 2003).  Thus, LXRs 
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activate genes involved in both the extrahepatic and hepatic (bile acid synthesis and 
excretion) arms of RCT.  The importance of LXR target gene activation, at least in part 
due to the induction of RCT, has been demonstrated by the fact that the synthetic LXR 
agonists, TO901317 and GW3965 inhibit the development of atherosclerosis when 
administered to atherosclerosis-prone apoE knockout and LDLR knockout mice (Joseph 
et al., 2002; Terasaka et al., 2003).  It is important to note that the reduction in 
atherosclerosis may also be due to LXR activation of other pathways (see below).  
Unfortunately, the pharmacological application of these effects is limited to date by the 
LXR induced activation of SREBP-1c gene transcription (described above), subsequent 
lipogenesis and resultant hepatic steatosis and hypertriglyceridemia (Schultz et al., 2000; 
Grefhorst et al., 2002).   
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Figure 1.8. LXR target genes function in reverse cholesterol transport (RCT).  In the figure, LXR 
target genes are indicated by green boxes.  Cholesterol is effluxed from macrophages via Abca1 and 
Abcg1 to pre-HDL. CETP transfers cholesterol esters from HDL to VLDL/LDL and PLTP transfers 
phospolipid in the reverse direction. VLDL is converted to LDL via the action of LPL.  Cholesterol can 
be taken up by the liver via the HDL receptor SRBI and the LDL receptor LDLR.  Cholesterol in the 
liver may be converted to bile acids via Cyp7a1 or effluxed directly into the bile via Abcg5/8.  
Cholesterol from the bile may be excreted or reabsorbed with dietary cholesterol to be transported back 
to the liver.  LXRs also activated SREBP-1c which produces TG to complex with cholesterol esters into 
VLDL for secretion into the plasma.  
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LXRs play a role in other pathways 
 Important new roles for LXRs have recently been identified.  Joseph and 
colleagues have shown that LXRs inhibit the macrophage response to LPS and bacterial 
infection through repression of such genes as inducible nitric oxide, cyclooxygenase-2, 
and NF-κB targets IL-1β and TNF-α (Joseph et al., 2003).  This may have relevance to 
atherosclerosis as LXR agonists inhibit inflammatory gene expression in aortas of 
atherosclerotic mice.  Another novel role of LXRs is in carbohydrate metabolism; LXRs 
decrease the expression of gluconeogenic enzymes such as PEPCK, among others 
(Stulnig et al., 2002).  Finally, LXRs may also play roles in signal transduction pathways 
and energy expenditure (Stulnig et al., 2002; Steffensen and Gustafsson, 2004). 
 
Summary of Section:  In summary, dietary cholesterol increases the expression of LXR 
target genes in the liver by increasing the LXR oxysterol ligand 24,25(S)-
epoxycholesterol.  These liver LXR target genes play a role in the hepatic arm of reverse 
cholesterol transport by influxing cholesterol via SRBI and the LDL receptor, in bile acid 
synthesis and excretion, and in SREBP-1c mediated lipogenesis.  Theoretically, LXR 
target genes may also play a role in some of the novel LXR pathways such as 
inflammatory processes and in carbohydrate metabolism. 
 
Proprotein Convertase Subtilisin Kexin (PCSK) Family 
 One of the genes identified and studied in this thesis, Pcsk9, is a member of the 
proprotein convertase subtilisin kexin family of proteins; thus this section will provide a 
background to this family. 
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The Subtilisin family of proteins 
There are five families of proteases, serine, threonine, cysteine, aspartic acid and 
metalloproteases.  The serine protease family, which all use an aspartic acid, histidine, 
serine (D,H,S) catalytic triad, may be further subdivided into 6 clans and 26 subfamilies; 
the largest two clans being the trypsin-like and subtilisin clans of serine proteases (Siezen 
and Leunissen, 1997).  Subtilisin serine proteases (also called subtilases) are an extremely 
ancient family of proteases with members in all three superkingdoms of life, Archaea, 
Bacteria, and Eukarya (protists, fungi, plants and animals).  The subtilisin clan is further 
subdivided into six subfamilies: subtilisin, thermitase, proteinase K, lantibiotic peptidase, 
kexin, and pyrolysin (Siezen and Leunissen, 1997).  The subtilases are either 
endopeptidases, which cleave within a protein chain, or tripeptidyl peptidases, which 
release an N-terminal tripeptide from a protein, and nearly all are translocated over a 
membrane under the direction of a signal peptide and themselves activated by 
proteolysis.   
 
The mammalian subtilisin proteases 
 There are nine endoproteolytic subtilases and two tripeptidyl peptidase subtilases 
in the mouse and human genomes.  Seven of the mammalian endoproteolytic subtilases, 
commonly referred to as PC1/3, PC2, furin, PC4, PC5/6, PACE4, and PC7/8, belong to 
the kexin subfamily (Gensberg et al., 1998); one, site 1 protease (S1P), has been reported 
to belong to the pyrolysin subfamily (Seidah and Chretien, 1999); and the newly 
identified member described in Chapter 2 and 3, Pcsk9, belongs to the proteinase K 
subfamily (Figure 1.9A).  Despite the differences in subfamily grouping, it has been 
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proposed by the HUGO gene nomenclature committee that all mammalian 
endoproteolytic subtilases use the stem Proprotein Convertase Subtilisin Kexin or Pcsk; 
however, for simplicity, the traditional gene names will be used here and the new 
nomenclature is referred to in Table 1.3 (page 41). 
 All of the subtilases have a signal peptide which targets the protein into the 
secretory pathway, a pro-peptide domain, a catalytic domain, a P or Homo-B domain, and 
a variable C-terminal domain (Figure 1.9B) (Gensberg et al., 1998; Zhou et al., 1999).  
The pro-peptide domain is involved in folding of the protease as an intramolecular 
chaperone and also acts as a competitive inhibitor of the protease (Bergeron et al., 2000).  
As has been established for furin, and probably applies to the other subtilases except PC2, 
the protease is synthesized in the ER, the prosegment is cleaved by autocatalysis and then 
remains tightly associated with the protease, acting as a potent inhibitor, until another 
event occurs (Figure 1.9B).  This second event could be movement to the protease’s final 
subcellular destination, a secondary cleavage, a pH drop in the trans-Golgi network 
(TGN) or secretory granule, or a combination of the these (Seidah and Chretien, 1999).  
The catalytic domain contains the canonical D,H,S serine protease catalytic triad and the 
oxyanion hole asparagine, a residue which is proposed to stabilize a negatively charged 
oxygen atom (oxyanion) that forms during the enzyme-substrate catalysis reaction 
(Siezen and Leunissen, 1997).  The P domain has been proposed to play roles in 
regulating the stability, calcium dependence and pH optimum of the protease.  The 
signature of this domain, RGD, is known for its role in integrin binding, however the role 
for this motif in the subtilases is unclear (Bergeron et al., 2000).  The C-terminal domain 
of the subtilases is the most variable domain; this domain contains transmembrane 
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segments in the case of furin, PC5/6, an isoform of PACE4, PC7/8, and S1P (Bergeron et 
al., 2000).  All of the mammalian subtilases have N-glycosylation sites; the importance of 
which has been demonstrated by the fact that deletion of these sites in PC1/3 and PC2 
leads to rapid ER associated degradation (ERAD) (Gensberg et al., 1998).    
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Figure 1.9. General properties of the mammalian endoproteolytic subtilases.  (A) Most of the 
mammalian subtilases belong to the kexin subfamily and cleave after basic residues; they are further 
subdivided due to their site of action.  One member belongs to the pyrolysin subfamily and cleaves after 
non-basic residues. (B) The mammalian subtilases have a pro-domain, a catalytic domain (active site 
residues D, H, S), a P-domain, and a unique C-terminal domain (CTD).  The proteases are synthesized in 
the ER and remain inactive due to inhibition by the pro-domain.  The proteases are trafficked along the 
secretory pathway in complex with the inhibitory pro-domain until another event leads to the removal of 
the pro-domain and thus activation of the protease.   
Functions of the Proprotein Convertase (PC) family of mammalian subtilases 
 As mentioned above, seven of the mammalian endoproteolytic subtilases, PC1/3, 
PC2, furin, PC4, PC5/6, PACE4, and PC7/8, belong to the kexin subfamily; these 
proteins are also known as proprotein convertases (PCs) and play a role in the limited 
proteolysis of inactive precursors to produce biologically active proteins and peptides 
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(Seidah and Chretien, 1999).  The types of proteins processed by PCs is extensive and 
includes precursors of neuropeptides (e.g. enkephalin), peptide hormones (e.g. insulin), 
proteolytic enzymes (e.g. themselves, matrix metalloproteases), growth factors (e.g. 
TGFβ), type-I membrane receptors (e.g. notch, insulin receptor), cell adhesion molecules 
(e.g. alpha integrins, collagen), cell surface glycoproteins of viruses and bacteria (e.g. 
HIV-1 gp160, influenza hemagglutinin), bacterial toxins, blood coagulation factors, cell 
signaling molecules, and transcription factors; see (Seidah and Chretien, 1999; Taylor et 
al., 2003) for a more complete list.   
 The target proteins of PCs may be processed intracellularly in the secretory 
pathway, at the cell surface, or in the extracellular milieu.  As such, PCs function in both 
the regulated (neural and endocrine cells) and constitutive (all cells) secretory pathways.  
Specifically, PC1/3, PC2, PC4, and PC5/6 isoform A function in the regulated pathway; 
whereas furin, PC5/6 isoform B, PACE4, , and PC7/8 function in the constitutive 
secretory pathway (Zhou et al., 1999).  Individual cell/tissue types do not express only 
one PC, but instead express a specific complement of PCs, with possible redundant 
functions (Bergeron et al., 2000).  However, no two PCs have identical expression 
patterns.  PCs cleave after basic sites in the consensus (K/R)-(X)n-(K/R), where n=0,2,4,6 
and X usually not Cys, Pro (Seidah and Chretien, 1999).  Homology modeling of PC 
catalytic domains with bacterial subtilisin structures has shown that PCs have increased 
negatively charged side chains on their substrate binding face, possibly accounting for 
selectivity towards positively charged substrates (Creemers et al., 1998).  After PC 
cleavage within the peptide chain, the C-terminal end of the product are often removed 
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by a member of the carboxypeptidase family, such as CPE, CPD, CPZ, and CPM 
(Creemers et al., 1998; Zhou et al., 1999). 
 It is easy to identify potential PC substrates using the above consensus; however, 
it is difficult to predict the substrate specificity of any given PC because substrate 
specificity is determined by multiple additional factors including cell type, subcellular 
localization, characteristics of the substrate itself, such as being soluble versus membrane 
anchored, and other factors (Taylor et al., 2003).  The study of PCs is further complicated 
by the fact that many PCs can cleave the same precursor in vitro; thus in vitro 
overexpression studies must be complimented by the study of naturally occurring 
mutants, gene knockouts/knockdowns and tissue colocalization of the PC and potential 
substrate (Bergeron et al., 2000).  Further complications may arise due to the low 
expression levels of PCs (Taylor et al., 2003).  The next sections summarize the potential 
and confirmed roles of the individuals PCs. 
PC1/3 (Pcsk1, SPC-3, NEC-1):  PC1/3 functions in the regulated secretory pathway and 
is localized to secretory granules in neuroendocrine derived cells of the central nervous 
system, pituitary, thyroid, pancreas, adrenals, intestine, and cardiovascular system 
(Creemers et al., 1998; Seidah and Chretien, 1999).  Substrates proposed from in vitro 
studies include proinsulin, growth hormone releasing hormone (GHRH), 
proopiomelanocortin (POMC), brain derived neurotrophic factor (BDNF), dynorphin, 
renin, and pituitary adenylate cyclase-activating polypeptide (PACAP); however, other 
PCs have been shown to be able to process many of these substrates (Seidah et al., 1999b; 
Seidah and Chretien, 1999; Bergeron et al., 2000; Taylor et al., 2003).  Analysis of PC1/3 
knockouts was crucial in demonstrating a definitive role for PC1/3 in proinsulin, GHRH, 
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and POMC processing (Zhu et al., 2002a; Zhu et al., 2002b; Taylor et al., 2003).  PC1/3 
knockouts are characterized by dwarfism due to an absence of mature GHRH, 
hyperproinsulinemia with euglycemia, defective POMC processing to ACTH, pre and 
postnatal lethality, and chronic diarrhea due to intestinal dysfunction.  Further analysis of 
the knockouts revealed a necessary role for PC1/3 in the processing of cholecystokinin 
(CCK) (Cain et al., 2004), oxytocin, and chromogranin A and B in certain tissues (Pan et 
al., 2005).  Analysis of two human patients with loss of function mutations in PC1/3 have 
demonstrated that many but not all of the roles of PC1/3 in the mouse can be applied to 
the human.  Both PC1/3 human patients had hyperproinsulinemia with postprandial 
hypoglycemia and intestinal dysfunction (leading to the death of one of the patients at 18 
months of age) (Jackson et al., 1997; Jackson et al., 2003).  In contrast to mouse 
knockouts, these patients did not have growth retardation, but did have obesity and 
hypogonadotropic hypogodism, indicating additional roles of PC1/3 in the human. 
PC2 (Pcsk2, SPC-2, NEC-2):  PC2, similar to PC1/3,  also functions in the regulated 
secretory pathway and is localized to secretory granules in neuroendocrine derived cells 
of the central nervous system, pituitary, thyroid, pancreas, adrenals, intestine, and 
cardiovascular system (Seidah and Chretien, 1999).  PC2 is unique among all PCs in that 
it is requires an additional intramolecular chaperone, 7B2 for proper folding, spatial and 
temporal activation; its autocatalytic self-cleavage occurs in the TGN; and it has an 
aspartic acid in place of the oxyanion hole asparagine.  Analysis of PC2 knockout 
animals has again been critical in defining the necessary roles of PC2 given the multitude 
of proposed substrates (Seidah and Chretien, 1999).  PC2 knockouts have chronic fasting 
hypoglycemia and an impaired rise in blood glucose during intraperitoneal glucose 
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tolerance test due to completely defective processing of proglucagon and resultant 
hyperplasia and dysfunction of pancreatic alpha cells (Furuta et al., 1997; Creemers et al., 
1998).  In addition, PC2 knockouts have abberant expression of two key pancreatic 
transcription factors, Nkx6.1 and Pdx-1, leading to improper development of pancreatic 
islets (Vincent et al., 2003).  Of note, prosomatostatin processing is also defective in PC2 
knockouts, but proinsulin processing can still occur (due to PC1/3).  PC2 knockouts have 
also shown necessary roles for PC2 in the processing of POMC derived ACTH, 
cholecystokinin, enkephalin, nociceptin, and dynorphin (Bergeron et al., 2000; Taylor et 
al., 2003).  Interestingly, PC2 knockouts have deficient processing of enkephalin in the 
hypothalamus and cortex, but normal processing in the adrenal and intestine (Miller et al., 
2003), demonstrating that the same hormone may be processed by different PCs in 
different tissues. 
Furin (Pcsk3, SPC-1, PACE):  Furin is a ubiquitously expressed PC of the constitutive 
secretory pathway (Seidah and Chretien, 1999).  Furin is a type I membrane protein and 
is localized to the TGN via a casein kinase II site and tyrosine motif in its C-terminus and 
its interaction with other proteins (Gensberg et al., 1998).  Specifically, furin that is not 
phosphorylated on the CKII site is retained in the TGN, phosphorylation causes exit from 
the TGN to the cell surface, and protein phosphatase-2 mediated dephosphorylation 
followed by clathrin-mediated endocytosis returns furin to the TGN (Zhou et al., 1999).  
From analysis of furin overexpression in vitro and furin deficient cell lines (LoVO and 
CHO RPE.40), furin has been proposed to be the housekeeping PC due to its ability to 
cleave an extremely large number of substrates.  Furin plays an essential role in 
development as furin knockouts show lethality at embryonic day 10.5 due to severe 
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ventral closure defects, abnormal yolk sacs, no axial rotation, and failure of the heart tube 
to fuse and undergo looping morphogenesis (Roebroek et al., 1998; Constam and 
Robertson, 2000a).  However, the specific role of furin in adult tissues is unknown and is 
possibly subjected to redundancy of function because conditional liver specific furin 
knockouts show no obvious phenotype and no tested substrates had a complete block of 
processing (Roebroek et al., 2004).   
PC4 (Pcsk4, SPC-5, NEC-3):  PC4 functions in the regulated secretory pathway only in 
testicular and ovarian germ cells.  PC4 male and female knockouts have decreased 
fertility due to a decrease in sperm fertilization efficiency, failure of resultant zygotes to 
develop past the blastocyst stage, and delayed ovarian folliculogeneis (Mbikay et al., 
1997; Taylor et al., 2003).  This phenotype is proposed to be due in part to an absence of 
processing of pituitary adenylate cyclase activating polypeptide (PACAP) (Taylor et al., 
2003), but may also be due to the defective processing of insulin-like growth factor-1 
(IGF-1), IGF-2, and members of the ADAM family of proteins, Adam1,2,3,5 (Basak et 
al., 2004). 
PC5 (Pcsk5, PC-6, SPC-6):  PC5 has two isoforms with different C-termini leading to 
different properties and functions.  PC5A is soluble and functions in the regulated 
secretory pathway in neuroendocrine cells; whereas PC5B is membrane-bound and 
functions in the constitutive secretory pathway in nearly all tissues.  Substrates for PC5A 
have been proposed, and a role for PC5A in metabolism has been suggested by the fact 
that its expression is up-regulated by high-fat feeding and by fasting-refeeding (Bergeron 
et al., 2000); however, the true functions of PC5A are still unclear and no knockout is 
available.  PC5B knockouts are available and are characterized by lethality at embryonic 
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day 10.5 (Taylor et al., 2003); however a detailed analysis of these knockouts has not 
been reported and the roles of PC5B are also unclear. 
PACE4 (Pcsk6, SPC-4):  PACE4, similar to furin, is a ubiquitously expressed PC of the 
constitutive secretory pathway (Gensberg et al., 1998).  PACE4 is also membrane bound 
and has been reported to process many of the same substrates as furin.  However, PACE4 
must have non-redundant roles in development as PACE4 knockouts have incompletely 
penetrant embryonic lethality at day 13.5-15.5 with abnormal left-right embryonic 
patterning leading to situs ambiguous, left pulmonary isomerism (bilateral left lungs), gut 
malformation, complex craniofacial malformations, and other phenotypes (Constam and 
Robertson, 2000b).  Interestingly, analysis of a hypertension locus on human 
chromosome 15q revealed a haplotype containing PACE4 polymorphisms that was 
associated with diastolic blood pressure levels (Li et al., 2004a).  It will be interesting to 
further define the potential role of PACE4 in this and other diseases. 
PC7/8 (Pcsk7, SPC-7, LPC):  PC7/8, similar to furin and PACE4, is a ubiquitously 
expressed PC of the constitutive secretory pathway (Gensberg et al., 1998).  PC7/8 is also 
membrane bound and has been reported to process many of the same substrates as furin.  
The function of PC7/8 is unclear and may be redundant with at least furin as PC7/8 
knockouts are born in expected Mendelian proportions with normal fertility and no 
obvious pathological phenotypes (Taylor et al., 2003). 
 
Function of Pcsk8/Site 1 protease (S1P)/Mbtps-1/SKI-1 
 Pcsk8 is also known as the site 1 protease (S1P), membrane bound transcription 
factor protease site 1 (Mbtps-1), and subtilisin-kexin-like 1 (SKI-1).  S1P functions in the 
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constitutive secretory pathway and has ubiquitous expression; however, it is unique in the 
mammalian subtilase family in that it is not a member of the kexin subfamily, and it has 
been shown to cleave after nonbasic sites rather than basic sites, in the consensus (K/R)-
X-(Hydrophobic)-(L/T) (Seidah and Chretien, 1999).  S1P is well known in the 
cholesterol field as one of the two proteases that activate the SREBP transcription factors 
(Brown and Goldstein, 1999) (described above).  S1P was identified as the site 1 protease 
by cDNA library complementation analysis of cholesterol auxotrophic mutant Chinese 
hamster ovary cells that had been mutagenized in the presence of transfected site 2 
protease cDNA (Rawson et al., 1998; Sakai et al., 1998).  The critical role of S1P in the 
processing of SREBP was shown by analysis of liver-specific S1P knockouts (Yang et 
al., 2001).  These animals have decreased levels of precursor and processed SREBP-1 
and SREBP-2 leading to a 2-fold decrease in SREBP target genes.  As predicted, this 
leads to a 75% decrease in cholesterol and fatty acid biosynthesis and decreased LDL 
removal from plasma.  S1P likely plays additional roles besides in the processing of 
SREBP as S1P has been shown to process brain derived neurotrophic factor (BDNF) 
(Seidah et al., 1999a) and Atf6, a transcription factor important for inducing the ER stress 
or unfolded protein response (Ye et al., 2000).  Furthermore, total S1P knockouts do not 
form a epiblast (one of the two layers of the very early embryoblast) and die prior to 
implantation (embryonic day 5) (Mitchell et al., 2001). 
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Table 1.3. Summary of the Mammalian Endoproteolytic Subtilases* 
 
Name Other 
Names 
Secretory 
Pathway 
Tissue 
distribution 
Soluble or 
Membrane 
Functions as deduced 
from mouse KO 
PC1/3 Pcsk1 
SPC-3 
NEC1 
Reg Neuroendocrine 
cells of various 
tissues 
 
Soluble Processes proinsulin, growth 
hormone releasing hormone, 
among others 
PC2 Pcsk2 
SPC-2 
NEC2 
Reg  Neuroendocrine 
cells of various 
tissues 
 
Soluble Processes proglucagon, among 
others 
Furin  Pcsk3 
SPC-1 
PACE 
Cons  Widespread Membrane 
bound 
Multiple functions, KO are 
embryonic lethal with 
developmental defects 
 
PC4 Pcsk4 
SPC-5 
NEC3 
 
Reg  Testicular  and 
ovarian germ cells 
Soluble KO demonstrated necessary  
role in fertility 
PC5/6A Pcsk5A 
SPC-6A 
Reg  Widespread Soluble Unknown, expression 
increased by high fat diet and 
fasting-refeeding 
 
PC5/6B  Pcsk5B 
SPC-6B  
Cons  Widespread Membrane 
bound 
KO are embryonic lethal, 
specific functions unknown 
 
PACE4 Pcsk6 
SPC-4 
Cons Widespread Soluble KO show low penetrant 
embryonic lethality, specific 
functions unknown 
 
PC7/8 Pcsk7 
SPC-7 
LPC 
 
Cons  Widespread Membrane 
bound 
May be redundant with furin, 
KO normal 
S1P Pcsk8 
Mbtps1 
SKI-1 
Cons  Widespread Membrane 
bound 
Processes SREBP and BDNF; 
must have other roles as KO 
are embryonic lethal 
Reg: regulated secretory pathway; Cons: constitutive pathway; KO: knockout 
 
 
A Disintegrin and Metalloprotease (ADAM) Family 
 One of the genes studied in this thesis, Adam11, is a member of the A Disintegrin 
and Metalloprotease family of proteins; thus this section will provide a background to 
this family. 
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The A Disintegrin and Metalloprotease (ADAM) family proteins 
 The A Disintegrin And Metalloprotease (ADAM) family of proteins are multi-
domain proteins that have been implicated in a wide variety of important biological 
processes (Blobel, 2005).  In the thirteen years since the cloning of the first two ADAMs, 
fertilin alpha (Adam1) and fertilin beta (Adam2) (Blobel et al., 1992), ADAMs have been 
identified in Schizosaccharomyces pombe, Caenorhabditis elegans, Drosophila 
melanogaster, and in vertebrates (Blobel, 2005); but are thought to be absent from 
bacteria and plants.  There are thirty-three ADAMs that have been cloned in the mouse, 
twenty-six in the human (see Table of ADAMs, http://www.people.virginia.edu/~jw7g/).  
Of the mouse genes, 14 of the 33 are expressed in somatic tissues and the other 19 are 
expressed only in the testis.  The 14 somatically expressed ADAMs can be further 
subdivided into 10 catalytically active ADAMs: Adam1,8,9,10,12,15,17,19,28,33; and 4 
catalytically inactive: Adam7,11,22,23.  The 19 testis expressed ADAMs can be further 
subdivided into 11 catalytically active ADAMs: Adam21,24,25,26,30,34,36,37,38,38,40 
and 8 catalytically inactive ADAMs: Adam2,3,4,5,6,18,29,32.  Of note, the difference in 
number of mouse and human ADAMs is solely in the number of testis-specific ADAMs.  
All of the somatically expressed ADAMs, with the exception of the Adam1 pseudogene, 
are present and expressed in mouse and human.  These proteins are synthesized in the 
endoplasmic reticulum, owing to the presence of a signal peptide, and are predicted to be 
cell surface proteins, although some have been found to colocalize with Golgi markers 
and hence may also be active intracellularly (Seals and Courtneidge, 2003).  Besides the 
large number of ADAMs, further complexity is added by the presence of multiple splice 
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forms of many ADAMs, including forms with alternative C-termini (Seals and 
Courtneidge, 2003). 
 
Roles of the multiple domains of ADAM proteins  
 ADAMs are made up of a N-terminal signal sequence, followed by a pro-domain, 
a metalloprotease domain, a disintegrin domain, a cysteine-rich domain, an EGF-like 
domain, a transmembrane domain, and a variable length C-terminal domain.  The pro-
domain functions to keep the metalloprotease inactive and acts as a molecular chaperone 
for proper folding of the ADAM in the secretory pathway (Seals and Courtneidge, 2003; 
Blobel, 2005).  The pro-domain of ADAMs is most likely cleaved off by furin or other 
proprotein convertases in the TGN; although some of the catalytically active ADAMs 
may undergo autocatalytic activation (Seals and Courtneidge, 2003; Blobel, 2005).   
 The metalloprotease domain of ADAMs classifies them in the metzincin subgroup 
of zinc metalloproteases, similar to the matrix metalloproteases (Seals and Courtneidge, 
2003).  However, the metalloprotease domains of only half of the ADAMs contain the 
catalytic-site consensus motif (HEXXH); those that do not contain this motif are 
predicted to be catalytically inactive (Blobel, 2005).   
 The disintegrin domain was named as such due to its homology to short soluble 
proteins in snake venom (disintegrins) that bind and inhibit platelet integrins via their 
RGD motif (Wolfsberg et al., 1995).  Only one ADAM, Adam15, has an RGD sequence; 
however, all ADAMs, except the most phylogenetically distant Adam10 and Adam17, 
have the generalized disintegrin loop sequence CRX5CDX2EXC (White, 2003).  In vitro, 
the testis-specific Adam2 and Adam3 bind such integrins as α9β1, α6β1, and α4β1 
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(White, 2003).  Catalytically active, somatically expressed Adam1,9,12,15,28 bind such 
integrins as α6β1, αvβ5, α5β1, αvβ3, and α4β1.  Catalytically inactive, somatically 
expressed Adam23 binds αvβ3.  However, it is unclear how and if any of these ADAM-
integrin interactions are important for in vivo function.  Other possible roles for the 
disintegrin domain include interactions with other proteins, substrate targeting, and pro-
domain removal (Blobel, 2005).   
 It was originally thought that the cysteine rich domain of ADAMs functions in 
cell fusion because a subset of ADAMs, Adam1,3,12,14, have a viral fusion peptide 
motif in this domain; however, this has not been shown experimentally.  Instead it is 
thought that the cysteine-rich domain plays a role in assisting or determining specificity 
of binding by the disintegrin domain (Seals and Courtneidge, 2003).  The cysteine-rich 
domain also has been shown to bind to the proteoglycan syndecan in Adam15 (White, 
2003).  Unlike the other domains, the function of the EGF-like domain is poorly 
understood (Seals and Courtneidge, 2003).  Finally, the highly variable cytoplasmic tails 
of ADAMs may be involved in inside-out regulation of metalloprotease activity, outside-
in cell signaling, regulation of ADAM expression, and in protein-protein interactions.  
Many ADAMs contain SH3-binding sites and/or serine-threonine and tyrosine kinase 
phosphorylation sites in their C-terminal tails.   
 
 Functions of ADAM family members 
 It is already clear that the ADAMs will function in multiple biological processes.  
To date, the study of ADAMs has focused mainly on the function of the testis-specific 
and testis-restricted ADAMs as adhesion molecules in fertilization and the functions of 
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the somatically expressed, catalytically active ADAMs as proteases in ectodomain 
shedding.  This latter function refers to the ability of ADAMs to act as sheddases, 
proteases which cleave proteins from the cell surface.  Shedding by ADAMs induces the 
release and activation of cytokines and growth factors and, as an opposite effect, cleaves 
and inactivates cytokine and growth factor receptors (Seals and Courtneidge, 2003).  
Other proteins may also be shed by ADAMs, as 2-4% of the cell surface proteins are 
subjected to ectodomain shedding (Blobel, 2005).   
 
Functions of the somatically expressed, catalytically active ADAMs 
 As stated, by far the most is known about the somatically expressed, catalytically 
active ADAMs, Adam1,8,9,10,12,15,17,19,28, and 33, and knockouts are available for 
all except Adam1 and Adam28 (Table 1.4, page 50).  The ADAMs will be described in 
the context of the subfamilies identified by phylogenetic analysis in Chapter 5 (Figure 
5.3, page 134). 
Adam10 and Adam17 – the distantly related ADAMs:  Multiple roles have been 
proposed for Adam10 (Seals and Courtneidge, 2003; White, 2003; Blobel, 2005), 
including in the Notch signaling pathway and as an amyloid alpha secretase.  
Furthermore, Adam10 has been proposed to be the main sheddase for EGF and 
betacellulin (Blobel, 2005), and to process prion proteins and extracellular membrane 
components (Seals and Courtneidge, 2003).  Analysis of Adam10 knockouts revealed 
multiple defects in the development of the nervous system and cardiovascular system 
with aberrant expression of Notch target genes, leading to death at embryonic day 9.5 
(Hartmann et al., 2002).  The Adam10 knockouts resemble Notch knockouts (Blobel, 
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2005) and solidify a role for Adam10 in Notch signaling.  Adam17 has also been 
proposed to play a role in many processes; for example, Adam17 has been shown to 
process and activate TNFα, heparin-binding EGF, and TGFα (Seals and Courtneidge, 
2003). On the other hand, Adam17 induces shedding of the TNF receptor, the EGFR 
family member HER4/erbB4 receptor, the IL-1 receptor, and nerve growth factor 
receptor, among others (Seals and Courtneidge, 2003).  The Adam17 knockouts, which 
die between embryonic day 16.5 and postnatal day 1, exhibit multiple defects (Peschon et 
al., 1998) and confirmed roles for Adam17 in TNFα, TNF receptor, L-selectin, and TGFα 
shedding (Peschon et al., 1998; Primakoff and Myles, 2000) and in multiple aspects of 
development (Blobel, 2005) 
Adam12, 15, 19, 33 Subfamily:  Adam12 was proposed to play a role in myogenesis, 
however, Adam12 knockouts have no pathological muscle phenotype, instead they 
exhibit low penetrance perinatal lethality and low penetrance brown adipose tissue loss 
(Kurisaki et al., 2003).  In addition, while Adam12 knockout mice do not have a defect in 
white adipose tissue on a normal diet, they show impaired adipogenesis on a high-fat diet 
leading to resistance to high fat diet induced obesity (Masaki et al., 2005).  Adam15 may 
play a role in pathological neovascularization as Adam15 knockouts have reduced 
neovascularization in the retina in response to a change in oxygen concentration, a known 
angiogenic stimulus, and decreased size of implanted tumors (Horiuchi et al., 2003).  
Adam15 in vitro has been shown to process extracellular membrane components (Seals 
and Courtneidge, 2003).  Of note, Adam15 does not appear to play a role in physiological 
or developmental angiogenesis as Adam15 knockouts have normal viability and fertility 
with no obvious phenotype (Horiuchi et al., 2003).  Adam19 is necessary for proper 
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morphogenesis of the endocardial cushion, the embryonic structure that gives rise to the 
interventricular membranous septum and the heart valves; therefore, Adam19 knockouts 
die in the perinatal period with ventricular septal defects and immature aortic and 
pulmonic valves (Zhou et al., 2004).  Adam33 has received much interest after a genome-
wide scan of 460 Caucasian families identified a locus on chromosome 20p13 that was 
linked to asthma and bronchial hyperresponsiveness.  Single nucleotide polymorphisms 
(SNPs) in Adam33, a gene in that locus, were found to be significantly associated with 
the asthma phenotype (Van Eerdewegh et al., 2002); the association of Adam33 SNPs 
with lung pathology has been confirmed in many additional studies.  However, the 
precise role of Adam33 in asthma and its normal physiological role remain to be 
determined.  Knockouts of Adam33 have recently been reported to have normal viability 
and fertility with no obvious phenotype (Blobel, 2005). 
Adam8, 28 Subfamily:  Adam8 has been implicated in variety of processes in expression 
and overexpression experiments; however the Adam8 knockout has normal viability and 
fertility with no obvious pathological phenotypes (Kelly et al., 2005).  Adam28 has been 
shown to be most highly expressed in the epididymis, like its subfamily member Adam7, 
and also in lung and leukocytes; furthermore, it has been shown to bind to the leukocyte 
integrin α4β1 (Howard et al., 2000; Bridges et al., 2002).  However, no knockout of 
Adam28 is available, thus the in vivo role of Adam28 is still unclear.  
Miscellaneous - Adam1, Adam9:  In the mouse, Adam1 is found on the sperm cell 
surface, and mediates binding of sperm to eggs (Evans et al., 1997).  No knockout of 
Adam1 is available; however, Adam2 knockouts which also lack Adam1 cell surface 
expression are infertile (see Adam2 below) (Cho et al., 1998; Seals and Courtneidge, 
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2003).  Since Adam1 is expressed in other tissues (Primakoff and Myles, 2000), these 
knockouts do not address other potential roles of Adam1.  Adam9 has been implicated in 
the shedding of heparin-binding epidermal growth factor-like growth factor (HB-EGF); 
however, Adam9 knockouts have normal HB-EGF shedding.  Adam9 knockouts also 
have normal viability and fertility with no obvious pathological phenotypes (Weskamp et 
al., 2002).   
 
Functions of the somatically expressed, catalytically inactive ADAMs 
 Little is known about the somatically expressed, catalytically inactive ADAMs, 
Adam7,11,22, and 23, although Adam22 and Adam23 knockouts are now available.  
Adam7 actually belongs to a subfamily with Adam8 and Adam28, two of the somatically 
expressed, catalytically active ADAMs, but will be described here (Table 1.4). 
Adam7 (in subfamily with Adam8 and Adam28, above):  Adam7 is expressed solely in 
the epididymis, the structure which connects the testis to the vas deferens and is 
necessary for sperm maturation, and the anterior pituitary gonadotropes; no Adam7 
expression is seen in any other tissues, including the testis (Cornwall and Hsia, 1997).  
Adam7 expression is regulated by androgens (Cornwall and Hsia, 1997), and is 
transferred to the sperm surface during the acrosome reaction (Oh et al., 2005).  These 
studies indicate a possible role for Adam7 in fertilization.   
Adam22 and Adam23 (subfamily with Adam11):  Adam22 and Adam23 are unique 
ADAMs in that they appear to be expressed only in the brain (Sagane et al., 1998), 
although caution should be noted in this statement as Adam11 was also proposed to be 
brain-specific in the Sagane study; whereas, we have shown there to be both a brain-
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specific Adam11 and a more ubiquitously-expressed Adam11 isoform (Chapter 5).  A 
definitive role for Adam22 and Adam23 in the nervous system has been established by 
the analysis of Adam22 and Adam23 knockout animals (Mitchell et al., 2001; Sagane et 
al., 2005).  Adam22 knockouts (Sagane et al., 2005) are indistinguishable from wild-type 
animals and found in expected Mendelian ratios up until postnatal day 10, suggesting 
normal embryogenesis.  However, at postnatal 10, Adam22 knockouts begin to display 
reduced weight and severe ataxia, or jerky, uncontrollable movements, leading to death 
between postnatal days 10 and 25.  This phenotype appears to be due to impaired 
differentiation of Schwann cells, leading to little or no myelination of peripheral nerves.  
The exact mechanism of this effect is unknown, although Adam22 has been shown to 
interact with the 14-3-3 intracellular signaling proteins to regulate cell adhesion and 
spreading (Zhu et al., 2003).  Similar to the Adam22 knockouts, Adam23 knockouts also 
exhibit reduced weight, severe tremors and ataxia, and death at approximately postnatal 
day 14 (Mitchell et al., 2001).  It is not known whether the phenotype of Adam23 
knockouts is associated with similar histopathological findings as Adam22 knockouts 
because a detailed analysis of the nervous systems in these animals has not been reported.  
Adam23 in vitro has been shown to regulate cell adhesion through an interaction with the 
integrin αvβ3 (Cal et al., 2000), and this may play a role in the in vivo phenotype.  
Interestingly, one of the five Caenorhabditis elegans ADAMs and the only catalytically 
inactive C. elegans ADAM, ADM-1/UNC-71, is most closely related to the 
Adam11,22,23 subfamily of ADAMs.  Worms with mutant ADM-1 exhibit an unc, or 
uncoordinated, phenotype due to the role of ADM-1 in motoneuron axon guidance 
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(Huang et al., 2003), indicating a similar or complementary role for ADM-1 and Adam22 
and Adam23 in nervous system function. 
 
Table 1.4. Knockouts and putative functions of the somatically expressed ADAMs 
 Knockout phenotype General pathways of function 
Somatically expressed, catalytically active 
 ADAM10 Embryonic lethal, e9.5 
Multiple defects in nervous and 
cardiovascular system 
 
Development of nervous and cardiovascular 
systems; Notch pathway 
 ADAM17 Lethal between e16.5 and postnatal day 1 
Multiple defects including defective lung 
and cardiac development 
Development of lung and cardiovascular 
systems; Growth factor, cytokine ligand and 
receptor shedding. 
    
 ADAM12 Low penetrance perinatal lethality 
Brown adipose defect; resistance to high-
fat diet induced obesity  
 
Adipogenesis in response to high-fat diet 
 ADAM15 Normal viability 
Reduced neovascularization in 
pathological models 
 
Pathological neovascularization 
 ADAM19 Perinatal lethality 
Cardiac septal and valve defects 
 
Development of cardiovascular system 
(morphogenesis of endocardial cushion) 
 ADAM33 Normal viability and fertility 
No obvious phenotypes 
Asthma and bronchial hyperresponsiveness 
(from analysis of human polymorphisms) 
    
 ADAM8 Normal viability and fertility 
No obvious phenotypes 
 
Unknown 
 ADAM28 None available Unknown 
    
 ADAM1 None available Expressed on sperm, role in fertility 
    
 ADAM9 Normal viability and fertility 
No obvious phenotypes 
Unknown 
    
Somatically expressed, catalytically inactive 
 ADAM7 None available Restricted expressed to epididymis, possible 
role in fertility 
    
 ADAM11 None available 
 
Unknown 
 ADAM22 Postnatal lethality, ataxia and tremors Nervous system; necessary for Schwann cell 
function (myelination) 
 
 ADAM23 Postnatal lethality, ataxia and tremors Nervous system 
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Functions of the testis-specific ADAMs 
 Eight of the 19 testis-specific ADAMs are catalytically inactive, Adam2,3,4,5,6, 
18,29,32; and eleven are catalytically active, Adam21,24,25,26,30,34,36,37,38,38,40 
(Table 1.5, page 52).  Outside of Adam2 (aka fertilin beta) and Adam3 (aka cyritestin), 
nothing outside of testis-restricted expression is known about these ADAM proteins. In 
contrast, much is known about Adam2 and Adam3, the only Adams of this class for 
which mouse knockouts are available.  Both Adam2 (Cho et al., 1998) and Adam3 
(Shamsadin et al., 1999) knockout males are infertile when mated to mutant or wild-type 
females; whereas mutant females have normal fertility when mated to wild-type males.  
Of note, sperm from Adam2 knockout animals also lack Adam1 expression, indicating 
that the fertility phenotype may be due to the loss of both proteins.  In any case, Adam2 
deficient sperm are present in normal numbers, have normal motility, and undergo 
normal acrosome reaction and activation; however the sperm are unable to bind to eggs 
with or without a zona pellucida and hence are unable to induce fertilization (Cho et al., 
1998).  Furthermore, in vivo, Adam2 deficient sperm are defective in migration into the 
fallopian tubes.  Adam3 deficient sperm are also present in normal numbers, have normal 
motility, and undergo normal acrosome reaction and activation, and Adam3 deficient 
sperm are also unable to bind to eggs with a zona pellucida (Shamsadin et al., 1999),  
However, in contrast to Adam2 deficient sperm, Adam3 deficient sperm can bind and 
induce fertilization of eggs without a zona pellucida and are not defective in uterine 
migration, indicating that Adam2 and Adam3 play separate, but critical, roles in sperm 
function.   
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Table 1.5. Knockouts and putative functions of the testis-specific ADAMs 
 Knockout phenotype General pathways of function 
Testis-specific, catalytically inactive 
ADAM2 Normal viability 
Male infertility 
Fertility; sperm-egg binding and motility in 
fallopian tubes 
 
ADAM3 Normal viability 
Male infertility 
 
Fertility; sperm-egg binding 
 
ADAMs4-6,18,29,32:  No KO available                              Functions unknown 
   
Testis-specific, catalytically inactive 
ADAMs21,24-26, 30, 34, 36-40:  No KO available             Functions unknown 
 
 
 
Perspective 
 While much is known about the regulation of plasma and liver cholesterol levels 
through extensive study of the LDLR pathway and the SREBP and LXR transcription 
factor networks, many more genes are likely to play important roles in these processes.  
This thesis describes efforts to identify novel genes through microarray technology and 
the subsequent characterization and functional analysis of two genes:  Pcsk9, a member 
of the proprotein convertase subtilisin kexin family and Adam11, a member of the a 
disintegrin and metalloprotease family.  The bulk of data presented focuses on the 
characterization of Pcsk9 and its role in regulation of LDLR levels. 
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CHAPTER 2:  MICROARRAY ANALYSIS OF LIVERS FROM CHOLESTEROL 
FED MICE IDENTIFIES NOVEL GENES IN CHOLESTEROL METABOLISM 
 
The dietary cholesterol feeding paradigm in mice and use of liver as a model system 
 In order to identify novel genes in cholesterol metabolism, we chose to use 
oligonucleotide microarray analysis of livers from the cholesterol fed mouse.  We fed six-
week old male and female C57BL/6 mice a semi-synthetic modified AIN76A diet, the 
Clinton/Cybulsky Rodent Diet with 10kcal% fat (Lichtman et al., 1999) and 0.0% 
cholesterol for one week.  After this period, mice were fed either the 0.0% cholesterol 
diet or the same semi-synthetic diet supplemented with 0.5% cholesterol for an additional 
week.  This feeding paradigm did not significantly raise plasma total, HDL or non-HDL 
cholesterol levels in males or females (Figure 2.1A, 2.1B, and 2.1C, respectively).  
Figure 2.1.  The dietary cholesterol feeding paradigm did not significantly change plasma 
cholesterol levels.  Male and female C57Bl/6 mice (n = 5 per group) were fed a semisynthetic
diet with 0.0% cholesterol (0.0%C, blue bars) or supplemented with 0.5% cholesterol 0.5%C, 
yellow bars) for seven days.  The feeding paradigm did not change the levels of plasma total (A), 
HDL (B), or non-HDL (C) cholesterol.
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In contrast, the feeding paradigm significantly raised the levels of total, free and 
esterified cholesterol in the liver in both sexes (Figure 2.2A, 2.2B and 2.2C, 
respectively).  Males increased liver total cholesterol, free cholesterol and cholesterol 
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ester by 4.4-fold, 1.2-fold, and 15.2-fold, respectively, and females increased 6.0-fold, 
1.8-fold, and 10.3 fold, respectively.  Therefore, despite no effect on plasma cholesterol 
levels, this feeding paradigm allowed a study of the effect of dietary cholesterol on liver 
gene expression.   
Figure 2.2.  The dietary cholesterol feeding paradigm did significantly raise hepatic 
cholesterol levels.  Male and female C57Bl/6 mice (n = 5 per group) were fed a semisynthetic
diet with 0.0% cholesterol (0.0%C, blue bars) or supplemented with 0.5% cholesterol (0.5%C, 
yellow bars) for seven days.  The feeding paradigm significantly increased the levels of hepatic 
total (A), free (B), and esterified (C) cholesterol.  # p<0.01; * p<0.001.
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Affymetrix oligonucleotide microarrays and data analysis 
 Previous studies in our laboratory using the above dietary cholesterol feeding 
paradigm were performed by Raymond Soccio using cDNA microarrays representing 
~6000 Unigene clusters (The Unigene database organizes expressed sequence tags, or 
ESTs and deposited mRNA sequences into contigs, and thus represents known and 
unknown genes).  These studies identified five known SREBP-target genes involved in 
cholesterol or fatty acid biosynthesis and one novel gene down-regulated by dietary 
cholesterol (Soccio et al., 2002).  To extend these studies with higher density 
microarrays, we fed mice according to the dietary cholesterol feeding paradigm and 
obtained liver RNA to probe the Affymetrix oligonucleotide microarray three-chip 
MGU74v2 set, which represents over 23,000 unique Unigene clusters.  Three 
 55
experiments were performed.  RNA was pooled from three male mice per diet in 
experiment 1 and separately from five male and five female mice per diet in experiment 
2.  For each of these pools two aliquots of RNA were studied.  In experiment 3, RNA 
from four individual male and four individual female mice per diet were studied 
separately.   
Microarray data from all three experiments were first analyzed with the 
Affymetrix Microarray Suite software (MAS5.0) as described in the Methods, to obtain 
pair-wise comparisons between low cholesterol fed and high cholesterol fed chips.  Four 
pair-wise comparisons were performed for the replicate pooled samples in experiments 1 
and 2, and 16 pair-wise comparisons were performed for the individual samples in 
experiment 3.  Genes were retained with signal values on at least one condition greater 
than 250, fold greater than |1.6|, and denoted changed by MAS5.0 on at least 75% of pair-
wise comparisons.  This analysis yielded 39, 45 and 50 down-regulated probe sets and 
28, 66, and 38 up-regulated probe sets in males in experiments 1, 2 and 3, respectively.  
This analysis yielded 32 and 39 down-regulated probe sets and 16 and 25 up-regulated 
probe sets in females in experiments 2 and 3, respectively (Table 2.1). 
 The design of experiment 3 allowed a statistical analysis of the microarray results.  
Using an ANOVA statistical analysis software package designed by Rimma Belenkya at 
the Rogosin Institute (Pavlidis and Noble, 2001), genes were determined to be 
significantly regulated by the 0.5% cholesterol diet if the signals in at least one group 
were greater than 250, fold greater than |1.6| and with an ANOVA p value<0.001.  Genes 
were also kept in the analysis if the ANOVA p value in experiment 3 was between 0.01 
and 0.001 and they also met the criteria for MAS5.0 comparison analysis in experiments 
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1 or 2.  This more stringent analysis yielded 48 down-regulated probe sets and 32 up-
regulated probe sets that showed regulation by dietary cholesterol in males and/or 
females. (Table 2.1). 
Table 2.1  Summary of Microarray experiments 
 
 
 
 
 
 
 
 
 
 
 
 
a Number of probe sets identified by MAS5.0 software for individual experiments or number  
identified in the combined analysis using the ANOVA software and MAS5.0.
  # Probe Setsa 
Experiment Design Decreased Increased 
Experiment 1 Males Pooled, 3 mice per group 39 28 
Experiment 2 Males Pooled, 5 mice per group 45 66 
Experiment 3 Males Individuals, 4 mice per group 50 38 
Experiment 2 Females  Pooled, 5 mice per group 32 16 
Experiment 3 Females Individuals, 4 mice per group 39 25 
   
Combined Statistical and 
MAS Analysis 
n/a 48 32 
 
Table 2.2 shows the 48 probe sets representing 37 Unigene clusters down-
regulated by dietary cholesterol, and Table 2.3 shows the 32 probe sets representing 32 
Unigene clusters up-regulated by dietary cholesterol in this study.  The tables also show 
p-values for experiment 3 as derived from the ANOVA analysis and the average folds for 
all pair-wise comparisons from each experiment as derived from the MAS5.0 software.  
The cholesterol regulated genes were clustered according to categories specified by 
Affymetrix.  
 
Genes down-regulated by dietary cholesterol 
 Among the 37 genes down-regulated by dietary cholesterol (Table 2.2), 19 were 
classified in cholesterol metabolism, fatty acid metabolism, or the metabolism of other 
lipids.  Many genes involved in lipid metabolism are regulated by the SREBP 
transcription factors when cellular sterols are low; therefore, dietary cholesterol feeding  
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Table 2.2  Genes down-regulated by a one-week high cholesterol diet 
MALES FEMALES 
MAS Fold Anova MAS Fold Anova 
NetAffx ID Gene name Ex.1,.2,.3 p-value Ex.2,3 p-value
LXR 
Agonist 
Arrayc 
Cholesterol Metabolism 
97518_at farnesyl diphosphate farnesyl transferase 1 a 
-1.7,-1.5,-2.0 4.3e-3  -1.6,-1.4 3.5e-4  NC 
99098_at farnesyl diphosphate synthetase a 
-5.1,-4.8,-8.7 1.2e-4  -3.9,-6.9 1.3e-4  NC 
160424_f_at farnesyl diphosphate synthetase a 
-3.8,-3.4,-6.3 9.5e-4  -2.9,-4.9 6.8e-4  NC 
94325_at HMG CoA synthase a 
-2.7,-2.4,-4.4 8.2e-3  -2.5,-1.6 4.1e-2  NC 
93868_at NAD(P) dependent steroid dehydrogenase-like b 
-3.3,-2.9,-5.1 6.4e-4  -2.5,-3.0 3.0e-3  NC 
98630_at NAD(P) dependent steroid dehydrogenase-like b 
-2.3,-1.7,-2.6 9.3e-5  -1.6,-1.8 4.7e-3  NC 
98631_g_at NAD(P) dependent steroid dehydrogenase-like b 
-2.2,-2.5,-4.5 7.1e-5  -2.2,-2.8 1.3e-2  NC 
105991_at NAD(P) dependent steroid dehydrogenase-like b 
-5.1,-8.3,-5.7 1.8e-4  -2.2,-3.9 1.9e-3  abs 
168360_f_at NAD(P) dependent steroid dehydrogenase-like b 
-2.6,-3.5,-4.1 5.7e-4  -2.5,-3.9 9.4e-4  n.d. 
111380_at phosphomevalonate kinase related a 
-2.1,-2.1,-4.1 2.3e-3  -2.2,-3.1 4.6e-3  NC 
167266_f_at phosphomevalonate kinase related a 
-1.7,-2.1,-2.7 1.9e-4  -2.1,-2.4 7.6e-4  n.d. 
96269_at isopentenyl-diphosphate delta isomerase a 
-4.1,-4.7,-6.6 1.1e-3  -4.8,-7.0 2.9e-3  NC 
164172_at isopentenyl-diphosphate delta-isomerase a 
-2.5,-2.7,-3.5 4.9e-4  -3.1,-3.2 1.3e-3  NC 
94322_at squalene epoxidase a 
-3.5,-2.3,-4.5 7.6e-3  -2.1,-3.5 1.1e-3  NC 
160388_at sterol-C4-methyl oxidase-like b 
-3.0,-3.0,-3.8 2.6e-3  -3.1,-2.9 8.0e-3  NC 
102768_i_at sterol-C5-desaturase b 
-1.9,-1.9,-2.2 6.5e-3  -1.7,-1.2 5.2r-2  NC 
102769_f_at sterol-C5-desaturase b -1.9,-2.2,-2.4 3.6e-4  -1.7,-1.3 8.2e-2  NC 
Fatty acid metabolism 
106070_at acetyl-Coenzyme A synthetase 2, ADP forming a 
-2.4,-2.3,-4.9 3.9e-3  -2.5,-2.2 1.4e-2  2.7 
97248_at diazepam binding inhibitor, acyl-CoA binding protein a 
-1.0,-1.3,-1.4 1.5e-3  -1.2,-1.9 8.8e-5  1.6 
160544_at fatty acid binding protein 5, epidermal 
-2.8,-1.6,-2.8 7.1e-4  -1.9,-2.6 1.0e-1  2.9 
101082_at malic enzyme a 
-1.2,-1.5,-3.0 3.2e-4  -1.8,-1.4 2.1e-2  4.8 
160391_at fatty acid (delta-5) desaturase a 
-1.5,-1.5,-2.3 1.8e-4  -1.5,-1.7 1.6e-3  NC 
Other lipid metabolism (or hypothesized role) 
99592_f_at Short chain aldehyde reductase (SCALD) b 
-1.6,-1.5,-2.1 2.1e-4  -1.7,-1.5 2.7e-3  NC 
100927_at phospholipid transfer protein 
-2.0,-1.0,-1.6 8.1e-3  -2.7,-2.2 2.5e-3  1.9 
139034_at RIKEN cDNA 1110033E03 (CTPCT related) a 
-0.5,-1.2,-1.7 5.7e-3  -1.1,-1.6 1.1e-1  n.d. 
169465_s_at transmembrane 7 superfamily member 2, lamin-B receptor  b 
-2.0,-2.4,-2.6 3.0e-4  -1.8,-3.2 1.1e-4  n.d. 
92437_at transmembrane 7 superfamily member 2, lamin-B receptor  b 
-2.0,-1.6,-1.8 1.4e-3  -1.5,-2.2 5.7e-4  NC 
113753_at StAR-related lipid transfer (START) domain containing 4 b 
-1.4,-1.5,-2.1 1.9e-3  -2.3,-2.2 2.2e-3  NC 
116072_at StAR-related lipid transfer (START) domain containing 4 b 
-1.5,-1.7,-2.2 4.8e-5  -1.8,-2.6 8.4e-4  NC 
Miscellaneous 
102200_at aquaporin 8 
-1.5,-1.2,-1.8 8.0e-3  -1.4,-1.4 5.5e-2  NC 
97334_at hairy and enhancer of split 6 b 
-1.0,-1.2,-1.2 9.9e-2  -1.3,-1.6 3.9e-4  NC 
138949_at heat shock 27kD protein 3 
-1.1,-1.3,-1.0 8.3e-1  -1.5,-2.3 2.9e-3  n.d. 
94378_at regulator of G-protein signaling 16 
-1.4,-1.9,-2.4 2.7e-3  -1.4,-1.6 1.4e-2  -2.8 
161609_at regulator of G-protein signaling 16 
-1.5,-2.0,-2.2 2.6e-3  -1.4,-1.4 7.6e-2  -1.8 
100758_at ribosomal protein S28 
-1.1,-0.9,-1.1 2.2e-1  -0.9,-1.6 1.6e-5  NC 
102098_at RIKEN cDNA 2410038A03 (ribosomal protein L44 related) 
-1.1,-1.0,-1.2 8.0e-2  -0.9,-1.6 1.9e-4  NC 
99115_at ubiquinol cytochrome c reductase hinge protein 
-1.1,-1.1,-1.2 1.8e-1  -0.9,-1.6 4.4e-4  NC 
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104072_at serum amyloid P-component 
-1.9,-2.4,-1.8 6.1e-4  -1.1,-1.4 1.3e-1  NC 
114299_at t-complex testis expressed 1 
-1.0,-1.4,-1.1 2.3e-1  -0.9,-1.7 1.8e-4  NC 
111819_at ubiquitously expressed transcript 
-0.9,-0.9,-1.1 5.5e-1  -0.7,-1.6 3.4e-5  NC 
Unclassified 
95749_at arginine-rich, mutated in early stage tumors 
-1.5,-1.5,-1.1 5.9e-1  -0.8,-1.7 9.1e-4  NC 
137560_at ESTs 
-0.9,-1.3,-1.6 3.7e-4  -1.2,-1.3 2.0e-1  n.d. 
131854_at ESTs, Weakly similar to NED4_MOUSE  
-1.7,-1.5,-1.5 6.9e-5   -1.0,-1.4 9.6e-4  n.d. 
108752_at expressed sequence AI747682 (Pcsk9) b 
-1.3,-1.8,-2.1 1.2e-3  -1.9,-1.9 1.1e-3  1.7 
109426_at liver-expressed antimicrobial peptide 2 
-1.0,-1.5,-1.3 3.4e-1  -0.9,-1.9 1.1e-4  NC 
168386_f_at RIKEN cDNA 1810044O22 (cytochrome B5 related) b 
-1.0,-1.8,-1.6 1.9e-3  -1.0,-1.3 1.6e-1  n.d. 
99854_at sulfotransferase-related protein SULT-X2 
-0.8,-0.7,-1.5 4.6e-1  -2.0,-2.8 7.0e-3  abs 
163290_at UI-1-CF0-apo-c-08-0-UI.s1 Mus musculus cDNA (Camk1d)
-1.7,-1.7,-2.0 3.0e-3  -1.4,-1.3 8.7e-3  NC 
a Published regulation by SREBP transcription factors at the time of the study  
b Published regulation by SREBP transcription factors at present 
c For the LXR agonist array NC refers to fold < |1.6|, n.d. refers to genes on C chip of MGU74v2 set, and abs refers to genes called 
absent 
 
should decrease the transcription of target genes.  At the time of original analysis, eleven 
of the 37 cholesterol down-regulated genes had previously been shown to be SREBP 
targets (Table 2.2, marked by superscript a), demonstrating the validity of the system to 
identify genes involved in cholesterol metabolism.  Farnesyl diphosphate farnesyl 
transferase, farnesyl diphosphate synthetase, HMG CoA synthase (Hmgcs), 
phosphomevalonate kinase, isopentenyl diphosphate delta isomerase, and squalene 
epoxidase (Sqle) are genes in the cholesterol biosynthetic pathway (Wang et al., 1994; 
Jackson et al., 1996; Tansey and Shechter, 2000; Sakakura et al., 2001).  Malic enzyme 
and acetyl-CoA synthetase are involved in fatty acid synthesis (Shimomura et al., 1998; 
Luong et al., 2000).  Acyl-CoA binding protein is implicated in acyl-CoA transport and 
steroidogenesis (Swinnen et al., 1998).  Fatty acid (delta-5) desaturase is necessary for 
the conversion of dietary linoleic acid (Ω3 series) and α-linolenic acid (Ω6 series) to the 
biologically active arachidonic acid (AA), eicosopentenoic acid (EPA) and 
docosahexaenoic acid (DHA) (Matsuzaka et al., 2002).  CTP-choline phosphate 
cytidyltransferase (CTPCT) is involved in phosphatidylcholine biosynthesis (Kast et al., 
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2001).  The other eight genes in the metabolism categories as well as the remaining 18 
genes in the miscellaneous and unclassified categories were not previously known 
cholesterol-regulated or SREBP targets.   
These 26 genes fall into four categories.  First, there are genes with an established 
role in cholesterol or fatty acid metabolism that had not yet been shown to be SREBP 
targets at the time of the original analysis, but have since been shown to be SREBP 
targets (Table 2.2, marked by superscript b).  NAD(P)-dependent steroid dehydrogenase, 
sterol C4 methyl oxidase, Sterol C5 desaturase, and the lamin B receptor (C14 sterol 
reductase, TM7SF2) are all enzymes in post-lanosterol cholesterol biosynthesis (Holmer 
et al., 1998; Moebius et al., 2000).  These genes were later shown to be SREBP target 
genes in a microarray study of SREBP transgenic mice (Horton et al., 2003).  
Cytochrome B5-related is necessary for the function of sterol C4 methyl oxidase  
(Fukushima et al., 1981); this gene has also since been shown to be an SREBP target 
(Horton et al., 2003).  Short chain aldehyde reductase (SCALD)/retinol dehydrogenase 
11, has been proposed to reduce fatty aldehydes that may result from oxidiation of 
unsaturated fatty acids and has since been shown to be a SREBP target gene (Horton et 
al., 2003; Kasus-Jacobi et al., 2003).  StAR-related lipid transfer (START) domain 
containing 4 (StarD4) has been proposed to play a role in intracellular cholesterol 
transport and has since been shown to be an SREBP target gene (Horton et al., 2003; 
Soccio et al., 2005).  The second category of genes are those with an established role in 
cholesterol or fatty acid metabolism but have not yet shown to be SREBP targets.  
Phospholipid transfer protein (PLTP) shuttles phospholipids to HDL particles (Repa and 
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Mangelsdorf, 2002).  Fatty acid binding protein 5 (Fabp5) can bind long chain fatty acids 
but its function is unknown (Kane et al., 1996; Hertzel and Bernlohr, 2000). 
In the third category of non-SREBP target, cholesterol down-regulated genes are 
genes that have been cloned and possibly some function ascribed but had not been shown 
definitively to play a role in cholesterol or fatty acid metabolism at the time of the study.  
Hairy and enhancer of split 6 (Hes6) is a helix-loop-helix transcription factor whose 
function is unknown; this gene has since been shown to be a SREBP target gene (Horton 
et al., 2003).   Aquaporin-8 is a MIP transmembrane domain protein expressed on bile 
canalicular membranes in the liver and may play a role in bile secretion (Ma and 
Verkman, 1999; Huebert et al., 2002); however, this gene has not been shown to be an 
SREBP target.  Serum amyloid P component (Apcs) is an acute phase reactant (de Haas, 
1999) that associates with HDL and VLDL and is found in atherosclerotic lesions (Li et 
al., 1995; Li et al., 1998); this gene has not been shown to be an SREBP target .  
Regulator of G protein signaling 16 (Rgs16) is a GTPase activating protein that 
attenuates heterotrimeric G-protein signaling, specifically the Gα13 pathway (Chen et al., 
1997; Johnson et al., 2003).  Ubiquitously expressed transcript (Uxt), has a potential 
transcription factor domain, however no function is known.  Other genes in this category 
include Hspb3, Leap-2, and Sult3a1.  Finally, the fourth set of genes is those that are 
completely novel genes predicted by the Celera database and/or correspond to full-length 
cDNA clones in Unigene.  Two of these genes will be discussed later, Camk1d (Chapter 
2) and particularly Pcsk9 (Chapters 3 and 4). 
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Genes up-regulated by dietary cholesterol 
 Among the 32 genes up-regulated by dietary cholesterol (Table 2.3), 13 genes 
were classified in metabolism.  Many genes involved in lipid metabolism are regulated by 
LXR transcription factors which activate gene transcription when bound to their 
oxysterol ligands.  These ligands are derived intracellularly from cholesterol; therefore, 
dietary cholesterol should up-regulate the expression of LXR target genes.  At the time of 
the original analysis, two of the up-regulated genes had previously been shown to be 
LXR targets (Table 2.3, marked by superscript a).  Abcg5 is involved in sterol transport 
in the intestine and liver (Repa et al., 2002).  Abca1 mediates cholesterol efflux and its 
mRNA is highly regulated by LXR in the macrophage (Costet et al., 2000).  Although in 
one previous study, liver Abca1 mRNA levels were not increased by an LXR agonist 
(Repa et al., 2000b), another study showed increased liver protein levels in mice fed a 
high-fat/high-cholesterol diet (Wellington et al., 2002).  In the current study, liver Abca1 
mRNA levels were increased by dietary cholesterol only in females.  The other 11 genes 
in the metabolism category and the remaining 19 genes in the other categories (seven in 
immune/acute phase response, two transcription factors, and ten unclassified) were not 
previously known LXR targets.  
 These 30 genes fall into three categories.  First, there are genes with a potential 
role in lipid metabolism that had not yet been shown to be LXR targets at the time of the 
original analysis, but have since been shown to be LXR targets (Table 2.3, marked by 
superscript b).  Cyp3a11 and Cyp3a16 are involved in the elimination of the secondary 
bile acid lithocholic acid (LCA) (Makishima et al., 2002).  Cytosolic acyl-CoA 
thioesterase 1 (Cte1) catalyzes hydrolysis of various length acyl-CoAs to free fatty acids  
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Table 2.3  Genes up-regulated by a one-week high cholesterol diet 
MALES FEMALES 
MAS Fold Anova MAS Fold Anova 
NetAffx ID Gene name Ex1.,2,3 p-value Ex.2,3 p-value 
LXR 
Agonist 
Arrayc 
Metabolism        
94354_at ATP-binding cassette, sub-family A, member 1 a 1.3,1.1,1.3 5.2e-2  1.3,1.6 1.7e-4  2.3 
114831_at ATP-binding cassette, sub-family G, member 5 a 1.9,2.5,2.2 9.4e-3  1.8,1.6 1.4e-2  2.1 
101638_s_at cytochrome P450, 3a16 b 1.5,3.4,3.1 3.0e-5  1.4,1.5 1.1e-4  2.3 
93770_at cytochrome P450, steroid inducible 3a11 b 1.4,2.7,2.6 2.8e-5  1.3,1.2 1.4e-4  1.8 
103581_at cytosolic acyl-CoA thioesterase 1 b 3.6,1.6,2.3 2.9e-3  1.0,1.1 4.9e-1  4.0 
160074_at dopa decarboxylase 1.4,1.6,1.5 8.1e-2  1.7,1.6 3.7e-3  1.7 
97317_at ectonucleotide pyrophosphatase/phosphodiesterase 2 1.2,1.2,1.3 1.1e-2  1.2,1.6 1.6e-4  NC 
101587_at epoxide hydrolase 1, microsomal b 1.4,2.0,2.0 3.5e-4  1.4,1.6 1.1e-2  1.9 
112669_at EST AI266984 (esterase related) 1.6,1.5,1.6 3.6e-4  1.6,1.4 8.9e-3  5.0 
168829_r_at START domain containing 7 0.5,1.0,1.0 2.9e-1  3.2,4.9 7.9e-4  n.d. 
100611_at lysozyme 0.9,1.9,2.0 1.6e-4  0.9,1.9 5.8e-3  abs 
101753_s_at P lysozyme structural 1.0,2.2,2.3 7.3e-5  0.9,1.7 2.2e-3  abs 
99571_at peroxisomal 3-oxoacyl-CoA thiolase b 1.5,1.5,1.7 2.8e-4  1.1,1.1 1.5e-1  3.6 
Immune/acute phase response          
92223_at complement component 1, q subcomponent, c polypeptide 1.0,1.4,1.6 1.4e-4  1.0,1.2 3.7e-2  NC 
94285_at histocompatibility 2, class II antigen E beta 1.0,1.7,1.7 3.6e-4  1.1,1.3 6.2e-3  NC 
94734_at orosomucoid 2 1.3,0.9,2.2 1.0e-2  1.9,2.2 2.2e-3  abs 
100333_at serum amyloid A 1 1.2,0.3,2.2 5.5e-3  1.6,1.7 1.2e-2  NC 
103465_f_at serum amyloid A 2 1.4,0.2,3.6 1.2e-2  2.9,3.2 2.7e-3  NC 
102712_at serum amyloid A 3 2.9,1.4,8.9 5.6e-3  2.1,3.7 2.0e-2  abs 
114603_at serum amyloid A 4 1.1,0.7,1.6 7.4e-4  1.7,1.2 2.8e-1  -2.5 
Transcription factors          
170720_r_at myeloid ecotropic viral integration site 1 2.1,1.3,1.4 1.1e-3  0.9,1.2 8.3e-1  n.d. 
140898_at zinc finger protein, multitype 2 1.4,2.2,1.9 5.9e-4  0.4,1.0 6.0e-1  n.d. 
Unclassified           
93445_at apoptosis inhibitor 6 b 1.0,1.7,1.7 6.5e-2  1.2,1.9 2.8e-4  1.7 
116554_at EST AW060611 (Adam11) b 7.1,5.4,5.0 9.5e-3  4.4,7.8 6.1e-7  12.8 
164261_at ESTs 2.1,1.4,2.2 2.5e-3  1.0,1.1 6.2e-1  4.7 
133804_at ESTs 1.1,1.7,1.7 1.2e-3  1.4,1.7 1.1e-2  n.d. 
103379_at f-box only protein 3 1.1,1.2,1.3 1.2e-1  1.1,1.7 4.8e-4  1.6 
129871_at ESTs 0.7,1.7,1.9 5.0e-4  2.3,1.1 9.9e-1  n.d. 
101872_at glutathione S-transferase, alpha 2, Yc2 1.6,2.9,1.8 5.4e-3  1.7,1.9 7.9e-2  1.6 
100012_at lysosomal-associated protein transmembrane 5 0.9,1.5,1.9 5.7e-4  1.6,1.2 1.7e-1  abs 
99071_at macrophage expressed gene 1 b 1.0,1.5,1.6 6.7e-3  1.1,1.7 7.1e-4  1.6 
96271_at RIKEN cDNA 2310075C12 gene 1.1,1.1,1.2 7.4e-2  1.2,1.6 1.3e-4  NC 
a Published regulation by LXR transcription factors at the time of the study  
b Published regulation by LXR transcription factors at present 
c For the LXR agonist array NC refers to fold < |1.6|, n.d. refers to genes on C chip of MGU74v2 set, and abs refers to genes called 
absent 
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(Hunt et al., 1999).  Microsomal epoxide hydrolase 1 (Ephx1) meditates bile acid uptake 
into the liver (von Dippe et al., 1996).  Peroxisomal 3-ketoacyl-CoA thiolase is an 
enzyme involved in peroxisomal beta oxidation of very long chain fatty acids (Reddy and 
Hashimoto, 2001).  All five of these genes were shown to be up-regulated by LXR 
agonists in the liver in our studies (below) and by Stulnig (Stulnig et al., 2002).  Second 
are genes with a potential role in lipid metabolism that have not yet been shown to be 
LXR targets.  The serum amyloid A (SAA) genes are apolipoproteins; SAA1-3 are acute 
phase reactants and SAA4 is constitutive.  These genes can transport cholesterol into 
HepG2 cells  (Liang et al., 1996), have been shown to be expressed in atherosclerotic 
lesions (Lewis et al., 2004), and interfere with the action of the HDL receptor, SRBI (Cai 
et al., 2005); however they have not been shown to be LXR target genes.   
Third are genes that have been cloned, possibly with a function ascribed, but had 
not been shown to play a role in lipid metabolism at the time of the original study.  An 
intriguing example is apotosis inhibitory 6 (Api6)/Spalpha/AIM, a member of the group 
B scavenger receptor family (Gebe et al., 2000), which includes SRBI, a protein that 
functions in reverse cholesterol transport.  Api6 was shown to be up-regulated by LXR 
agonists in the liver in our studies (below) and in two other studies (Stulnig et al., 2002; 
Joseph et al., 2004).  Api6 has been shown to contribute to atherosclerosis development 
(Arai et al., 2005) via inhibition of macrophage apoptosis (Joseph et al., 2004).  This 
category of genes also include a number of other immune related genes, two transcription 
factors, Meis1 and Fog-2, and genes for which no function was ascribed at the time of the 
original study, such as F-box only protein 3 (Fbx3), a member of the F-box protein 
family, Lysosomal-associated protein transmembrane 5 (Laptm5), macrophage expressed 
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gene 1 (Mpeg1/Mps1), and a disintegrin and metalloprotease domain 11 (Adam11).  
Mpeg1 and Adam11 were shown to be up-regulated by LXR agonists in the liver in our 
studies (below) and by Stulnig (Stulnig et al., 2002).  Adam11 will be discussed in 
Chapter 5.  The fourth category of genes includes ESTs for which no gene has been 
cloned. 
 
Confirmation of regulation by RT-PCR analysis for selected array genes 
 Microarray studies involve determining the expression levels of tens of thousands 
of genes within one experiment and can identify false positives; therefore, it is crucial to 
confirm the regulation of genes of interest by an independent method.  We chose to 
confirm genes that fit with the initial goal of the microarray experiment which was to 
identify novel genes with previously unknown roles in cholesterol metabolism and 
determine their function.  We decided that genes that appeared to be highly regulated 
and/or possessed interesting domains suggestive of function would fit our criteria.  As a 
control, we also confirmed the regulation of known SREBP and LXR targets.  For the 
confirmation experiments, we used quantitative RT-PCR (Q-PCR), a method which 
allows relatively rapid screening of multiple samples; Northern blotting was also used in 
certain cases.  The results are shown as fold changes on Q-PCR and listed next to the fold 
changes for microarray experiment 3 (Tables 2.4, 2.5). 
For the down-regulated genes (Table 2.4), this analysis was performed for two 
known SREBP-1 target genes, Acetyl CoA carboxylase (Acac) and ATP citrate lyase 
(Acly); three known SREBP-2 target genes, HMG CoA reductase (Hmgcr), Hmgcs, and 
Sqle, and and six other genes.  Acly, Acac and Hmgcr were decreased on the experiment 
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3 microarray; however, they were not on the final list of genes as they did not reach the 
statistical significance cutoff.  In the Q-PCR experiments, Acac was down-regulated 2.3-
fold in males only, and Acly was down-regulated 2.9-fold in males only.  Hmgcr was 
down-regulated 7.9-fold in males only, Hmgcs was down-regulated 4.5- and 2.3-fold in 
males and females, respectively, and Sqle was down-regulated 38.6- and 27.8-fold in 
males and females, respectively.  
 Confirmation experiments were also performed for six genes not known to be 
SREBP targets at the time of the original study: four of which had been previously 
cloned, Fabp5, Rgs16, StarD4, and Uxt; and two novel genes (Table 2.4).  Fabp5 was 
down-regulated 6.0- and 3.1-fold in males and females, respectively.  Rgs16 was down-
regulated 1.8-fold in males and less than 1.6 fold in females, yet this did not reach 
significance in either case.  StAR related lipid transfer domain containing 4 (StarD4) has 
previously been shown by Q-PCR analysis to be down-regulated by dietary cholesterol in 
females (Soccio et al., 2002).  This was confirmed in the current study for males in which 
there was 2.3-fold down-regulation.  Ubiquitously expressed transcript (Uxt) was not 
significantly regulated in males and females.   
The other two down-regulated genes that were subjected to confirmation were 
initially probe sets corresponding to expressed sequence tags (ESTs) that had not been 
cloned; these are probe sets 108752 and 163290.  The cloning of the gene corresponding 
to probe set 108752, which was named Pcsk9, will be described in Chapter 3.  In this 
confirmation study, Pcsk9 was down-regulated 6.5- and 8.6-fold in males and females, 
respectively (Table 2.4).  The cloning of probe set 163290 will be described here.  The 
location of probe set 163290 in the mouse genome was determined by BLAST analysis to 
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the Celera draft of the mouse genome.  The probe set was identical to sequences in the 
3’untranslated region (utr) of a predicted incomplete gene with homology to the 
calcium/calmodulin-dependent protein kinase family.  Based on homology and gene 
predictions, the coding region and 5’utr were cloned by RT-PCR and 5’rapid 
amplification of cDNA ends (RACE), respectively.  The cloned cDNA was determined to 
be the orthologue of a recently cloned cDNA from human leukocytes (Verploegen et al., 
2000) and was named calcium/calmodulin-dependent protein kinase 1d (Camk1d) 
(GenBank Accession Number: AY273822).  This gene is a member of the calcium 
calmodulin dependent protein kinase family and is most closely related to CaMKI.  
Camk1d was down-regulated 2.2-fold in males only (Table 2.4).   
Table 2.4.  Confirmation of selected down-regulated genes by Q-PCR 
     MALES FEMALES 
Category NetAffx ID Gene name Array (Ex3) Taqman Array (Ex3) Taqman 
SREBP-1 110755_at Acaca -1.9* -2.3* NC NC 
 160207_at Aclya -1.9* -2.9* NC NC 
       
SREBP-2 104285_at Hmgcra -2.0* -7.9* NC NC 
 94325_at Hmgcs -4.4* -4.5* -1.6* -2.3** 
 94322_at Sqleb -4.5* -38.6* -3.5** -27.8** 
       
Known  160544_at Fabp5b -2.8** -6.0** -2.6* -3.1** 
genes 94378_at Rgs16 -2.2** -1.8NS -1.6* NC 
 113753_at Stard4b -2.1** -2.3* -2.2 -2.5* 
 111819_at Uxt NC NC -1.6** NC 
       
Novel 163290_at Camk1db -2.0** -2.2** NC NC 
 108752_at Pcsk9b -2.1** -6.5** -1.9 -8.6** 
n=5-6 mice per group, * p<0.05, **p<0.005, NS = not significant, NC = fold < |1.6| 
a Not on final list of regulated genes in microarray study 
b Confirmed by Northern blot 
For the up-regulated genes, confirmation experiments were performed for one 
known LXR target gene (Abcg5) and five other genes (Table 2.5).  Abcg5 was up-
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regulated 4.0- and 2.2-fold in males and females, respectively.  The five other genes were 
not known LXR targets and all were previously cloned.  Adam11 was the most highly up-
regulated gene in this study; it was up-regulated 11.7- and 10.5-fold in males and 
females, respectively. Api6 was up-regulated 1.7- and 1.8-fold in males and females, 
respectively.  Fbxo3 was up-regulated 2.0-fold in females only. Laptm5 was up-regulated 
1.8-fold in males only although this was not significant.  Saa3 was up-regulated 11.4- and 
6.0-fold in males and females, respectively.   
Table 2.5.  Confirmation of selected up-regulated genes by Q-PCR 
     MALES FEMALES 
Category NetAffx ID Gene name Array (Ex3) Taqman Array (Ex3) Taqman 
LXR 114831_at Abcg5 a 2.2* 4.0** 1.6* 2.2** 
       
Known 116554_at Adam11a 5.0* 11.7** 7.8** 10.5** 
genes 93445_at Api6 1.7 1.7* 1.9** 1.8** 
 103379_at Fbxo3 NC NC 1.7** 2.0* 
 100012_at Laptm5 1.9** 1.8NS NC NC 
 102712_at Saa3 8.9* 11.4* 3.7* 6.0* 
n=5-6 mice per group, * p<0.05, **p<0.005, NS = not significant, NC = fold < |1.6| 
a  Confirmed by Northern blot 
Temporal patterns of gene expression after dietary cholesterol feeding 
 The original microarray investigated the expression of genes after 7 days of 
cholesterol feeding, a time period long enough that the effects seen could be 
compensatory changes to a high cholesterol diet versus direct effects of the high 
cholesterol diet.  Therefore, we determined the effect of dietary cholesterol on the gene 
expression of the confirmed array genes over time.  Male C57Bl/6 mice were fed the 0% 
cholesterol diet for one week, then switched to the 0.5% cholesterol diet for 0,1,2,4 or 7 
days; liver RNA was extracted for Q-PCR analysis from each group.  The down-
regulated genes showed two temporal patterns of regulation by dietary cholesterol as 
shown in Figure 2.3A.  Hmgcr, Hmgcs, Sqle, and Pcsk9 were down-regulated 70-90% 
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after one day of cholesterol feeding and remained down through day 7.  In contrast, Acly, 
Camk1d and Fabp5 were down-regulated only 20-40% after one day of cholesterol 
feeding, trended towards up-regulation on day 2, and then were further down-regulated 
between 50-75% through day 7.   
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Figure 2.3. Time course of regulation by dietary cholesterol for confirmed genes.  Twenty male 
C57Bl/6 mice were fed a 0.0% cholesterol diet for one week; four mice were sacrificed at the one-
week time point and the remaining mice were switched to a 0.5% cholesterol diet.  Four mice were 
sacrificed at days 1, 2, 4 and 7 of feeding.  RNA was prepared from liver and subjected to Q-PCR.  
Gene expression was normalized to Hprt and day 0 values set equal to one.  (A) Hmgcr, Hmgcs, 
Pcsk9, and Sqle mRNA levels were significantly (p<0.05) down-regulated beginning at day 1 and 
remained at similar down-regulated levels through day 7.  In contrast, Acly, Camk1d, and Fabp5 levels 
moderately declined at day 1, increased at day 2, and then slowly declined through day 7. (B) Adam11 
and Abcg5 levels increased immediately at day 1 to significant levels and continued to increase 
through day 7 of feeding.  Api6 and Fbxo3 levels increased immediately to significant levels at day 1 
and remained at similar levels through day 7.  Saa3 levels did not significantly increase until day 4 of 
feeding and increased at day 7.
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 The up-regulated genes showed three temporal patterns of regulation as shown in 
Figure 2.3B.  The known LXR target gene, Abcg5, was up-regulated after one day of 
cholesterol feeding by 2.5-fold and this increased by day 7 to 4.5-fold.  Adam11 showed 
a similar pattern, as it was up-regulated 5.9-fold after one day of cholesterol feeding and 
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12.1-fold by day 7.  Api6 and Fbxo3 were significantly up-regulated after one day of 
cholesterol feeding by 1.9- and 1.5-fold, respectively, but remained at approximately 
these levels through day 7.  A third pattern was observed for Saa3, which was not 
significantly up-regulated until day 4 of cholesterol feeding. 
 
Expression of down-regulated genes in SREBP transgenic mice 
To determine whether the selected down-regulated genes discussed above were 
SREBP targets, Q-PCR analysis was performed on liver RNA from transgenic mice over-
expressing the transactivation domain of SREBP-1a and SREBP-2 (Shimano et al., 1996; 
Horton et al., 1998a).  In these mice SREBP-1a or SREBP-2 activate transcription 
regardless of cellular cholesterol levels, and target genes should be up-regulated relative 
to levels in littermate controls.  In this experiment, the known SREBP-2 target genes, 
Hmgcr, Hmgcs, and Sqle were significantly up-regulated in both male and female 
SREBP-1a and SREBP-2 transgenic mice compared to littermate controls as expected 
(Figure 2.4A,B).  A similar pattern was observed for Pcsk9, which was significantly up-
regulated in male and female SREBP-1a transgenic mice by 14.7- and 6.1-fold, and in 
SREBP-2 transgenic mice by 6.4- and 4.0-fold, respectively.  Although not on the 
Affymetrix microarray, control SREBP-1a target genes, Acac and Acly, were also 
assayed by Q-PCR.  These genes were highly up-regulated in male and female SREBP-1a 
mice and marginally or not at all in SREBP-2 mice (data shown for Acly only, Figure 
2.4A,B).  A similar pattern was observed for Fabp5, which was significantly up-regulated 
in male and female SREBP-1a transgenic mice by 7.3- and 26.0-fold, respectively, and 
unchanged in SREBP-2 transgenic mice.  Similarly, Camk1d was significantly up-
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regulated in male and female SREBP-1a transgenic mice by 5.6- and 3.1-fold, 
respectively and unchanged in SREBP-2 transgenic mice. 
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Figure 2.4.  Regulation of down-regulated genes in SREBP transgenic mice.  Liver RNA was 
isolated from male and female SREBP-1a (A) and SREBP-2 (B) transgenic mice and littermate controls 
(n = 5 or 6 mice per group) and gene expression was measured by Q-PCR. Gene expression was 
normalized to cyclophilin A and control values set equal to one. Hmgcr, Hmgcs, Sqle, and Pcsk9 were 
up-regulated in both SREBP-1a and SREBP-2 transgenic mice.  Acly, Camk1d and Fabp5 were up-
regulated in SREBP-1a transgenic mice and moderately or not at all up-regulated in SREBP-2 
transgenic mice.   Tg: transgenic.  * p < 0.05; ** p < 0.005.
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Expression of all dietary cholesterol regulated genes in mice treated with the LXR 
agonist, TO901317 
 To determine which of the genes are potential LXR targets, the regulated genes in 
Tables 2.2 and 2.3 were examined by microarray analysis using RNA from the liver of 
male mice treated for 30 hours with the LXR agonist, TO901317 (Schultz et al., 2000).  
This microarray experiment was performed like dietary cholesterol experiment 2 above, 
with two aliquots from a single RNA pool derived from five male mice per condition.  
Only the MGU74v2 A and B chips were used for this experiment for the following 
reasons: 1) in the dietary cholesterol experiments, 35-38% and 21-26% of the genes were 
called present on the A and B chips, respectively; whereas only 10-12% of the genes 
were called present on the C chip; and 2) only 13 of the 80 regulated probe sets in the 
dietary cholesterol experiment were found on the C chip.  
As shown in Table 2.2, all genes classified in cholesterol metabolism that were 
down-regulated by dietary cholesterol showed no change in expression after treatment 
with the LXR agonist.  In contrast, four of the five genes involved in fatty acid 
metabolism that were down-regulated by dietary cholesterol were up-regulated by the 
LXR agonist, consistent with the fact that LXRs activate SREBP-1c (Repa et al., 2000a).  
Finally, only two other genes down-regulated by dietary cholesterol were moderately up-
regulated by the LXR agonist.  Phospholipid transfer protein (PLTP) was up-regulated 
1.9-fold by the LXR agonist; this gene was shown to be regulated by LXR (Cao et al., 
2002).  Also, Pcsk9 was up-regulated 1.7-fold by the LXR agonist. 
 As shown in Table 2.3, nine of the thirteen metabolism genes up-regulated by 
dietary cholesterol were also up-regulated by treatment with the LXR agonist.  None of 
 72
the genes classified as immune/acute phase response genes that were up-regulated by 
dietary cholesterol were up-regulated by the LXR agonist.  Finally, six of the 10 
unclassified genes were up-regulated by the LXR agonist.  Ten cholesterol up-regulated 
genes were not found to be regulated by the LXR agonist for several reasons: five were 
on the C chip and not evaluated, three were called absent in the LXR experiment, and two 
were unchanged.  Since only two of the up-regulated genes, Abcg5 and Abca1, were 
previously demonstrated LXR targets, this experiment suggested thirteen additional LXR 
regulated genes.  As discussed above, eight of these genes, Cyp3a11, Cyp3a16, cytosolic 
acyl-CoA thioesterase 1, microsomal epoxide hydrolase, 3-ketoacyl-CoA thiolase, Api6, 
Adam11, and Mpeg1 were also shown to be regulated by the LXR agonist in another 
microarray study (Stulnig et al., 2002).  The other five genes are dopa decarboxylase, 
carboxylesterase 6, Fbxo3, glutathione S-transferase alpha2 Yc2, and an unknown EST.  
Q-PCR analysis was used to confirm the LXR regulation of three of the genes, Adam11, 
Api6, and Fbxo3, the absence of regulation of the Saa3 gene, and a control LXR target, 
Abcg5 (Figure 2.7).  In this experiment, Abcg5 was regulated 2.7-fold, Adam11 34-fold, 
Api6 1.7-fold, and Fbxo3 1.4-fold (significant).  Saa3 was not regulated by the LXR 
agonist in the confirmation experiment as well.  The fold change in Fbxo3 may be lower 
than expected because Fbxo3 was only regulated by dietary cholesterol in female mice 
and the LXR agonist experiment was performed only in male mice. 
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Figure 2.5. Q-PCR confirmation of selected genes regulated by the LXR agonist. Seven-week old 
male C57BL/6 mice were fed the 0.0% cholesterol diet for one week and then gavaged with vehicle 
alone (5% ethanol, 95% sesame oil) or with vehicle plus 10mg/kg TO901317 twice over 30 hours (n = 
5 mice per group).  Liver RNA was subjected to Q-PCR analysis. Gene expression was normalized to 
cyclophilin A and vehicle values set equal to one. Abcg5, Adam11, Api6, Fbxo3 were up-regulated by 
the LXR agonist.  * p < 0.05; ** p<0.005.
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CHAPTER SUMMARY: 
 This chapter describes the use of Affymetrix microarrays to identify genes in 
mouse liver regulated by dietary cholesterol (0.0% versus 0.5% cholesterol wt/wt).  The 
goal of these experiments was to identify novel genes important in cholesterol 
metabolism.  Three independent experiments were performed and data were analyzed 
with Affymetrix Microarray Suite and ANOVA statistical software.  There were 69 genes 
consistently regulated by dietary cholesterol (37 down-regulated and 32 up-regulated).  
The array results were confirmed by Q-PCR for eight of ten down-regulated genes and 
five of six up-regulated genes.  A time course of dietary cholesterol feeding over one 
week revealed different temporal patterns of gene regulation for these confirmed genes.  
Six down-regulated genes were examined in transgenic mice over-expressing truncated 
nuclear forms of SREBP-1a and SREBP-2, and all were induced in these mice.  A second 
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microarray analysis of mice treated with the LXR agonist TO901317 confirmed that 13 
of the 32 cholesterol up-regulated genes were also LXR activated.  This array result was 
confirmed by Q-PCR for three of four genes.  In summary, these studies identified and 
confirmed six novel dietary cholesterol-regulated genes, three putative SREBP target 
genes, Camk1d, Fabp5, and Pcsk9, and three putative LXR target genes, Adam11, Api6, 
and Fbxo3. 
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CHAPTER 3: CLONING AND CHARACTERIZATION OF PCSK9, 
A NOVEL CHOLESTEROL-REGULATED GENE 
 
Cloning of Proprotein Convertase Subtilisin Kexin 9 
Chapter 2 described the use of Affymetrix microarrays to identify novel genes 
regulated by dietary cholesterol.  The microarrays identified a number of genes of 
unknown function and ESTs that had not been cloned; however, we wanted to narrow our 
studies to a smaller number of genes.  Our selection criteria for study were genes or ESTs 
that were very highly regulated or possessed domains that suggested an interesting 
function.  The Affymetrix probe set 108752 fit both of these criteria.  Probe set 108752 
was down-regulated by dietary cholesterol between 1.8- and 2.1-fold in males and 1.9-
fold in females on the microarray and 6.5-fold in males and 8.6-fold in females by Q-
PCR confirmation.  The sequence corresponding to probe set 108752 contained no 
information in the Affymetrix database, NetAffx, and thus was BLASTed to the NCBI 
database and the Celera draft of the mouse genome.  In the NCBI database, the probe set 
matched sequence in 22 ESTs from two different Unigene clusters, but no complete 
cDNAs.  In the Celera draft of the mouse genome, the probe set matched sequence in the 
3’utr of a predicted gene on mouse chromosome 4, mCG2400, which was predicted to 
encode an incomplete mRNA, mCT1608; no in-frame ATG codon was found in this 
predicted mRNA.  The predicted incomplete protein, mCP22398, was BLASTed to the 
NCBI database and found to have 34-37% homology to subtilisin-like serine proteases 
from bacteria, yeast and fungi.   
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 In order to clone the full-length cDNA corresponding to probe set 108752, further 
in silico analysis was performed.  Directly 5’ to the predicted mCT1608 eight exon 
transcript was a gene encoding a predicted three exon transcript, mCT1602.  These 
predicted transcripts were used to BLAST the NCBI database and identify corresponding 
ESTs; these ESTs were assembled into a contig that contained mCT1602, an intervening 
sequence, and mCT1608 (Figure 3.1A).  This contig was BLASTed to the mouse genome 
and found to be composed of 12 exons; furthermore, an in-frame start and stop could be 
identified.  Primers corresponding to sequences at the start and stop were used to amplify 
an approximately 2.1kb band from C57BL/6 liver cDNA (Figure 3.1B).  Multiple PCR 
products were sequenced to identify the full-length open-reading frame (ORF) of 2,124 
nucleotides (nt).  This ORF showed highest homology to bacterial, yeast and fungal  
subtilisin-like serine proteases.  When a BLAST search was performed to mouse proteins 
only, the highest homology was to the eight members of the mammalian subtilisin serine 
protease family (see Introduction).  The ORF (GenBank Accession Number: AY273821) 
was sent to the HUGO gene naming committee and the name Proprotein Convertase 
Subtilisin/Kexin 9 (Pcsk9) was chosen in concordance with the updated naming of the  
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Figure 3.1. Cloning of mouse and human 
Pcsk9.  (A) In silico analysis of predicted 
transcripts from Celera and ESTs in the 
public database were used to predict a 12-
exon ORF for mouse Pcsk9  (B) PCR using 
primers at the predicted start and stop of 
mouse Pcsk9 amplified a single 2.1kb band 
from mouse liver cDNA.  (C) PCR using 
primers at the predicted start and stop of 
human Pcsk9 amplified a single 2.1kb band 
from human liver cDNA and HepG2 cDNA.
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mammalian subtilisin serine protease family.  The Pcsk9 ORF was used to BLAST the 
human genome, and primers corresponding to the predicted start and stop were used to 
amplify an approximately 2.1kb band from Clontech human liver and HepG2 cDNA 
(Figure 3.1C).   Multiple PCR products were sequenced to identify the full-length human 
ORF of 2,079nt.  
 
Cloning of 5’ end of mouse and human Pcsk9 transcript 
 In order to define the 5’end of the Pcsk9 transcript, 5’-RACE was performed.  
There were four groups of products for the mouse Pcsk9 5’end.  All of the mouse 
products contained two in-frame start codons separated by 36 nucleotides; the more 5’ 
ATG was chosen as the start site for the Pcsk9 ORF.  Using this start site, the four 
different groups of 5’utr of mouse Pcsk9 contained 225, 194, 166, and 136 nucleotides of 
upstream untranslated region.  In contrast, the two groups of human products contained 
only one in-frame start codon that corresponded to the second ATG found in mouse 
Pcsk9; furthermore, three codons were absent from exon one of human Pcsk9.  Therefore, 
the mouse protein is 16 amino acids longer than the human protein.  The two groups of 
5’utr of human Pcsk9 contained 309 or 292 nucleotides of upstream untranslated region.  
The 5’utr of mouse and human Pcsk9 are 50% identical. 
 
Domain structure of mouse and human Pcsk9 proteins 
 Mouse and human Pcsk9 proteins, like other mammalian subtilisin proteases are 
made up of an N-terminal signal peptide, a pro-domain, a peptidase S8/subtilisin catalytic 
domain, a putative P-domain, and a unique C-terminus (Figure 3.2).  Using the SignalP 
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web program (Nielsen et al., 1997; Bendtsen et al., 2004), it was predicted that the signal 
peptide is cleaved after alanine-47 in mouse Pcsk9 and at alanine-30 in human Pcsk9.  
Both mouse and human Pcsk9 contain the canonical serine protease catalytic triad of 
aspartic acid (D202/D186 in mouse/human), histidine (H242/H226), and serine 
(S402/S386) in the subtilisin domain (Siezen and Leunissen, 1997).  They also contain 
the oxyanion hole asparagine (N333/N317), a residue which is proposed to stabilize a 
negatively charged oxygen atom (oxyanion) that forms during the enzyme-substrate 
catalysis reaction (Siezen and Leunissen, 1997).  Mouse Pcsk9 contains a RRGD514 and 
human Pcsk9 an RRGE498 motif in the P-domain that is proposed to play a role in protein 
folding (Seidah et al., 2003).  Mouse and human Pcsk9 have one N-glycosylation site at 
N549/N533 in the unique C-terminus.   
1 70747 168 490
C-terminal domainPro-domainSP Subtilase (Peptidase S8)
A47
Cat
D202
Cleavage site
FAQ  SIP171
Cat
H242
Cat
S402
OAH
N333
N-glyc
N549RGD514
Figure 3.2.  Domain structure of mouse PCSK9 protein.  The mouse PCSK9 protein is 707 amino 
acids and is made up of a signal peptide (SP), a pro-domain, a subtilase (peptidase S8) serine 
protease domain, and a unique C-terminal domain.  The positions of the signal peptide cleavage 
(Ala-47) and the pro-domain cleavage (Gln-168) are marked.  Also shown are the catalytic site 
residues (Cat), the oxyanion hole (OAH), and the N-glycosylation site (N-glyc).  
 
 The PredictProtein server (Rost et al., 2004) was used to predict other potential 
sequence motifs in Pcsk9; this analysis demonstrated many possible differences between 
mouse and human Pcsk9 in addition to some conserved sites.  The server predicted a 
conserved N-glycosylation site at N549/N533 and a conserved amidation site at 
SGRR511/SGKR495.  Mouse Pcsk9 is predicted to have a cAMP/cGMP-dependent protein 
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kinase phosphorylation site at RRCS84; this site is not present in human Pcsk9.  There are 
four predicted protein kinase C phosphorylation sites that are conserved between mouse 
and human Pcsk9; mouse Pcsk9 has an additional seven predicted sites, and human Pcsk9 
has an additional five predicted sites.  There are eight predicted casein kinase II 
phosphorylation sites that are conserved between mouse and human Pcsk9; mouse Pcsk9 
has an additional four predicted sites and human Pcsk9 has an additional three predicted 
sites.  There are seven predicted N-myristoylation sites that are conserved between mouse 
and human Pcsk9; mouse Pcsk9 has an additional four predicted sites and human Pcsk9 
has an additional two predicted sites.  Finally, human Pcsk9 is predicted to have a 
prokaryotic membrane lipoprotein lipid attachment site, CHQQGHVLTGC562; the 
corresponding site in mouse Pcsk9 is CHQKDHVLTGC578.  In the consensus for this 
motif, the first six residues can be any amino acid except D, E, R, or K; thus mouse Pcsk9 
specifically contains sites that make this motif inactive.  In bacteria, a glyceride-fatty acid 
lipid is attached to the final cysteine residue of the motif, directing cleavage upstream of 
the cysteine residue by lipoprotein signal peptidase/signal peptidase II (Hayashi and Wu, 
1990); this post-translational modification is found on many bacterial proteins.  This 
motif has been described in the human solute carrier family 26 (SLC26A) proteins, which 
are anion exchangers; however no role for the motif has been reported (Lohi et al., 2002; 
Makela et al., 2002).    
 
Homology of mouse and human Pcsk9 to each other and to Subtilisin BPN 
 Mouse and human Pcsk9 proteins were aligned with the ClustalW algorithm.  
Mouse and human Pcsk9 proteins are only 78% identical and 82% similar over the whole  
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A
A
A
= identical residues in all 3 sequences
= identical residues in 2 sequences
= similar residues
= Processing site
= Catalytic triad residues
= oxyanion hole
= structurally conserved subtilisin residues
= N-glycosylation site
= motifs (signal peptide, RRGE/D   
motif, prokaryotic membrane 
lipoprotein attachment site)
= human mutations/SNPs
Figure 3.3. Multiple sequence alignment of mouse and human Pcsk9 and the canonical subtilisin 
protein from Bacillus amyloliquefaciens.  Mouse Pcsk9 (mSP), human Pcsk9, and B. 
amyloliquefaciens BPN (basbpn) were aligned using the ClustalW algorithm.  The alignment 
(identical residues in green/yellow and similar in blue) demonstrates the high sequence homology 
between mouse and human Pcsk9 and bacterial subtilisins within the protease domain.  This includes 
residues marked by a red arrow which are the most highly conserved residues in all subtilisins and 
have been shown to play important structural roles.
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protein.  The subtilisin catalytic domains retain the highest sequence similarity at 87% 
identity; whereas the C-terminal domains are most divergent, at 65% identity.  Mouse 
and human Pcsk9 were also aligned to a canonical subtilisin protease from Bacillus 
amyloliquefaciens called BPN (Siezen and Leunissen, 1997) (Figure 3.3).  Mouse and 
human Pcsk9 are only 16% identical to BPN over the entire proteins; however, they are 
25% identical and 42% similar to BPN in the subtilisin domain, indicating high sequence 
homology between the catalytic portion of the mammalian proteins and bacterial 
counterparts.  The alignment indicates the positions of the catalytic triad residues and 
oxyanion hole, which are conserved between mammalian Pcsk9 and BPN.  The most 
highly conserved residues in bacterial subtilisins (Siezen and Leunissen, 1997), which 
play a role in structural stability, are indicated by brown arrows in the alignment.  Many 
of these residues are also conserved in mammalian Pcsk9. 
 The subtilisin serine protease family is classified into six subfamilies (Siezen and 
Leunissen, 1997), true subtilisin, thermitase, proteinase K, lantibiotic peptidase, and 
kexin.  As indicated previously, a BLAST of Pcsk9 protein indicated highest homology 
to subtilisin proteases from bacteria, yeast and fungi instead of the previously known 
mammalian subtilisins of the kexin subfamily; therefore, we performed a multiple 
sequence alignment of all nine mammalian subtilisin proteases with representative 
members of each subtilisin subfamily from lower eukaryotes and prokaryotes (Figure 
3.4).  As expected, Pcsk1-7 (PC1/3, PC2, furin, PC4, PC5/6, PACE4, and PC7), showed 
closest homology to the kexin subfamily.  Pcsk8 (S1P) did not show homology to any 
subfamily, despite it being reported to be a member of the pyrolysin subfamily (Seidah 
and Chretien, 1999).  Pcsk9 showed greatest sequence homology to the cluster of 
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proteinase K subfamily members: vaproa, protease A from the bacteria Vibrio 
alginolyticus; taprok, proteinase K from the fungus Tritirachium album; and scprb1, 
protease B from the yeast Saccharomyces cerevisiae.   
Kexin Subfamily
Lantibiotic Subfamily
Pyrolysin Subfamily
Proteinase K Subfamily
Thermitase Subfamily
True subtilisin Subfamily
Figure 3.4. Phylogenetic tree of 
representative members of the subtilisin 
serine protease subfamilies and the 
mammalian subtilisins.  The phylogenetic 
tree was created from a ClustalW alignment 
of the nine mammalian subtilisins with 
representative members of the six subtilisin 
subfamilies.  Pcsk1-7 align with the kexin 
subfamily members Ce AEX-5 (nematode 
Caenorhabditis elegans aex-5) and klkex1 
(yeast Kluyveromyces lactis kexin).  Pcsk8 
does not align within a subfamily.  Pcsk9 
aligns with the proteinase K subfamily 
members vaproa (bacteria Vibrio 
alginolyticus protease A), taprok (fungus 
Tritirachium album proteinase K) and 
scprb1 (yeast Saccharomyces cerevisiae
protease B).
 
 
Construction of Pcsk9 expression plasmids, adenovirus and creation of Pcsk9 
peptide antibodies 
 In order to study the characteristics and function of Pcsk9, multiple expression 
constructs were made and a peptide antibody to Pcsk9 was created (see Methods for 
details).  Two peptide antibodies were created, one to a peptide corresponding to mouse 
Pcsk9 amino acid 500-520 (α-mPcsk9-500) and one to a peptide corresponding to amino 
acid 583-603 (α-mPcsk9-583).  Both of these peptides are predicted to be unique to Pcsk9 
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by a BLAST to the mouse genome.  These antibodies were tested in rat hepatoma McA-
RH7777 cells transfected with a Flag tagged Pcsk9 expression construct (Pcsk9-Flag) and 
an untagged Pcsk9 expression construct (Pcsk9-pcDNA3).  Both the α-mPcsk9-500 and 
α-mPcsk9-583 antibodies recognized a pro-form of Pcsk9 at approximately 79kDa and a 
processed form at approximately 62kDa; these bands were not recognized if the 
antibodies were incubated with the peptides used to make the antibodies (Figure 3.5).   
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7777 + Pcsk9-pcDNA3
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293 + Pcsk9-Flag
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Figure 3.5.  Characterization of Pcsk9 peptides antibodies and expression constructs.  Peptide 
antibodies to Pcsk9 were created (Ab500 and Ab583).  McA-RH7777 (1,2), HEK293 (5) and COS1 
(6) cells were transfected with Pcsk9-Flag; cell lysates (1,5,6) and media (2) were blotted with the α-
Pcsk9 antibodies.  McA-RH7777 cells were also transfected with an untagged Pcsk9-pcDNA3 
expression construct; cell lysates (3) and media (4) were blotted with the α-Pcsk9 antibodies.  These 
antibodies recognized a 79kDa pro-form in cells and a 62kDa processed form in cells and media; the
bands could be blocked by pre-incubation of the antibody with the antigenic peptides.
 
These sizes are in good agreement with a recent study which used mass spectroscopy to 
show that the pro-form of human Pcsk9 is 74.3kDa and the processed form is 60.5kDa 
(Benjannet et al., 2004).  The antibodies also identified the processed Pcsk9 in the media 
of cells transfected with the Pcsk9 constructs, indicating that Pcsk9 is secreted in cells 
when overexpressed.  In addition to the expression constructs, an adenovirus expressing 
the Pcsk9 ORF under the control of a constitutively active CMV promoter was made.  
 84
When infected into multiple cell lines, this adenovirus induced expression of Pcsk9 in the 
cells and media (data not shown).   
 
Pcsk9 is localized to the ER and Golgi apparatus 
 The other proprotein convertases, Pcsk1-7 and S1P have been shown to be 
localized within the TGN or in secretory granules within the cell (Gensberg et al., 1998; 
Bergeron et al., 2000), consistent with their role in processing proteins in the secretory 
pathway.  In order to investigate whether Pcsk9 has a similar subcellular localization, a 
Pcsk9-green fluorescent protein (GFP) fusion protein expression construct was made (C-
terminally tagged GFP).  This construct was expressed in HepG2 cells treated with a red 
fluorescent marker of the endoplasmic reticulum, ER-Tracker-Red and with a red 
fluorescent marker of the Golgi apparatus, BODIPY-TR-C5-ceramide.  Pcsk9-GFP was 
expressed only in the cytoplasm and appeared to be most concentrated in the perinuclear 
region (Figure 3.6A,B, green panel).  The perinuclear staining seemed to be brighter on 
one side of the nucleus, indicating a polarized pattern.  This pattern suggested 
colocalization with the Golgi marker C5-ceramide (Figure 3.6B, red panel), which also 
displayed a polarized perinuclear staining pattern, versus colocalization with ER-Tracker, 
which displayed a more diffuse perinuclear pattern (Figure 3.6A, red panel). 
 In order to further study the subcellular localization pattern, subcellular 
fractionation of cells was performed using a seven-step sucrose gradient.  This protocol 
was performed on HepG2 cells infected with either control adenovirus (Ad empty) or 
Pcsk9 expressing adenovirus (Pcsk9-Ad).  ER fractions were identified with a western 
blot to calnexin, Golgi fractions by an enzymatic assay for α-mannosidase, and TGN  
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ER-Tracker Red Pcsk9-GFP Merge
Bodipy-C5-ceramide Pcsk9-GFP Merge
A
D
B C
E F
Figure 3.6.  Pcsk9-GFP colocalized with ER and Golgi markers in HepG2 cells.  HepG2 cells were 
transfected with Pcsk9 tagged at the C-terminal end with GFP (GFP) and stained with the endoplasmic 
reticulum marker ER-Tracker Red (A,B,C) and the Golgi marker Bodipy-C5-ceramide (D,E,F); images 
were acquired using confocal microscopy.  Panel A shows the distribution of ER-Tracker Red, panel D 
shows the distribution of Bodipy-C5-ceramide, panel B,E shows the distribution of Pcsk9-GFP and 
panel C,F shows the merged images.  Approximately 50 cells were examined for each marker and 
images shown are representative of the pattern seen in all cells examined.
 
fractions by a western blot to TGN38.  As shown in Figure 3.7A, the fractions containing 
maximum TGN38, α-mannosidase and calnexin activity were well separated.  In cells 
infected with Ad empty, the distribution of endogenous Pcsk9 was detected (of note, the 
mouse Pcsk9 antibodies did not recognize Pcsk9 in whole cell HepG2 lysates, but did 
recognize bands of the correct size in these fractions, presumably due to enrichment of 
the Pcsk9 protein).  Overlay of the distribution of endogenous pro-Pcsk9 and Pcsk9 
(Figure 3.7) demonstrated that pro-Pcsk9 was mainly expressed in the ER, whereas the 
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processed form of Pcsk9 was expressed only in the TGN.   In cells infected with Pcsk9-
Ad, the pro-Pcsk9 was still mainly in the ER; however, the processed Pcsk9 was found at 
similar levels throughout the ER, Golgi, and TGN (data not shown).   
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Figure 3.7. Subcellular fractionation of HepG2 cells demonstrated that processed Pcsk9 is 
normally expressed in the TGN.  Lysates from untreated HepG2 cells were subjected to a 7-step 
sucrose gradient.  The collected fractions were analyzed for the Golgi marker α-mannosidase by 
enzymatic assay and the ER marker calnexin and the TGN marker TGN38 by western blotting.  The 
distribution of Pcsk9 was determined by Western blotting using the α−Pcsk9-500 and α-Pcsk9-583 
antibodies.  Band intensities from Western blotting were measured using Image Pro Plus.  Values were 
normalized to protein and expressed as a percentage of the maximum value for each marker.  
Endogenous pro-Pcsk9 was mainly found in the calnexin-positive fractions; whereas the processed 
Pcsk9 was found entirely in the TGN38-positive fractions.  
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Pcsk9 tissue expression in vivo 
 In order to determine the tissues that express Pcsk9, non-quantitative RT-PCR and 
Northern blotting was performed.  As described above, the 5’utr of the Pcsk9 transcript 
was determined by 5’RACE and the ORF by PCR.  In order to determine the expected 
transcript size, the length of the 3’utr was needed, so the genomic sequence downstream 
of the stop codon was analyzed for poly-A signals (AATAAA).  A poly-A signal was 
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found to be present 50 nucleotides downstream of the Affymetrix probe set sequence 
108752, predicting a transcript of 3.4kb.  
 For RT-PCR, cDNA was made from white adipose, brain, heart, kidney, liver, 
small intestine and spleen from low and high cholesterol fed mice (white adipose only 
from low cholesterol fed mice).  PCR primers in the predicted 3’utr of Pcsk9 amplified a 
product from all of these tissues (Figure 3.8A), with the most abundant bands being from 
low cholesterol fed liver and small intestine.   
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Figure 3.8.  Tissue distribution of Pcsk9 
mRNA.  (A) C57Bl/6 mice were fed a 0.0% 
cholesterol (L) or 0.5% cholesterol (H) diet 
and multiple tissues were isolated.  Primers 
within the Pcsk9 3’untranslated region were 
used on cDNA prepared from the indicated 
tissues.  (A: adipose tissue, N: no template 
control.)  (B)  A probe within the Pcsk9 
3’untranslated region and to a portion of the 
Actin open reading frame were used to probe a 
Clontech multiple tissue Northern blot.  Pcsk9 
was mainly expressed in the liver.
 
Since RT-PCR is extremely sensitive and can amplify products from very low 
amounts of template, a multiple tissue Northern (MTN) blot from Clontech was also 
blotted with a probe made from a portion of the Pcsk9 ORF.  Pcsk9 was shown to be 
expressed most highly in the liver, and to a lower level in kidney (Figure 3.8B).  Darker 
exposures did not reveal the presence of any bands in heart, brain, spleen, lung, muscle or 
testis.  Small intestine was not present on the MTN blot; however, Pcsk9 was found to be 
present in small intestine by Northern blotting as well (see below).   
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Pcsk9 is regulated by dietary cholesterol putatively via the SREBP transcription 
factors at the RNA and protein levels 
The original observation that led to the cloning of Pcsk9 was that the mRNA was 
down-regulated by dietary cholesterol feeding in mouse liver as assayed by microarray 
and Q-PCR analysis.  This observation was confirmed by Northern blotting of liver 
mRNA from male and female mice (Figure 3.9A) with a probe to a portion of the Pcsk9 
ORF.  The control SREBP-2 target gene of the cholesterol biosynthetic pathway, Sqle, 
was also down-regulated in these samples.  To investigate whether Pcsk9 was regulated 
by dietary cholesterol in other tissues, a Northern blot of mRNA from brain, heart, 
kidney, liver, small intestine, and spleen was probed.  As expected from the MTN and 
RT-PCR results above, Pcsk9 was expressed mainly in liver and small intestine, with a 
small amount in kidney; furthermore, Pcsk9 mRNA was down-regulated by dietary 
cholesterol in both liver and small intestine (Figure 3.9B).  In order to determine whether 
the regulation of Pcsk9 levels by sterols was also at the protein level, endogenous Pcsk9 
protein levels were assayed by Western blotting in three hepatoma cells lines, rat Fu5AH 
(Figure 3.9C), rat McA-RH7777 (Figure 3.9D), and mouse Hepa1-6 (Figure 3.9E).  In all 
three cell lines, Pcsk9 protein levels in cells were decreased by treatment with cholesterol 
and 25-hydroxycholesterol (sterols) and were increased by treatment with statins, which 
inhibit cholesterol biosynthesis and thus cause sterol depletion.  Furthermore, endogenous 
Pcsk9 protein was shown to be secreted into the medium of Fu5AH and McA-RH7777 
cells; the levels of this secreted protein were also regulated by sterols and statins. 
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Figure 3.9. Pcsk9 mRNA and protein levels are regulated by sterol levels.  (A) Northern blot of liver 
RNA pooled from male and female C57Bl/6 mice fed a 0.0% cholesterol diet (L) or a 0.5% cholesterol 
diet (n = 5 mice per group).  Blots were probed for a portion of the Pcsk9 3’untranslated region, squalene 
epoxidase (Sqle) and actin.  (B) Northern blot of RNA from multiple tissues pooled from male C57Bl/6 
mice fed a 0.0% cholesterol diet (L) or a 0.5% cholesterol diet (H) (n = 5 mice per group).  Pcsk9 mRNA 
was down-regulated by dietary cholesterol in the liver and small intestine (sm int).  Fu5AH (C) and McA-
RH7777 (D) cells were cultured in media containing 10% lipoprotein deficient serum plus ethanol 
(vehicle), 1µg/ml 25-hydroxycholesterol and 10µg/ml cholesterol (sterols), or 1µg/ml mevinolin (statin).  
Cell lysates (C) and media (M) were collected and blotted with α-Pcsk9-500 antibody.  Both the pro-form 
of Pcsk9 (pP) and processed form (P) were regulated by sterols.  (E) Hepa1-6 cells were cultured in 
media containing 10% lipoprotein deficient serum plus ethanol (vehicle), 1µg/ml 25-hydroxycholesterol 
and 10µg/ml cholesterol (sterols), or 1µg/ml mevinolin (statin).  Cell lysates were collected and blotted 
with α-Pcsk9-583 antibody.  The processed form (P) of Pcsk9 was regulated by sterols.    
α-Pcsk9-500 α-Pcsk9-500 α-Pcsk9-583
 
 As described in Chapter 2, down-regulation of gene transcription by cellular sterol 
levels is mediated by the SREBP family of transcription factors.  In order to assay 
regulation by SREBP, transgenic mice that overexpress a constitutively nuclear and 
hence active form of SREBP-1a and -2 were assayed.  Pcsk9 mRNA, similar to other 
SREBP-2 regulated cholesterol biosynthetic enzymes, was up-regulated in both SREBP-
1a and SREBP-2 transgenic mice as assayed by Q-PCR (Chapter 2).  In order to confirm 
these results, a Northern blot of mRNA from the livers of SREBP-1a and SREBP-2 
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transgenic mice was probed.  As expected, Pcsk9 and Sqle were up-regulated in both 
SREBP-1a and SREBP-2 transgenic mice; whereas, the proposed lipogenic gene Fabp5 
was only up-regulated in SREBP-1a mice (Figure 3.10A).  Pcsk9 was also up-regulated 
at the protein level in SREBP-2 transgenic mice (Figure 3.10B). 
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Figure 3.10. Pcsk9 mRNA and protein levels are regulated by SREBPs.  (A) Northern blot of liver 
RNA pooled from SREBP-1a transgenic mice (BP1a Tg), SREBP-2 transgenic mice (BP2 Tg) and their 
respective non-transgenic littermate controls (C) (n = 5 mice per group).  Blots were probed for Pcsk9, 
the cholesterol biosynthetic enzyme squalene epoxidase (Sqle) and the fatty acid binding protein 5 
(Fabp5).  (B) Western blot of liver proteins from three SREBP-2 transgenic mice (BP2, lanes 4-6) and 
three non-transgenic littermate controls (lanes 1-3).  Pcsk9 was up-regulated by the SREBP transcription 
factors at the mRNA and protein level.  (C) The 5’upstream regions of mouse and human Pcsk9 were 
analyzed for potential SREBP response elements (SREs) in conserved regions using rVISTA.  One site 
was identified immediately upstream from the transcription start sites identified by 5’RACE.
α-Pcsk9-500+583
 
  SREBPs bind to sites called sterol regulatory elements (SREs) in the promoters 
of genes; these sites have the idealized consensus 5’-TCACNCCAC (Edwards et al., 
2000; Eberle et al., 2004). Conserved regions of the mouse and human Pcsk9 promoters 
were identified using the program VISTA (Loots et al., 2002), and these regions were 
searched for potential SREs.  In 20,000 nucleotides of upstream region, VISTA identified 
two regions of homology between mouse and human Pcsk9 promoters, one at -338 to -
142 from the ATG in mouse (-488 to -292 in human), and one at -1590 to -1526 (-1715 to 
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-1651).  The first region contained a potential SRE (GGTGGCGTGATCT) at -198 in 
mouse or -345 in human (Figure 3.10C); this is directly upstream from one of the 
potential transcript start sites.  The second region also contained a potential SRE 
(GTGGGATGAGACC) at -1577 in mouse or -1703 in human (data not shown).   
 Another observation in the original microarray study (Chapter 2) was that the 
Pcsk9 mRNA was up-regulated 1.9-fold in mice treated with an LXR agonist, TO901317 
(Table 2.2).  In order to confirm this result, a Northern blot of mRNA from heart, kidney, 
liver and small intestine was probed for Pcsk9.  Pcsk9 was again expressed in kidney, 
liver and small intestine, and the mRNA was up-regulated by the LXR agonist treatment 
in all three tissues (Figure 3.12A).   
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Figure 3.11.  Up-regulation of Pcsk9 by the LXR 
agonist TO901317.  (A) Northern blot of RNA pooled 
from multiple tissues from male C57Bl/6 mice treated 
with 5% sesame oil in ethanol vehicle (V) or vehicle 
plus 10mg/kg of the LXR agonist TO901317 (T) for 30 
hours (n = 5 mice per group).  Northern blots probed 
for Pcsk9, the LXR target gene Abcg5 and Actin.  
Pcsk9 was up-regulated by TO901317 in kidney, liver 
and small intestine (sm int).   (B) Hepa1-6 cells were 
treated with ethanol (vehicle), 1µg/ml 22(R)-
hydroxycholesterol (22ROC), 10µM TO901317 (TO) 
or 22(R)-hydroxycholesterol plus TO901317 
(22ROC+TO).  Protein lysates were blotted using the 
α-Pcsk9-583 antibody.  Pcsk9 protein was up-regulated 
by TO901317 but down-regulated by 22(R)-
hydroxycholesterol.  
 
Pcsk9 protein was also up-regulated by the LXR agonist, as assayed in Hepa1-6 cells 
treated with TO901317; however, treatment with another LXR ligand, 22(R)-
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hydroxycholesterol, down-regulated Pcsk9 protein levels (Figure 3.12B), as may be 
expected due to oxysterol mediated suppression of  SREBP-2 processing (Wang et al., 
1994).  Therefore, the effect of TO901317 may be due to LXR up-regulation of SREBP-
1c; however, this effect is not as strong as the sterol regulated regulation by SREBP-2. 
 
Pcsk9 sequence variants 
Quantitative trait locus mapping (QTL) can be used to identify genes that play a 
role in complex polygenic diseases.  In the mouse, this technique involves crossing two 
strains of genetically distinct mice that differ in a phenotype of interest, and identifying 
regions of the genome that co-segregate with the phenotype.  Two crosses have identified 
loci on chromosome four that segregate with apoB levels or non-HDL cholesterol levels.  
Ko et al (Ko et al., 2001) crossed human apoB transgenic (HuBTg) mice on C57BL/6 
background to HuBTg mice on 129 background and identified a locus for apoB levels on 
chromosome 4 between markers D4Mit89 and D4Mit204, or 45.6Mb and 131.9Mb 
(Ensembl genome).  In our laboratory, Effie Sehayek (Sehayek et al., 2003) crossed 
C57Bl/6 and CASA/Rk mice and identified a locus for plasma non-HDL cholesterol 
levels on chromosome 4 between markers D4Mit9 and D4Mit204, or 93.4Mb and 
131.9Mb.  The peak for the latter locus was nearest to D4Mit46, at 102.9Mb.  Since 
Pcsk9 is located at 104.8Mb on chromosome 4, the Pcsk9 ORF was sequenced in 
C57Bl/6 and CASA/Rk mice to identify polymorphisms.  The C57Bl/6 sequence was 
obtained from the cloning results (above) which agreed 100% with the genomic sequence 
in the Ensembl database.  The CASA/Rk sequence was obtained by sequencing clones 
derived from eight independent PCR reactions.  Changes were scored as variants only if 
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they were found in all clones.  These experiments resulted in the identification of two 
insertion SNPs and eight nonsynonomous missense SNPs between C57Bl/6 and 
CASA/Rk (Table 3.1).  The CASA/Rk sequence agreed with the human sequence in 3 of 
10 SNPs, the C57Bl/6 sequence agreed with the human sequence in 5 of 10 SNPs, and 
neither strain agreed with the human sequence in 2 of 10 SNPs.  Using the PredictProtein 
(Rost et al., 2004) and NetPhos (Blom et al., 1999) servers, sites that may have potential 
functional consequences were identified.  The insertion GE191 SNP that is present in the 
CASA/Rk sequence was reported by PredictProtein to introduce a casein kinase II 
phosphorylation site.  The NetPhos server predicted that T421 would be phosphorylated 
in C57Bl/6; this residue is alanine in CASA/Rk.  The NetPhos server predicted that Y465 
would be phosphorylated in CASA/Rk/6; this residue is histidine in C57Bl/6.  
Table 3.1.  Sequence polymorphisms between C57Bl/6 and CASA/Rk mouse strains 
C57 aa# Domain C57 Casa Rat Human Prediction 
29 pro PPL Abs Abs Abs  
318 cat R Q Q Q  
515 CTD W R R R  
       
191 cat Abs GE Abs Abs CK2 site in Casa 
480 cat H Q H H  
658 CTD S P S S  
315 cat A T T A  
465 cat H Y Q H Tyr phos site in Casa 
       
421 cat T A A E Thr phos in C57 
547 CTD R C R Q  
Pro: pro-domain; cat: catalytic domain; CTD: C-terminal domain; phos: phosphorylation 
 
CHAPTER SUMMARY 
 This chapter summarizes the cloning of proprotein convertase subtilisin kexin 9 
(Pcsk9), the gene corresponding to one of the regulated ESTs in the microarray study 
described in Chapter 2.  Pcsk9 was shown to encode a subtilisin serine protease with 
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conserved sequence elements necessary for function.  Pcsk9 was shown to be a divergent 
member of the mammalian subtilisin family and most similar to the proteinase K 
subfamily of subtilisin proteases found in prokaryotes and lower eukaryotes.  The Pcsk9 
protein was expressed in various cell lines and the processed form of Pcsk9 was secreted 
into the medium of cells both when overexpressed and endogenously.  Pcsk9-GFP 
colocalized with ER and Golgi markers by confocal microscopy and the endogenous 
processed form was expressed in TGN fractions of HepG2 cells.  Pcsk9 was most highly 
expressed in the liver of mice, with expression also in the small intestine and kidney.  
Pcsk9 mRNA and protein levels were regulated by cellular sterols levels putatively via 
the SREBP transcription factors.  These results demonstrate that Pcsk9 is a protein of the 
secretory pathway and is regulated by cholesterol levels, indicating that Pcsk9 may play a 
role in cholesterol metabolism.   
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CHAPTER 4: PCSK9 REGULATES LDL RECEPTOR FUNCTION 
AND LDL CHOLESTEROL LEVELS 
 
Injection of Pcsk9-Ad in mice induces overexpression of Pcsk9 in mouse liver 
In order to study the function of Pcsk9, in vivo overexpression studies were 
performed.  An adenovirus was created to induce constitutive overexpression of Pcsk9.  
The Pcsk9 adenovirus (Pcsk9-Ad) was injected into 8-week old C57BL/6 male mice at 
concentrations of 1x108 to 3x109 particle forming units (pfu) per mouse and compared to 
mice injected with PBS alone or 1x109 pfu of a control empty adenovirus (Ad empty).  
As shown in Figure 4.1, the livers of mice injected with PBS or Ad empty have no 
immunoreactive Pcsk9 protein at the depicted exposure.  However, injection of 
increasing concentrations of Pcsk9-Ad produced increasing amounts of both the pro and 
processed forms of Pcsk9 protein.  Since processing of Pcsk9 is an intramolecular self-
catalyzed event (Naureckiene et al., 2003), the presence of the processed form in these 
mice indicates the adenovirus expresses catalytically active Pcsk9. 
Pcsk9
γ-tubulin
1   2   3   4   5   6   7   8   9  10 11 12 13 
Figure 4.1.  Adenoviral mediated expression of Pcsk9 in mice.  (A) Male C57BL/6 mice of greater 
than 10 weeks of age and fed a chow diet were injected via the tail vein with PBS (Lanes 1 and 2), Ad 
empty (Lanes 3 and 4), or an adenovirus constitutively expressing the murine C57BL/6 Pcsk9 ORF 
under the control of a CMV promoter (Pcsk9-Ad, Lanes 5-12).  Pcsk9-Ad was injected at increasing 
concentrations from 1x108 pfu/mouse to 1x109 pfu/mouse (Lanes 5-12). As a control, McA-RH7777 
cells were infected with Pcsk9-Ad at a multiplicity of infection of 2000 (Lane 13).  Liver homogenates 
were immunoblotted with α-Pcsk9-500+583 and α-gamma tubulin. 
pro-Pcsk9
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Adenoviral mediated expression of Pcsk9 increases plasma LDL cholesterol levels 
The effect of adenoviral mediated Pcsk9 expression on plasma cholesterol levels 
was determined.  Injection of Pcsk9-Ad into C57BL/6 mice resulted in elevated plasma 
total cholesterol levels compared to injection of Ad empty (147±17 mg/dl versus 72±6 
mg/dl, p=0.0003) (Figure 4.2A).  Ultracentrifugal separation of plasma was used to show 
that this increase in total cholesterol was due to an increase in plasma non-HDL chol- 
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Figure 4.2. Overexpression of Pcsk9 in wild-type 
mice increased LDL cholesterol levels.  (A) 
Plasma was isolated from wild type male C57BL/6 
mice injected with Ad empty and Pcsk9-Ad, and 
HDL and non-HDL plasma fractions were 
separated by ultracentrifugation.  Cholesterol and 
triglyceride levels in these fractions were measured 
by enzymatic assay.  Overexpression of Pcsk9 
caused an increase in total cholesterol, non-HDL 
cholesterol, and triglycerides with no change in 
HDL cholesterol levels.  (B,C) Plasma was pooled 
from at least two wild type animals (C57 WT), 
animals injected with Ad empty and animals 
injected with Pcsk9-Ad, fractionated by FPLC, and 
cholesterol (B) and triglycerides (C) measured by 
enzymatic assay.  Two runs of Pcsk9-Ad injected 
mice are shown to demonstrate reproducibility.  
Wild type mice and mice injected with Ad empty 
had mainly HDL-derived cholesterol and VLDL 
derived triglyceride.  Mice injected with Pcsk9-Ad 
had similar levels of HDL- and VLDL-derived 
cholesterol, but had high levels of LDL-derived 
cholesterol;furthermore, they had high levels of 
VLDL and LDL-derived triglyceride.  
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-esterol levels (86±14 mg/dl versus16±3 mg/dl, p=0.0002) with no change in HDL 
cholesterol (56±2 mg/dl versus 51±2 mg/dl, p=NS).  There was also an increase in 
plasma triglycerides (91±25 mg/dl vs. 47±2 mg/dl, p=0.03).  To determine the specific 
lipoprotein fraction responsible for the increase in non-HDL cholesterol in Pcsk9-Ad 
infected mice, fast protein liquid chromatography (FPLC) was used to separate 
lipoprotein fractions.  As shown in Figure 4.2B, the increase in non-HDL cholesterol in 
Pcsk9-Ad injected mice was due to a specific increase in LDL cholesterol, with little or 
no change in cholesterol in VLDL or chylomicrons.  There was a 6.9-fold increase in the 
area under the LDL peak in Pcsk9-Ad versus Ad empty injected mice, versus a 1.4-fold 
increase in the area under the VLDL peak.  As shown in Figure 4.2C, the increase in 
triglycerides in Pcsk9-Ad injected mice was found to be in both the VLDL and LDL 
fractions, with the majority of the increase in triglycerides found in the LDL fractions.  
There was a 6.2-fold increase in the area under the LDL peak in Pcsk9-Ad versus Ad 
empty injected mice, versus a 1.7-fold increase in the area under the VLDL peak. 
 
The Pcsk9-Ad induced increase in LDL cholesterol is dependent on the LDLR 
An increase in LDL cholesterol levels could be due to an increase in production of 
apoB containing lipoproteins or a decrease in clearance of LDL by the LDLR in the liver.  
To determine if the Pcsk9-Ad induced increase in LDL cholesterol was dependent on the 
LDLR, Pcsk9-Ad was injected into LDLR knockout mice.  Similar to what was observed 
in wild-type C57BL/6 mice, the livers of LDLR knockout mice injected with Ad empty 
had no immunoreactive Pcsk9 and injection of increasing concentrations of Pcsk9-Ad 
produced increasing amounts of both the pro and processed forms of Pcsk9 (Figure 4.3).  
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Figure 4.3 Adenoviral mediated overexpression of Pcsk9 in LDLR KO mouse liver.  Male LDLR 
knockout mice on a C57BL/6 background of greater than 10 weeks of age and fed a chow diet were 
injected via the tail vein with Ad empty (Lanes 1-5) or increasing concentrations of Pcsk9-Ad (Lanes 6-
10).  Liver homogenates were immunoblotted with with α-Pcsk9-500+583 and α-gamma tubulin. 
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Figure 4.4. Pcsk9-induced increase in LDL 
cholesterol levels was dependent on the LDLR. 
(A) Plasma was isolated from LDLR knockout mice 
injected with Ad empty and Pcsk9-Ad, and HDL and 
non-HDL plasma fractions were separated by 
ultracentrifugation.  Cholesterol and triglyceride 
levels in these fractions were measured by 
enzymatic assay.  LDLR knockout mice injected 
with Ad empty had elevated total cholesterol, non-
HDL cholesterol, and triglyceride with no change in 
HDL cholesterol levels.  Overexpression of Pcsk9 
did not cause a further increase in total, non-HDL 
cholesterol, or triglyceride levels in LDLR knockout 
mice.  (B,C) Plasma was pooled from at least two 
LDLR knockout animals (LDLRKO), animals 
injected with Ad empty and animals injected with 
Pcsk9-Ad, fractionated by FPLC, and cholesterol (B) 
and triglycerides (C) measured by enzymatic assay.  
Two runs of Pcsk9-Ad injected mice are shown to 
demonstrate reproducibility. Cholesterol and 
triglyceride compositions of all lipoproteins in 
LDLR knockout mice injected with Pcsk9-Ad was 
indistinguishable from that of uninjected LDLR 
knockout mice (LDLRKO) and LDLR knockout 
mice injected with Ad empty.
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 As shown in Figure 4.4A, although all LDLR knockout mice had higher levels of 
total cholesterol, non-HDL cholesterol and triglycerides than wild type mice, no 
significant differences in these lipid levels were observed between Pcsk9-Ad and Ad 
empty injected LDLR knockout mice (total, 202±26 mg/dl vs. 205±27 mg/dl, p=NS; non-
HDL, 135±19 mg/dl vs. 145±23 mg/dl, p=NS; triglycerides, 96±20 mg/dl vs. 89±25 
mg/dl, p=NS).  HDL-cholesterol was unchanged in Pcsk9-Ad versus Ad empty injected 
LDLR knockout mice and levels were similar to wild-type mice.  The distribution of 
cholesterol in FPLC separated lipoprotein fractions is shown in Figure 4.4B.  The 
increases in non-HDL cholesterol in Pcsk9-Ad injected, Ad empty injected, and 
uninjected LDLR knockout mice were all due to a specific increase in LDL cholesterol.  
The increases in triglycerides were also found to be in the LDL fractions (Figure 4.4C).   
 
Pcsk9-Ad injection results in the absence of liver LDLR protein with normal mRNA 
levels 
The effects of Pcsk9 overexpression on liver LDLR mRNA and protein levels 
were examined.  There was a large increase in Pcsk9 mRNA levels in Pcsk9-Ad versus 
Ad empty injected mice, as expected (Figure 4.5A).  There was no change in LDLR 
mRNA levels, indicating that Pcsk9 overexpression was not affecting LDLR 
transcription.  LDLR transcription is mainly regulated by the SREBP-2 protein.  Thus, to 
support the hypothesis that Pcsk9 was not affecting SREBP mediated transcription, it was 
also shown that there was no change in Sqle and Hmgcr mRNA levels in Pcsk9-Ad 
versus Ad empty injected mice.  Effects on LDLR protein levels were determined by 
Western blotting with an antibody to the mouse LDLR cytoplasmic tail (Figure 4.5B).  
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Wild-type C57BL/6 mice have two bands at approximately 160 kDa, the size of the 
mature LDLR.  The upper band is present in LDLR knockout mice; whereas, the lower 
band is absent, indicating that the lower band represents the LDLR.  This lower band is 
virtually absent in Pcsk9-Ad injected mice, whereas it is unaffected in Ad empty injected 
mice.  Protein from PBS injected, Ad empty injected, Pcsk9-Ad injected and LDLR 
knockout mice were also electrophoresed under non-reducing conditions (Figure 4.5C).  
Again, the upper band was shown to be an artifact. 
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Figure 4.5. Overexpression of Pcsk9 resulted in an absence of LDLR protein with normal LDLR 
mRNA levels.   (A) The levels of Pcsk9, LDLR, Sqle, Hmgcr, and Abcg5 mRNA in livers of mice 
injected with Ad empty and Pcsk9-Ad was measured by Q-PCR; combined results of two experiments 
are shown. Gene expression was normalized to cyclophilin A and Ad empty values set equal to one. 
Overexpression of Pcsk9 did not change the levels of LDLR mRNA. (B) The levels of LDLR protein 
in livers of mice injected with Ad empty and Pcsk9-Ad was detected by immunoblotting with an 
antibody specific to the murine LDLR cytoplasmic tail.  Wild type C57BL/6 mice had a predominant 
LDLR band at approximately 160kDa; this band was absent in LDLR knockout mice.  Mice injected 
with Ad empty had normal levels of LDLR protein; whereas mice injected with Pcsk9-Ad had a 
complete absence of LDLR protein. (C) Western blot performed under non-reducing conditions 
confirms that the extra band is an artifact.
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Pcsk9-Ad injection does not alter hepatic cholesterol levels or gallbladder bile 
composition 
The effects of Pcsk9-Ad on other physiological measures related to cholesterol 
metabolism were studied.  As shown in Table 4.1, there were no differences in hepatic 
total, free or esterified cholesterol between Pcsk9-Ad and Ad empty injected mice.  In 
addition, there were also no differences in gallbladder bile concentrations of cholesterol, 
bile acids, or phospholipids (Table 4.1). 
Table 4.1. Liver cholesterol and gallbladder bile composition  in mice overexpressing Pcsk9a 
Liver Cholesterolb,c  Gallbladder Compositiond 
 Ad empty Pcsk9-Ad   Ad empty Pcsk9-Ad 
Total cholesterol 3.11 + 0.72 3.12 + 0.16  Cholesterol, mg/dl 62.3 + 20.4 53.8 + 10.9 
Free cholesterol  2.49 + 0.66 2.42 + 0.19  Bile Acids, mM 130.9 + 54.1 140.7 + 21.9 
Cholesterol ester 0.81 + 0.31 0.74 + 0.17  Phospholipid, mg/dl 1430 + 406 1254 + 182 
a Combined results of two experiments are shown 
b Liver cholesterol is given as milligrams of cholesterol per gram of liver weight 
c n = 4 mice for Ad empty, n = 8 mice for Pcsk9-Ad 
d n = 3 mice for Ad empty, n = 4 mice for Pcsk9-Ad 
 
Overexpression of Pcsk9 in vitro decreases LDLR protein levels and function 
 In order to determine if the effects of Pcsk9 overexpression on LDLR protein 
levels and function could be recapitulated in vitro, several cell lines were transfected or 
infected with Pcsk9 expression constructs or adenovirus.  Then, LDLR protein levels 
were measured and LDLR function was assayed by measuring DiI-LDL (DiI, 1,1’-
dioctadecyl-3,3,3’,3’-tetramethyl-indocarbocyanine perchlorate) uptake and/or binding.  
The validity of this assay was shown in cells transfected with a mouse LDLR construct 
(Figure 4.6); overexpression of the LDLR led to an increase in DiI-LDL binding and 
uptake in McA-RH7777 cells, as expected.   
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p Figure 4.6. Validation of DiI-LDL binding and uptake 
experiments.  McA-RH7777 cells were transfected with a LDLR 
expression construct or empty vector (pcDNA).  For Binding 
experiments, cells were incubated with DiI-LDL at 4°C for one 
hour, and for Uptake experiments, cells were incubated with DiI-
LDL at 37°C for two hours.  Fluorescence was normalized to total 
protein and values for pcDNA set equal to one.  As expected, 
transfection of the LDLR increased DiI-LDL binding and uptake.
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In addition, to determine whether the catalytic activity of Pcsk9 was required for its 
action on the LDLR, a catalytically inactive mutant Pcsk9 was constructed by using site-
directed mutagenesis to change the active site residue S402 to an alanine (Pcsk9S402A).  
As shown in Figure 4.7, transfection or infection of Pcsk9WT into rat hepatoma McA-
RH7777 cells or human hepatoma HepG2 cells resulted in expression of the pro- and 
processed forms of Pcsk9; whereas, Pcsk9S402A resulted in the expression of only the 
pro-form as expected since Pcsk9 processing is due to autocatalytic self-cleavage.  
Furthermore, in Pcsk9WT cells, the processed form of Pcsk9 was secreted into the 
medium.  Of note, in Pcsk9S402A cells, the pro-form of Pcsk9 still traversed the 
secretory pathway and was secreted into the medium. 
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Figure 4.7. Expression of wild-type and a catalytic mutant 
of Pcsk9 in vitro.  McA-RH7777 (7777) cells and HepG2 
cells were infected with Ad empty (E), Pcsk9-Ad (P9WT) or 
an adenovirus expressing a catalytically inactive mutant 
Pcsk9, Pcsk9S402A-Ad (P9M).  A western blot using α-
Pcsk9 shows that Pcsk9-Ad induces the expression of pro-
Pcsk9 (pP) and the processed Pcsk9 (P) which is secreted into 
the media.  In contrast, Pcsk9S402A induces the expression of 
only pro-Pcsk9 which is secreted into the media. 
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 McA-RH7777 cells were first used to assay the effects of Pcsk9 overexpression in 
vitro.  Overexpression of wild type Pcsk9 caused a 72% decrease in LDLR protein, 
whereas catalytically inactive Pcsk9S402A caused a 15% decrease in LDLR protein 
(Figure 4.8A).  This corresponded to a 52% and 15% decrease in the binding of DiI-LDL, 
respectively (Figure 4.8B).  In addition, overexpression of Pcsk9WT was shown to cause 
a decrease in DiI-LDL uptake into the cell over time (Figure 4.8C).   
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Figure 4.8. Overexpression of Pcsk9 in McA-RH7777 cells decreased LDLR protein, LDL 
binding, and uptake. (A) McA-RH7777 cells were transiently transfected with pcDNA empty vector 
(Lane 1), wild type Pcsk9-pcDNA (Lane 2), and the mutant Pcsk9(S402A)-pcDNA (Lane 3).  
Overexpression of wild type Pcsk9 resulted in 72% decrease in LDLR protein, whereas overexpression 
of catalytically inactive Pcsk9 caused a 15% decrease in LDLR protein.  (B) Specific binding of DiI-
LDL was measured in transiently transfected McA-RH7777 cells, normalized to total protein, and the 
value for pcDNA set equal to one.  Overexpression of wild type Pcsk9 resulted in a 52% decrease in 
DiI-LDL binding, whereas overexpression of catalytically inactive Pcsk9 resulted in a 15% decrease in 
DiI-LDL binding.  (C) Uptake of DiI-LDL was measured in McA-RH7777 cells infected with Ad 
empty or Pcsk9-Ad and normalized to Hoechst DNA staining.  Overexpression of Pcsk9 resulted in a 
decrease in DiI-LDL uptake over time.
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Because the majority of the biosynthetic analysis of the LDLR has been done with 
a specific monoclonal to human LDLR, IgG-C7 (Beisiegel et al., 1981), human HepG2 
cells were also analyzed for an effect of Pcsk9 overexpression.  The IgG-C7 recognizes a 
precursor LDLR at 120kDa and a mature LDLR at 160kDa.  Although transfection of the 
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Pcsk9 constructs into HepG2 cells led to expression of Pcsk9 protein, no effects were 
seen on LDLR protein levels or DiI-LDL binding (data not shown).  Since it was possible 
that low transfection efficiency could be the reason for the lack of an effect, HepG2 cells 
were infected with Ad empty or Pcsk9-Ad.  Infection of Pcsk9-Ad into HepG2 cells 
caused a highly significant decrease in levels of the precursor and mature LDLR protein 
(Figure 4.9A); importantly, no effect of Pcsk9 was seen on the levels of the transferrin 
receptor (TfR), another cell surface protein.  Furthermore, using immunoprecipitation of 
biotin-labeled LDLR, it was found that Pcsk9-Ad induced a decrease in cell surface 
LDLR (Figure 4.9B).  The Pcsk9 induced decrease in LDLR protein levels in HepG2 
cells had functional consequences, as Pcsk9 overexpression was found to cause a 65% 
decrease in DiI-LDL binding (Figure 4.9C). 
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Figure 4.9. Overexpression of Pcsk9 in HepG2 cells decreased 
whole cell LDLR, cell surface LDLR and LDL binding.  (A)
HepG2 cells were infected with control Ad empty (Empty) or Pcsk9-
Ad (Pcsk9) and whole cell lysates were collected after 36 hours. Cell 
lysates were subjected to Western blotting for LDLR, transferrin
receptor (TfR), and Pcsk9.  M, mature LDLR; P, precursor LDLR; pP, 
pro-Pcsk9; C, cleaved Pcsk9.  Pcsk9 decreased whole cell LDLR 
levels.  (B) HepG2 cells were infected with Ad empty or Pcsk9-Ad.  
After 36 hours, cell surface proteins were biotinylated at 4°C, lysates 
collected and immunoprecipitated for the LDLR.  Proteins were 
visualized with avidin-HRP.  Pcsk9 decreased cell surface LDLR 
levels.  (C) HepG2 cells were infected with Ad empty or Pcsk9-Ad 
and specific DiI-LDL binding was measured. Fluorescence was 
normalized to total protein and values for Ad empty set equal to one.  
Pcsk9 decreased DiI-LDL binding.
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Microscopic analysis of the effects of Pcsk9 on LDLR function 
 In order to present visual, qualitative data in support of the quantitative DiI-LDL 
binding experiments above concerning the effects of Pcsk9 on LDLR levels and function, 
fluorescence microscopy was used.  McA-RH7777 cells were transfected with Pcsk9-
GFP and incubated with DiI-LDL for one hour at 4ºC to allow binding to the cell surface.  
As shown in Figure 4.10A, by epifluorescence microscopy, cells which were not 
transfected with Pcsk9-GFP (cells that are not green) have red staining on the cell surface 
due to DiI-LDL binding.  In contrast, cells which were transfected with Pcsk9-GFP (cells 
that are green) have little to no red staining on the cell surface.  The same result was 
obtained using confocal microscopy (Figure 4.10B).   
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Figure 4.10. DiI-LDL binding in cells transfected with Pcsk9-GFP.  
(A) McA-RH7777 cells were transfected with Pcsk9-GFP (green) and 
treated with DiI-LDL (red) at 4°C for two hours to allow DiILDL
binding to cell surface.  Cells were examined with epifluorescence 
microscopy.  Cells transfected with Pcsk9-GFP do not bind DiI-LDL.  
(B) The experiment was repeated using confocal microscopy and 
higher power magnification.  (C) Western blot of cells transiently 
transfected with Pcsk9-Flag and Pcsk9-GFP show that Pcsk9-GFP is 
processed and secreted into the medium as expected. pP: pro-Pcsk9; P: 
processed Pcsk9.
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These results indicated not only that Pcsk9 decreased the ability of the cell to bind LDL, 
but they also suggest that secreted Pcsk9 at the concentration released from transfected 
cells could not affect the LDL binding of adjacent, non-transfected cells.  Of note, the 
Pcsk9-GFP construct was processed as normal, and Pcsk9 of increased molecular weight 
due to the GFP tag was secreted into the medium (Figure 4.10C).   
 A complementary experiment was performed in HepG2 cells; cells were co-
transfected with LDLR-yellow fluorescent protein (YFP) and empty vector or Pcsk9-cyan 
fluorescent protein (CFP).  Co-transfection of LDLR-YFP with empty vector caused 
yellow LDLR staining at the cell surface and in round intracellular structures (Figure 
4.11A).  In contrast, co-transfection of LDLR-YFP with Pcsk9-CFP caused a decrease in 
yellow LDLR staining at the cell surface (Figure 4.11B,C).  The yellow LDLR staining in 
the round intracellular structures remained.  Some of the round intracellular structures 
have co-localized LDLR-YFP and Pcsk9-CFP (merge is green).   
 McA-RH7777 cells were transfected with an internalization defective mutant of 
the LDLR, A18 (Hunziker et al., 1991), tagged with GFP (LDLRA18-GFP) and infected 
with control lacZ adenovirus (lacZ-Ad) or Pcsk9-Ad.  The LDLRA18 (Y828A) mutant is 
unable to bind to ARH and undergo clathrin-mediated endocytosis.  As shown in Figure 
4.11D, LDLRA18-GFP in lacZ-Ad infected cells was also found at the cell surface and in 
intracellular vesicles.  In contrast, Pcsk9-Ad infection caused an absence of cell surface 
LDLRA18-GFP.  These results indicated that ARH/clathrin-mediated endocytosis of the 
LDLR was not required for the Pcsk9 induced decrease in LDLR levels.  Finally, 
overexpression of Pcsk9 was able to decrease the levels of wild-type LDLR and 
internalization defective mutant LDLRA18 (Figure 4.11E) by western blotting.   
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Figure 4.11. Microscopic evaluation of the effect of Pcsk9 overexpression on the LDLR.  (A) HepG2 
cells were transiently transfected with wild-type LDLR tagged with YFP (LDLR-YFP) and empty vector 
(pcDNA3) and examined with confocal microscopy.  LDLR-YFP (yellow channel) is expressed at the 
cell surface.  (B,C) HepG2 cells were transiently transfected with LDLR-YFP and Pcsk9-CFP.   In the 
presence of Pcsk9-CFP (blue channel), LDLR-YFP is not found at the cell surface (yellow channel).  
Merge shows partial colocalization of Pcsk9-CFP and LDLR-YFP.  (D) McA-RH7777 cells were 
transiently transfected with internalization defective LDLRA18-GFP and infected with control 
adenovirus (lacZ-Ad) or Pcsk9-Ad.  LDLRA18-GFP is at the cell surface in control cells but is absent 
from the cell surface in the presence of Pcsk9.  (E) Confirmation that Pcsk9 can decrease the levels of 
wild-type and mutant LDLR by Western blotting.  M: M, mature LDLR; P, precursor LDLR; pP, pro-
Pcsk9; C, cleaved Pcsk9. 
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Overexpression of Pcsk9 has no effect on LDLR synthesis 
Overexpression of Pcsk9 reduces LDLR protein levels with no effect on mRNA 
levels, indicating that Pcsk9 affects LDLR synthesis or degradation. First, the effect of 
Pcsk9 on LDLR protein synthesis was investigated.  HepG2 cells infected with Ad empty 
or Pcsk9-Ad were pulsed with 35S-Met/Cys for 5, 10, 20 and 30 minutes.  As shown in 
Figure 4.12A, there were equivalent levels of labeled precursor LDLR in cells pulsed for 
5, 10, and 20 minutes in control and Pcsk9 overexpressing cells.  These results indicate 
that Pcsk9 overexpression had no effect on the synthesis of the LDLR (Figure 4.12B).  Of 
note, after 30 minutes of pulse, a decrease in the precursor LDLR was seen, suggesting an 
effect of Pcsk9 on degradation of the LDLR.  It is important to note for this and future 
biosynthetic experiments that the TCA precipitable counts, a measure of whole cell 
protein synthesis, were the same between Ad empty and Pcsk9-Ad treated cells. 
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Figure 4.12. Overexpression of Pcsk9 did not affect synthesis of the LDLR.  (A) HepG2 cells were 
infected with Ad Empty (Empty) or Pcsk9-Ad (Pcsk9).  Cells were pulse labeled with 35S -Met/Cys for 
5, 10, 20, and 30 minutes and immunoprecipitated for the LDLR.  P, precursor LDLR.  (B)
Quantification of the results in part A; band intensities were quantified with Image Pro Plus.
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Overexpression of Pcsk9 accelerates the degradation of the mature LDLR 
In order to investigate whether overexpression of Pcsk9 stimulated LDLR 
degradation, HepG2 cells infected with Ad empty or Pcsk9-Ad were pulsed with 35S-
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Met/Cys for 30 minutes and chased for 0.5, 1.5, 2.5, 3.5, 5.5, 7.5, and 9.5 hours.  As 
shown in Figure 4.13A, overexpression of Pcsk9 caused rapid degradation of the mature 
LDLR.  In Ad empty treated cells, the levels of the mature LDLR increased until 2.5 
hours, and then gradually decreased to 52% of peak levels by 9.5 hours of chase (Figure 
4.13B).  In comparison, in Pcsk9-Ad treated cells, the levels of the mature LDLR started 
to increase until 1.5 hours, and then were already in rapid decline at 2.5 hours, such that 
the level of LDLR in Pcsk9 treated cells was 8% of peak levels by 5.5 hours of chase.  
Furthermore, the half-life of the mature LDLR was approximated to be 7 hours in Ad 
empty treated cells (compare 2.5 hours versus 9.5 hours); whereas the half-life was 
approximated to be slightly over 1 hour in Pcsk9-Ad treated cells (compare 1.5 hours 
versus 2.5 hours).  Of note, overexpression of Pcsk9 also caused a small increase in the 
rate of degradation of the precursor LDLR.  
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Figure 4.13.  Overexpression of Pcsk9 
accelerated the degradation of the 
mature LDLR. (A) HepG2 cells were 
infected with Ad- Empty or Pcsk9-Ad 
(Pcsk9WT or P9wt).  Cells were pulse 
labeled with 35S -Met/Cys for 30 minutes, 
chased for 0, 0.5, 1.5, 2.5, 3.5, 5.5, 7.5, 
9.5 hours, and immunoprecipitated for the 
LDLR. M, mature LDLR; P, precursor 
LDLR.  (B) Band intensities were 
measured using ImageQuant and graphed 
to demonstrate that Pcsk9 increases the 
degradation of the mature LDLR.  
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 The IgG-C7 antibody recognizes the repeat #1 of the ligand binding domain 
(LBD) of the LDLR, which is found at the N-terminus.  To differentiate between a Pcsk9 
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induced degradation of the entire LDLR or a Pcsk9 induced loss of the IgG-C7 (C7) 
epitope, other antibodies were used (Figure 4.14A).  A rabbit anti-rat LDLR from Fred 
Kraemer (K) to repeats 4-5 of the LBD and a rabbit anti-mouse LDLR from Joachim 
Herz (H) to the C-terminal tail of the LDLR were used to immunoprecipitate endogenous  
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Figure 4.14.  Pcsk9-induced degradation of the LDLR did not depend on the antibody used to 
immunoprecipitate the LDLR.  (A) Diagram of the three antibodies used to immunoprecipitate 
endogenous LDLR from cells.  C7 is a monoclonal antibody to repeat #1 in the ligand binding domain of 
the human LDLR; K is a polyclonal antibody to repeats #4-5 in the ligand binding domain of the rat 
LDLR; H is a polyclonal antibody to the C-terminal tail of mouse LDLR.  (B) HepG2 or McA-RH7777 
cells were infected with Ad- Empty (E) or Pcsk9-Ad (P).  Cells were pulse labeled with 35S -Met/Cys for 
30 minutes and chased for 1 and 4 hours, and immunoprecipitated for the LDLR using the indicated 
antibody. M, mature LDLR; P, precursor LDLR. (C) Diagram of the antibodies used to 
immunoprecipitate transfected LDLR-GFP from McA-RH7777 cells.  C7 is as in part A, G is a 
monoclonal antibody to GFP.  (D) McA-RH7777 cells were infected with Ad- Empty (E) or Pcsk9-Ad 
(P).  Cells were pulse labeled with 35S -Met/Cys for 30 minutes and chased for 0, 1 and 4 hours, and 
immunoprecipitated for the LDLR using the indicated antibody.  Regardless of the antibody used, Pcsk9 
induced degradation of the LDLR.
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LDLR from McA-RH7777 cells.  Cells infected with Ad empty or Pcsk9-Ad were pulsed 
with 35S-Met/Cys for 30 minutes and chased for 1 and 4 hours.  As shown in Figure 
4.14B, Pcsk9-Ad caused a decrease in LDLR levels after 4 hours of chase regardless of 
whether the C7, K, or H antibodies were used to immunoprecipitate the LDLR.  Next, an 
anti-GFP monoclonal antibody (G) was used to immunoprecipitate LDLR-GFP from 
transfected McA-RH7777 (Figure 4.14C).  Cells infected with Ad empty or Pcsk9-Ad 
were pulsed with 35S-Met/Cys for 30 minutes and chased for 0, 1, and 4 hours.  Pcsk9-Ad 
induced a decrease in LDLR-GFP levels regardless of whether the C7 or G antibodies 
were used (Figure 4.14D). 
 
The Pcsk9 induced degradation of the mature LDLR requires Pcsk9 serine protease 
activity 
As shown above in Figure 4.10A, the catalytically inactive mutant Pcsk9, 
Pcsk9S402A, does not induce a significant decrease in LDLR in McA-RH7777 cells.  
This was confirmed by infection of HepG2 cells with an adenovirus expressing 
Pcsk9S402A (Pcsk9S402A-Ad), where infection of Pcsk9S402A-Ad caused a decrease in 
precursor LDLR levels at steady state but no change in mature LDLR levels (Figure 
4.15A).  HepG2 cells were then infected with Ad empty or Pcsk9S402A-Ad and pulsed 
with 35S-Met/Cys for 30 minutes and chased for 0, 0.5, 1.5, 2.5, 3.5, 5.5, 7.5, 9.5 hours.  
As shown in Figure 4.15B, the Pcsk9 induced degradation of the precursor LDLR still 
occurred in cells overexpressing Pcsk9S402A.  However, while there was less input into 
the mature LDLR pool, the Pcsk9S402A catalytic mutant did not rapidly accelerate the 
degradation of the mature LDLR.  In Ad empty treated cells, the levels of the mature 
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LDLR increased until 2.5 hours, and then gradually decreased to 41% of peak levels by 
9.5 hours of chase (Figure 4.15C).  In Pcsk9S402A-Ad treated cells, the levels of the 
mature LDLR also increased until 2.5 hours, and then gradually decreased to 47% of 
peak levels by 7.5 hours of chase, indicating a small decrease in half-life in Pcsk9S402A 
treated cells, but not nearly to the level seen in Pcsk9WT treated cells.  
30min pulse, 4hr chase
+Pefabloc
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Time (hr)
Figure 4.15.  Degradation of the mature LDLR required Pcsk9 catalytic activity.  HepG2 cells 
were infected with Ad empty (Empty), wild-type Pcsk9-Ad (Pcsk9WT) or catalytically inactive 
Pcsk9S402A (Pcsk9S402A or P9m) (A) Steady state levels of LDLR and Pcsk9.  Wild-type Pcsk9 
decreased both mature (M) and precursor (P) LDLR; whereas Pcsk9S402A did not decrease levels of 
mature LDLR.  pP, pro-Pcsk9, C, cleaved Pcsk9. ( B) Cells were pulse labeled with 35S -Met/Cys for 30 
minutes, chased for 0, 0.5, 1.5, 2.5, 3.5, 5.5, 7.5, 9.5 hours, and immunoprecipitated for the LDLR.  (C) 
Band intensities in part B were measured using ImageQuant and graphed to demonstrate that 
Pcsk9S402A does not affect the degradation of the mature LDLR.  (D) Cells were pulse labeled with 
35S -Met/Cys for 30 minutes, chased for 4 hours in the presence of the serine protease inhibitors 
Pefabloc, and immunoprecipitated for the LDLR.  Percent LDLR vs. Empty indicates the average 
percent of LDLR in Pcsk9 treated cells versus empty treated cells calculated from two or more 
experiments.  Wild-type Pcsk9 did not decrease the levels of mature LDLR in the presence of Pefabloc.
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In order to confirm these experiments, HepG2 cells infected with Ad empty or 
Pcsk9-Ad were pulsed with 35S-Met/Cys for 30 minutes and chased for four hours in the 
absence or presence of Pefabloc, a stable derivative of the serine protease inhibitor 
phenylmethylsulphonylfluoride (PMSF).  PMSF has been shown to inhibit purified Pcsk9 
cleavage of a fluorescent substrate in vitro (Naureckiene et al., 2003).  As shown in 
Figure 4.15D, addition of Pefabloc prevented the Pcsk9-induced degradation of the 
mature LDLR.  A decrease in the levels of precursor LDLR remained in Pefabloc treated 
cells.  These experiments lend support to the experiments with Pcsk9S402A, and indicate 
that the Pcsk9-induced degradation of the mature LDLR requires Pcsk9 catalytic activity. 
 
The Pcsk9 induced degradation of the LDLR does not depend on the proteasome 
The two major mediators of intracellular protein degradation are the proteasome 
and lysosome. To investigate whether the proteasome mediates Pcsk9 induced 
degradation of the LDLR, HepG2 cells infected with Ad empty or Pcsk9-Ad were pulsed 
with 35S-Met/Cys for 30 minutes and chased for four hours in the absence or presence of 
the proteasome inhibitors MG132 and lactacystin.  As shown in Figure 4.16A, Pcsk9 was 
still able to increase the degradation of the LDLR in the presence of MG132 and 
lactacystin, indicating that the Pcsk9 induced degradation of the LDLR does not occur in 
the proteasome.  In order to determine if the proteasome was inhibited in these studies, 
cell lysates were incubated with the fluorescent proteasome substrate Suc-LLVY-AMC.  
As shown in Figure 4.16B, the amount of fluorescence released by proteasome mediated 
cleavage of the substrate was decreased in cells treated with MG132 and lactacystin. 
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Figure 4.16.  Pcsk9 induced degradation of 
the LDLR did not depend on the proteasome.  
(A) HepG2 cells were infected with Ad empty 
or Pcsk9-Ad.  Cells were pulse labeled with 35S 
-Met/Cys for 30 minutes, chased for 4 hours in 
the presence of the proteasome inhibitors 
MG132 or lactacystin, and immunoprecipitated 
for the LDLR.  M, mature LDLR; P, precursor 
LDLR. Percent LDLR vs. Empty is as described 
in Figure 4.15D.  (B) To measure proteasome 
activity in these cells, lysates were incubated 
with the proteasome substrate Suc-LLVY-AMC 
for 1 hour.  Fluorescence due to cleaved AMC 
by the proteasome was measured, adjusted to 
background, normalized to total protein and the 
untreated value set equal to one. 
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The Pcsk9 induced degradation of the LDLR does not depend on various classes of 
lysosomal and non-lysosomal proteases 
To investigate whether the Pcsk9 induced degradation of the LDLR occurs in 
lysosomes, HepG2 cells infected with Ad empty or Pcsk9-Ad were pulsed with 35S-
Met/Cys for 30 minutes and chased for four hours in the presence of the acidotropic agent 
ammonium chloride.  This resulted in decreased conversion of precursor to mature 
LDLR, making interpretation of this experiment difficult.  However, the decreased 
amount of mature LDLR that was made was protected from degradation by Pcsk9 in the 
presence of ammonium chloride (Figure 4.17A), indicating that the degradation of the 
LDLR by Pcsk9 may occur in a pH sensitive compartment like the lysosome.  The major 
proteases in lysosomes are cysteine proteases of the cathepsin family.  To investigate the 
role of this protease class, HepG2 cells infected with Ad empty or Pcsk9-Ad were pulsed 
with 35S-Met/Cys for 30 minutes and chased for four hours in the presence of the cysteine 
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protease inhibitor E64d.  The Pcsk9 induced degradation of the LDLR occurred in the 
presence of E64d, indicating that the effect was not mediated by cysteine proteases 
(Figure 4.17B).  The quantification of this data is shown in Table 4.2.  That the cysteine 
proteases were inhibited in these experiments was demonstrated in cell lysates incubated 
with the cysteine protease substrate Z-RR-AMC, in which the amount of fluorescence 
was decreased by E64d treatment (Figure 4.17C).   
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Figure 4.17.  Pcsk9 induced degradation of the 
LDLR occured in a pH dependent compartment 
but did not depend on cysteine proteases.  (A,B)
HepG2 cells were infected with Ad empty or 
Pcsk9-Ad.  Cells were pulse labeled with 35S -
Met/Cys for 30 minutes, chased for 4 hours in the 
presence of the lysomotrophic agent NH4Cl (A) or 
the cysteine protease inhibitors E64d (B) and 
immunoprecipitated for the LDLR.  M, mature 
LDLR; P, precursor LDLR.  (C) To measure 
cysteine protease activity in these cells, lysates 
were incubated with the substrate Z-RR-AMC for 1 
hour. Fluorescence due to cleaved AMC by the 
cysteine proteases was measured, adjusted to 
background, normalized to total protein and the 
untreated value set equal to 100. 
A
M
C
 fl
uo
re
sc
en
ce
 
 In order to determine if other classes of proteases play a role in Pcsk9 induced 
degradation of the LDLR, HepG2 cells infected with Ad empty or Pcsk9-Ad were pulsed 
for 30 minutes and chased for four hours in the presence of ALLN to inhibit calpain 
proteases, pepstatin to inhibit aspartic acid proteases, and phosphoramidon to inhibit 
metalloproteases.  As shown in Table 4.2, Pcsk9 was still able to increase degradation of 
the LDLR in the presence of all of these inhibitors. 
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Table 4.2.  Pcsk9 induced LDLR degradation in the presence of protease inhibitors 
 
 
 
 
 
 
The Pcsk9 induced degradation of the LDLR requires transport out of the ER 
To localize the cellular site of Pcsk9 induced degradation of the LDLR, HepG2 
cells infected with Ad empty or Pcsk9-Ad were pulsed with 35S-Met/Cys for 30 minutes 
and chased for four hours in the presence of brefeldin A (BFA), which inhibits transport 
out of the ER.  As shown in Figure 4.18, Pcsk9 was not able to degrade the LDLR in the 
presence of BFA.   The single smaller LDLR band shown has been described previously 
(Shite et al., 1990b; Shite et al., 1990a).  Since BFA also collapses Golgi contents into the 
ER, cells were treated with BFA in the presence of nocodazole to prevent retrograde 
transport.  As shown in Figure 4.18, Pcsk9 was also unable to promote the degradation of 
the LDLR in the presence of BFA and nocodazole.  These results indicate that Pcsk9 
induced degradation of the LDLR occurs in a post-ER compartment.  
Empty Pcsk9
Untreated BFA BFA+noc
Empty Pcsk9 Empty Pcsk9
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M
Figure 4.18.  Pcsk9 induced degradation of the LDLR depended on exit from the ER. HepG2 cells 
were infected with Ad Empty (Empty) or Pcsk9-Ad (Pcsk9).  Cells were pulse labeled with 35S-
Met/Cys for 30 minutes, chased for 4 hours in the presence of BFA, and BFA plus nocodazole (noc), 
and immunoprecipitated for the LDLR.  M, mature LDLR; P, precursor LDLR. 
 
  
Percent LDLR in Pcsk9 
compared to Empty 
Inhibitor Protease Class 120kDa 160kDa 
Untreated n/a 27.7 15.2 
NH4Cl n/a 18.8 84.0 
E64d Cysteine 26.4 19.9 
ALLN Proteasome, Calpain 17.1 14.7 
Pepstatin Aspartic Acid 14.5 14.7 
Phosphoramidon Metalloproteases 22.3 14.4 
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 The next question was whether transport past subsequent areas of the secretory 
pathway was necessary for the Pcsk9 induced LDLR degradation.  Inhibition of protein 
transport out of the Golgi has been reported to be induced by incubation of cells at 20ºC 
(Saraste et al., 1986) or in low concentrations of monensin (Furukawa et al., 1992) .  Use 
of the former technique was complicated by the fact that Pcsk9 in vitro is reported to be 
catalytically inactive below 25ºC (Naureckiene et al., 2003).  Furthermore, as shown in 
Figure 4.19, both of these treatments inhibited processing of the precursor LDLR to the 
mature LDLR, preventing an analysis of Pcsk9-induced degradation of the mature LDLR.  
It is of interest, however that the precursor LDLR does appear to be protected from Pcsk9 
induced degradation with both of these treatments (recall that the degradation of the 
precursor LDLR did not require Pcsk9 catalytic activity).   
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Figure 4.19.  Pcsk9 induced LDLR 
degradation may occur in the Golgi.  HepG2 
cells were infected with Ad Empty (Empty) or 
Pcsk9-Ad (Pcsk9).  Cells were pulse labeled 
with 35S-Met/Cys for 30 minutes, chased for 4 
hours at 37°C and 20°C (A) or in the absence 
and presence of 1µM monensin (B) and 
immunoprecipitated for the LDLR.  M, mature 
LDLR; P, precursor LDLR.  (C) HepG2 cells 
were infected with Ad empty (E) or Pcsk9-Ad 
(P) and subjected to sucrose gradient 
subcellular fractionation to isolate ER, 
intermediate (Int), Golgi and TGN fractions.  
Steady-state levels of LDLR within these 
fractions was determined by 
immunoprecipitation followed by western blot 
for the LDLR.
E
TGN Golgi ERInt
P E P E P E P
C
 
 118
 Subcellular fractionation was used to attempt to isolate portions of the secretory 
pathway and determine whether steady state LDLR levels were decreased by Pcsk9.  The 
same technique was used as described in Chapter 3, and fractions from ER, intermediate 
ER-Golgi, Golgi, and TGN were pooled and immunoprecipitated for the LDLR.  As 
shown in Figure 4.19, there was decreased LDLR in all compartments.  The decrease in 
the ER was unexpected given the BFA results above, and may be due to the difference in 
assaying newly synthesized LDLR versus LDLR at steady state.  There was very little 
LDLR in the TGN in the Pcsk9-Ad infected cells, which may suggest that the Pcsk9 
induced degradation occurred prior to or within this compartment.   
 
Overexpression of Pcsk9 has no effect on LDLR endocytosis 
 Autosomal recessive hypercholesterolemia (ARH) results from defective 
endocytosis of the LDLR due to the absence of ARH protein, which mediates LDLR 
binding to clathrin (Cohen et al., 2003).  Since LDLR cell surface levels are decreased by 
Pcsk9 overexpression, it is possible that the rate of endocytosis is increased, targeting the 
LDLR for premature degradation.  This is unlikely given the data above that Pcsk9 can 
still decrease the levels of transfected internalization defective LDLR; however, it 
remains a formal possibility that Pcsk9 could induce internalization and degradation by 
an alternative mechanism.  To investigate this possibility, cells were treated for variable 
lengths of time with monensin to inhibit LDLR recycling, while allowing endocytosis to 
continue (Michaely et al., 2004).  At each time point, cell surface proteins were 
biotinylated and immunoprecipitated for the LDLR.  The amount of biotinylated LDLR 
visualized with avidin-HRP at each time point represents the amount of LDLR remaining 
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at the cell surface.  As shown in Figure 4.20A, infection with Ad empty and Pcsk9-Ad 
both caused a reduction in cell surface LDLR over the duration of monensin treatment.  
Furthermore, the rate of disappearance of the LDLR, and thus the rate of endocytosis, 
was identical in control and Pcsk9 overexpressing cells (Figure 4.20B). 
M
M
Empty
Pcsk9
Time of monensin treatment
0 min 30min 60min 120min
0 20 40 60 80 100 120
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Empty
Pcsk9
Time (min)
Fr
ac
tio
n 
of
 s
ta
rt
in
g 
m
at
er
ia
l
A
B
Figure 4.20.  Overexpression of Pcsk9 did not affect 
endocytosis of the LDLR  (A) HepG2 cells were infected 
with Ad Empty (Empty) or Pcsk9-Ad (Pcsk9).  Cells were 
treated with monensin to block recycling of receptors for the 
indicated times.  At the end of the incubation, cell surface 
proteins were biotinylated at 4°C, lysates collected and 
immunoprecipitated for the LDLR. Proteins were visualized 
with avidin-HRP.  Twice as much sample was loaded and 
the blot exposed for a longer time to be able to visualize the 
LDLR in Pcsk9 treated samples.  (B) Quantitation of the 
fraction of the LDLR remaining at the cell surface 
demonstrating the rate of endocytosis of the LDLR.  The 
results indicate that Pcsk9 does not increase the rate of 
LDLR endocytosis.
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Pcsk9 does not induce the release of a soluble N-terminal LDLR fragment 
 Pcsk9 is a protease and the catalytic activity of Pcsk9 has been shown to be 
required for LDLR degradation; therefore, the existence of a cleavage product has been 
actively sought.  Unfortunately, no evidence of any cleavage product in cells was seen in 
the biosynthetic experiments using any of the LDLR antibodies.  Therefore, it was 
hypothesized that Pcsk9 could cleave the LDLR in the secretory pathway or at the cell 
surface, and this N-terminal LDLR fragment could be released into the medium.  HepG2 
cells were infected with Ad empty and Pcsk9-Ad, the media spun at 100,000xg to remove 
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fragmented membranes, and immunoprecipitated for the LDLR using IgG-C7.  No LDLR 
or fragment was detected in the medium of Ad empty or Pcsk9-Ad treated cells (Figure 
4.21).  Furthermore, no LDLR or fragment was immunoprecipitated from the medium of 
HepG2 cells or McA-RH7777 cells pulsed with 35S-Met/Cys for 30 minutes and chased 
for four hours (data not shown).   
Figure 4.21.  Pcsk9 did not induce the cleavage 
and release of a soluble LDLR.  HepG2 cells 
were infected with Ad empty or Pcsk9-Ad.  
Media was collected, spun at 100,000xg to pellet 
broken membranes, and immunoprecipitated for 
the LDLR.  Western blots were performed on 
whole cell lysates (Cells) and media LDLR 
immunoprecipitates (Media) using α−LDLR and
α−Pcsk9 antibodies.
WB: 
LDLR
WB: 
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Pcsk9 knockdown in vitro using small interfering RNAs (siRNA) 
 The above studies to elucidate Pcsk9 function used overexpression, a system that 
creates non-physiologically high levels of the protein of interest.  Therefore, to further 
study Pcsk9 function, gene knockdown was performed in vitro with small interfering 
RNAs (siRNAs).  Three cell lines were chosen to study:  rat hepatoma McA-RH7777 and 
mouse hepatoma Hepa1-6 cells were shown to express Pcsk9, and Pcsk9 was regulated 
by sterols in these cell lines; and human hepatoma HepG2 cells were used in the majority 
of the overexpression studies.  The Pcsk9 mRNA was scanned for regions of 19-
nucleotides or longer that were identical between mouse, rat and human Pcsk9.  As Pcsk9 
has relatively low interspecies sequence conservation, only eight regions were identified 
in the 3.5kb transcript.  Of those, one region contained a siRNA identified by the 
Dharmacon prediction algorithm; this siRNA was called mhPs-1.  When transfected into 
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McA-RH7777 and Hepa1-6 cells, mhPs-1 induced a significant decrease in the amount of 
Pcsk9 protein as compared to mock, GFP siRNA, and apoM siRNA treated cells (Figure 
4.22A, B).  A modified version of mhPs-1 for use in vivo caused a similar or greater 
decrease in Pcsk9 protein.  Despite the decrease in Pcsk9, however, no effect was seen on 
levels of LDLR protein (Figure 4.22A, B).   
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Figure 4.22.  siRNA mediated knockdown of Pcsk9 in mouse and rat hepatoma cells did not affect 
LDLR protein levels.  Hepa1-6 mouse hepatoma cells (A) and McA-RH7777 rat hepatoma cells (B)
were not treated (Untx), mock treated, or transiently transfected with siRNAs to GFP (GFPsi), 
apolipoprotein M (apoMsi), the mhPs-1 siRNA to Pcsk9, and an in vivo modified version of mhPs-1 
siRNA (mhPs-1*).  Protein lysates were collected and Western blots performed for Pcsk9 and LDLR.  
Compared to untreated, mock and nonspecific siRNAs, mhPs-1 siRNA decreased levels of Pcsk9 protein 
in both cell types; however, mhPs-1 siRNA had no effect on LDLR protein levels.
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When transfected in HepG2 cells, mhPs-1 induced an 86% decrease in Pcsk9 
mRNA levels (no antibody to human Pcsk9 was available), and the in vivo modified 
mhPs-1 induced a 90% decrease in Pcsk9 mRNA (Figure 4.23A) as compared to mock 
treated cells.  In contrast to the results with rodent hepatoma cell lines, these siRNAs 
caused an increase in both the mature (top exposure) and immature (bottom exposure) 
LDLR (Figure 4.23B).  A Dharmacon SMARTpool hPcsk9 siRNA (hPs-pool) also 
increased LDLR levels. 
 In order to determine if the mechanism was similar to Pcsk9 overexpression, 
HepG2 cells transfected with a control siRNA (siControl) or mhPs-1 were pulsed with 
35S-Met/Cys for 30 minutes and chased for 0,1,2,4, and 8 hours.  As shown in Figure 
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4.23C, there was increased LDLR in the mhPs-1 treated cells at 0,1,2, and 4 hours, 
indicating either a decrease in degradation rate or increase in synthesis.  Therefore, 
HepG2 cells transfected with a control siRNA (siControl) mhPs-1 were pulsed with 35S-
Met/Cys for 5, 10, 20 and 30 minutes.  Surprisingly, there was a clear increase in 
synthesis of the LDLR in mhPs-1 treated cells (Figure 4.23D).  
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Figure 4.23.  siRNA mediated knockdown of Pcsk9 in human hepatoma cells increased LDLR 
protein by increasing LDLR synthesis.   HepG2 human hepatoma cells were mock treated or transiently 
transfected with control siRNA (siControl), the mhPs-1 siRNA to Pcsk9, an in vivo modified version of 
mhPs-1 siRNA (mhPs-1*), and a Dharmacon siRNA SMARTpool to Pcsk9 (hPs-pool).  (A) For Q-PCR, 
Pcsk9 expression levels were normalized to cyclophilin B and the value for mock set equal to one.  
Compared to mock, mhPs-1 and hPs-pool significantly (**p<0.001) decreased Pcsk9 mRNA levels. (B) 
Protein lysates were collected and Western blots performed for LDLR.  Compared to siControl treated 
cells, mhPs-1 and hPs-pool siRNAs increased levels of mature LDLR (top, light exposure) and immature 
LDLR (bottom, dark exposure).  (C) HepG2 cells were treated with siControl (siCon) or mhPs-1 siRNA.  
Cells were pulse labeled with 35S -Met/Cys for 30 minutes, chased for 0, 1, 2, 4, and 8 hours, and 
immunoprecipitated for the LDLR. M, mature LDLR; P, precursor LDLR. (D) HepG2 cells were treated 
with siControl (siCon) or mhPs-1 siRNA.  Cells were pulse labeled with 35S -Met/Cys for 5,10,20,and 30 
minutes and immunoprecipitated for the LDLR.  mhPs-1 increased the synthesis of the LDLR.
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 These results were contradictory to the overexpression studies, bringing up the 
issue of possible off-target effects of the mhPs-1 siRNA.  Therefore, three other Pcsk9 
siRNAs were studied.  As shown in Figure 4.24A, all siRNAs except mhPs-3 decreased 
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Figure 4.24.  Different Pcsk9 siRNAs resulted in different effects on LDLR mRNA and protein 
levels.   HepG2 human hepatoma cells were transiently transfected with control siRNA (siControl), and 
five siRNAs to Pcsk9: mhPs-1, mhPs-3, hPs-3, hPs-5, and hPs-pool.  (A) RNA was isolated from cells 
and assayed by Q-PCR.  Pcsk9 and LDLR expression levels were normalized to cyclophilin B and the 
value for siControl set equal to one. Compared to siControl, all siRNAs except mhPs-3 significantly 
decreased Pcsk9 mRNA levels.  As compared to siControl, mhPs-1, hPs-3 and hPs-pool significantly 
increased LDLR mRNA levels; whereas hPs-5 had no effect.  *p<0.05; **p<0.005, NS: not significant.  
(B) Protein lysates were collected and Western blots performed for LDLR.  Band intensities were 
measured using Image Pro Plus.  Compared to siControl treated cells, (top, light exposure), all siRNAs 
except mhPs-3 increased levels of mature LDLR (top, light exposure); whereas mhPs-1 and hPs-pool 
siRNAs increased levels of precursor LDLR (bottom, dark exposure).  (C) Summary of siRNA 
experiments in HepG2 cells.  M: mature; P: precursor.
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Pcsk9 mRNA levels as compared to siControl.  As shown in Figure 4.24B, mhPs-1, hPs-
3, hPs-5 and hPs-pool increased the levels of mature LDLR by 4.3-, 4.2-, 2.1- and 2.4-
fold, respectively.  In contrast, mhPs-1 and hPs-pool increased the levels of precursor 
LDLR by 8.0- and 3.7-fold; whereas, hPs-3 and hPs-5 only increased the levels of 
precursor LDLR by 1.6-fold.  Furthermore, mhPs-1, hPs-pool, and hPs-3 also increased 
LDLR mRNA levels by 3.0-, 3.0-, and 3.5-fold; whereas, hPs-5 did not significantly 
increase LDLR mRNA levels (Figure 4.24A).     
 These results are summarized in Table 4.24C, and indicate that two of the Pcsk9 
siRNAs increased LDLR levels presumably through an increase in LDLR transcription; 
whereas one of the Pcsk9 siRNAs increased LDLR levels without increasing LDLR 
transcription. 
 
Pcsk9 does not appear to play a role in apoB secretion 
 The original observation in mice was that overexpression of Pcsk9 led to an 
increase in LDL cholesterol levels.  An increase in LDL cholesterol levels could be due 
to effects on uptake by the LDLR or to effects on secretion of apoB containing 
lipoproteins.  The fact that Pcsk9 could not increase LDL cholesterol levels in LDLR 
knockout mice pointed to the former as the mechanism of Pcsk9 action.  However, to 
confirm the hypothesis that Pcsk9 does not play a role in apoB secretion, Pcsk9 was 
overexpressed in McA-RH7777 cells by adenovirus, overexpressed in HepG2 cells by 
adenovirus, and knocked down using Pcsk9 siRNA in HepG2 cells.  Cells were pulse 
labeled with 35S-Met/Cys and apoB was immunoprecipitated from the media.  As shown 
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in Figure 4.25A, B, neither overexpression nor knockdown of Pcsk9 affected apoB levels 
in the media. 
Ad Empty Pcsk9-Ad
McA-RH7777 cells
siCon mhPs-1 hPs-3 lacZ-Ad Pcsk9Ad
HepG2 cells
A
B
B-48
B-100
B-48
B-100
Figure 4.25. Neither overexpression nor siRNA 
mediated knockdown of Pcsk9 affected apoB 
secretion.  McA-RH7777 cells were infected with 
Ad empty or Pcsk9-Ad (A) and HepG2 cells were 
transiently transfected with siControl, mhPs-1 
siRNA, or hPs-3 siRNA and infected with lacZ-Ad 
or Pcsk9-Ad (B).  Cells were pulsed with 35S-
Met/Cys, chased in cold medium, and the media 
was immunoprecipitated for apolipoprotein B.  
Pcsk9 overexpression or knockdown did not affect 
the amount of apoB-100 or apoB-48 secreted into 
the medium.  
 
 
CHAPTER SUMMARY 
This chapter describes studies aimed at elucidating the function of Pcsk9, a gene 
identified in the microarray study in Chapter 2 and cloned and characterized as described 
in Chapter 3.  In order to study the function of Pcsk9 in mice, an adenovirus 
constitutively expressing murine Pcsk9 (Pcsk9-Ad) was used.  Pcsk9 overexpression in 
wild type mice caused a two-fold increase in plasma total cholesterol and a five-fold 
increase in non-HDL cholesterol, with no increase in HDL cholesterol, as compared to 
mice infected with a control adenovirus.  FPLC analysis showed that the increase in non-
HDL cholesterol was due to an increase in LDL cholesterol.  This effect was dependent 
on the LDLR, as LDLR knockout mice infected with Pcsk9-Ad had no change in plasma 
cholesterol levels as compared to knockout mice infected with a control adenovirus.  
Furthermore, while overexpression of Pcsk9 had no effect on LDLR mRNA levels, there 
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was a near absence of LDLR protein in animals overexpressing Pcsk9.  These results 
were confirmed in vitro by the demonstration that overexpression of Pcsk9 in McA-
RH7777 and HepG2 cells caused a reduction in LDLR protein and LDL binding.  
Overexpression of Pcsk9 in HepG2 cells had no effect on LDLR synthesis, but caused a 
dramatic increase in the degradation of the mature LDLR and a lesser increase in the 
degradation of the precursor LDLR.  In contrast, overexpression of a catalytically 
inactive mutant Pcsk9 prevented the degradation of the mature LDLR; whereas increased 
degradation of the precursor LDLR still occurred.  The Pcsk9 induced degradation of the 
LDLR was not affected by inhibitors of the proteasome, lysosomal cysteine proteases, 
aspartic acid proteases, or metalloproteases, but was affected by the lysomotrophic agent 
NH4Cl.  The Pcsk9 induced degradation of the LDLR was shown to require transport out 
of the ER, and preliminary results indicate that the degradation occurs prior to the TGN.  
These results indicate that overexpression of Pcsk9 induces the degradation of the LDLR; 
this is presumably the mechanism by which Pcsk9 decreases LDLR levels and increases 
LDL cholesterol levels in mice. 
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CHAPTER 5:  STUDIES ON ADAM11, A NOVEL CHOLESTEROL-
REGULATED GENE 
 
Cloning of A Disintegrin and Metalloprotease 11 (ADAM11) 
As described in Chapter 3, our selection criteria for choosing genes or ESTs from 
the microarray to study were that they were highly regulated or possessed domains that 
suggested an interesting function.  Affymetrix probe set 116554 fit both criteria.  Probe 
set 116554 was up-regulated by dietary cholesterol between 5.0- and 7.1-fold in males 
and between 4.4- and 7.8-fold in females on the microarray, making it the most highly 
up-regulated gene in the study.  Probe set 116554 was up-regulated 11.7-fold in males 
and 10.5-fold in females by Q-PCR confirmation.  The sequence corresponding to probe 
set 116554 contained no information in the Affymetrix database, NetAffx, and thus was 
BLASTed to the Celera and Ensembl drafts of the mouse genome.  The probe set 
corresponded to sequence approximately 2,800 nucleotides downstream from the 3’ end 
of the Adam11 gene (NCBI NM_009613).  Since the probe set was approximately 56,000 
nucleotides upstream of the next predicted gene, it was assumed that the probe set 
corresponded to the Adam11 transcript and that the annotation was incorrect. 
The NM_009613 mRNA sequence was BLASTed to the mouse genome and 
shown to be composed of 27 exons.  Primers corresponding to the reported start and stop 
positions in exon 1 and 27, respectively, of NM_009613 were used to attempt to amplify 
the Adam11 ORF from liver cDNA.  Despite numerous attempts with multiple PCR 
systems, a product could not be amplified.  It was suspected that either the annotation 
was incorrect or there was an alternative transcript, therefore, 5’ and 3’ RACE was 
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performed using liver cDNA from high cholesterol fed mice (when Adam11 is induced).  
For 5’RACE, nested primers in the predicted exons 3 and 2 amplified a single band that 
corresponded to the predicted exons 3, 2 and 1 of NM_009613 and 44 nucleotides of 
5’untranslated region.  For 3’RACE, nested primers in the predicted exons 23 and 24 
amplified a major band of approximately 3,000 nucleotides that did not correspond to the 
NM_009613 sequence.  The amplified band contained exons 24, 25 and 26 but did not 
splice to the predicted exon 27 and instead continued into intron 26 to an in-frame stop 
and 3’utr sequence.  Of note, this 3’utr sequence contained the Affymetrix probe set 
116554 and a poly-A signal.  For annotation purposes, the alternative sequence 
corresponding to the 3’RACE results was called Transcript A, and the NM_009613 
sequence was called Transcript B. 
To try to clarify these confusing results, the following primers were used with 
cDNA from LXR agonist treated liver:  5’primer, 16nt upstream of the predicted ATG; 
3’primer A, 97nt downstream of Exon 27 stop/460nt downstream of Exon 26 stop; and 
3’primer B, spanning Exon 26-27 junction (Figure 5.1A, B).  When primer A was used, 
two products were amplified at equal intensity, both corresponding to Transcript A’s 
3’end, indicating that Transcript A was the predominant form in liver cDNA (Figure 
5.1C).  The only way Transcript B was amplified was using the “forced” primer B.  In 
both cases, the lower amplified band corresponded to the NM_009613 exon structure 
(except at the 3’end), called “full-length”; whereas the upper band corresponded to a 
product with 178 nucleotides of intron 6 attached to the 5’end of exon 7.  This alternative 
transcript introduces an in-frame stop in the new exon 7, and was called “premature”.  
This experiment was repeated using brain cDNA, and in this case, both primers A and B  
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Figure 5.1. Cloning of Adam11 revealed four types of transcripts in liver.  (A) To amplify Adam11 
from liver cDNA, the following primers were used: 5’primer: 16nt upstream of the predicted ATG, 3’ 
Primer A: 97nt downstream of Exon 27 stop/460nt downstream of Exon 26 stop, and 3’ Primer B: 
spanning Exon 26-27 junction .  (B) The predicted sizes of transcripts A and B using the depicted 
primers.  (C) Primer A amplified two transcripts from mouse liver cDNA, the bottom band corresponded 
to the A transcript that encodes a full length protein, Adam11 A transcript, full-length (Af) and the top 
band corresponded to the A transcript that has a premature stop, Adam11 A transcript, premature stop 
(Ap). Primer B amplified two transcripts from mouse liver cDNA, the bottom band corresponded to the 
B transcript that encodes a full length protein, Adam11 B transcript, full-length (Bf) and the top band 
corresponded to the B transcript that has a premature stop, Adam11 B transcript, premature stop (Bp). 
(D) Schematic of the four transcripts from mouse liver.  The break between exons 2 and 3 represents the 
long, 7kb intron 2.  
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amplified sequence corresponding to NM_009613, or Transcript B (data not shown).  The 
four types of transcripts are depicted in Figure 5.1D. 
 Of note, the current public mouse genome assembly (Mouse Build 33c) contains 
predictions for both Adam11 transcripts.  In contrast, the current public human genome 
assembly (Human Build 35a) does not have a prediction for Transcript A, instead it has 
predictions for Transcript B and yet another transcript with a truncated 5’end.  There are 
ESTs in the NCBI database which could only correspond to Transcript A; however, no 
cloning was undertaken for human Adam11; therefore, the predominant transcripts 
present in human tissues is still an open question. 
 
Domain structure and sequence elements of Adam11 protein 
 Adam11, like all members of the ADAM family, is a multi-domain protein 
containing a signal peptide, a pro-domain, a metalloprotease/reprolysin domain, a 
disintegrin/cysteine-rich domain, an EGF-like domain, a transmembrane domain, and a 
unique C-terminus (Figure 5.2).  Using the SignalP web program (Nielsen et al., 1997; 
Bendtsen et al., 2004), it was predicted that the signal peptide is cleaved after Gly-24 in 
mouse Adam11 and at the homologous position, Gly-23 in human Adam11.  The 
propeptide domain contains four cysteines which are potentially involved in disulfide 
bridges.  Both mouse and human Adam11 contain the canonical proprotein convertase 
basic cleavage site RRKR (RRKR229 in mouse and RRKR225 in human) at the junction 
between the pro-domain and metalloprotease domain; these sites can theoretically be 
cleaved by any of the seven kexin subfamily PCs.  Similar to about half of the 
mammalian ADAM family members, the metalloprotease domain of Adam11 was 
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predicted to be inactive due to the absence of residues necessary in the coordination of 
zinc which are in turn necessary for catalysis (Figure 5.2).  The metalloprotease domain 
contains six cysteine residues potentially involved in disulfide bridges.  The Adam11 
disintegrin and cysteine rich domain contains the sequence found in many ADAMs that is 
necessary for integrin binding, CREAVNECDIAETC520 in mouse (-C516 in human), 
specifically this sequence in Adam11 is identical to the sequence in Adam23 which has 
been shown to mediate binding of Adam23 to integrin αvβ3 (Cal et al., 2000).  The 
disintegrin and cysteine rich domain also contains 28 cysteine residues potentially 
involved in disulfide bridges.  Adam11 has an EGF-like domain signature, 
CICQPDWTGKDC713 in mouse Adam11 (-C709 in human). The PredictProtein server 
(Rost et al., 2004) was used to identify the Adam11 transmembrane domain as extending 
from Ile-740 to Gly-757 in mouse and Ile-736 to Gly-753 in human Adam11.  Finally, 
the two alternative transcripts of Adam11 predict two different C-termini. In the context 
of the two transcripts identified, the liver mainly expressed premature and full-length 
Transcript A, presumably leading to the production of the pro-domain of Adam11 and to 
a full-length protein called Adam11A (Figure 5.2B).  The brain, on the other had, mainly 
expressed full-length Transcript B, presumably leading to the production of a full-length 
protein called Adam11B (Figure 5.2B).   
 The PredictProtein (Rost et al., 2004) and NetPhos (Blom et al., 1999) servers 
were also used to identify potentially interesting sequence motifs in mouse and human 
Adam11 (numbering will be given for mouse Adam11).  Both mouse and human 
Adam11 contain four potential N-glycosylation sites, at N-100 and N-167 in the pro-
peptide, and N-609 and N-677 in the cysteine-rich domain.  There is one predicted 
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amidation site at CGRK585 in both mouse and human Adam11.  Mouse and human 
Adam11 also have three predicted cAMP-dependent protein kinase phosphorylation sites, 
five predicted protein kinase C phosphorylation sites, nine predicted casein kinase II 
phosphorylation sites, and 14 predicted myristoylation sites (mouse Adam11 contains one 
additional myristoylation site).  None of these sites are in the alternative C-termini; 
however NetPhos did identify a potential serine phosphorylation site in the C-terminus of 
Transcript B that is absent in Transcript A.    
QTLGQNLGMMWN     CREAVNECDIAETC
QSLAQNLGIQWE     CRDAVNECDITEYC
HELGHNLGIQHD     CRPAEDVCDLPEYC
CTDMetalloproteaseProSP Disintegrin/Cysteine rich EGF TM
Adam11
Adam23
Adam1
(binds αvβ3)
A
B Transcript A and B premature stop will encode:
Transcript A C-term: TGWGFKNIRRGRYDPTQQGAV
Transcript B C-term: TGWGFKNIRRGRSGGA
ProSP
Transcript A and B full length will encode:
CTDMetalloproteaseProSP Disintegrin/Cysteine rich EGF TM
Figure 5.2. Domain structure of Adam11 and the structure of proteins predicted to be encoded by 
the four identified transcripts.  (A) Mouse ADAM11 protein is made up of a signal peptide (SP), a 
pro-domain, a metalloprotease domain, a disintegrin/cysteine rich domain, an EGF-like domain, a single 
transmembrane domain, and a cytoplasmic C-terminal domain (CTD).  Adam11 does not contain the 
histidine residues (H in red) within the metalloprotease domain that are necessary for protease activity.  
Adam11 contains a similar potential integrin binding loop as Adam23.  (B) The four transcripts identified 
are predicted to encode three proteins: the premature stop transcripts encode only the pro-domain; 
whereas the full length transcripts encode a full length protein.  Transcript A and B differ at their C-
terminal ends.
241 229 450 681 778
TM
TM
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Homology of mouse and human Adam11 to each other and to other ADAM family 
members 
 Mouse and human Adam11 were aligned using the ClustalW program and found 
to be 95% identical over the entire proteins (data not shown).  The majority of the 
sequence differences were in the pro-domain, such that the mature Adam11 sequence 
after the RRKR cleavage site is 99% identical between mouse and human Adam11.    
 The ADAM family of proteins is large, with 33 ADAMs in the mouse genome.  
ADAMs may have redundant function within subfamilies; therefore, a phylogenetic tree 
of mouse ADAM proteins was created to determine if Adam11 was a member of an 
ADAM subfamily.  As shown in Figure 5.3, Adam10 and Adam17 are the most divergent 
ADAM family members, being 23% identical to each other but only 13-18% identical to 
all other ADAM family members.  In contrast, the other 31 ADAMs all have at least 20% 
identity to all other ADAMs.  In addition, five subfamilies of mouse ADAMs can be 
identified that have greater than 30% identity within the subfamily.  Adam 21,24-
26,29,34-40 form one subfamily where members have between 40-90% identity.  Adam 
2,3,5,18,32 form a subfamily with 30-38% identity between members.  Adam 
12,15,19,33 form a subfamily with 30-45% identity between members.  Adam 7,8,28 
form a subfamily with 30-38% identity between members.  Finally, Adam11 falls into a 
subfamily with Adam22 and Adam23; Adam11 has 52% identity to Adam22 and 51% 
identity to Adam23. 
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ADAMs with metalloprotease motif 
(HEXGHXXGXXHD):
ADAMs 1, 8-10, 12,15, 17, 19,21, 
24-26, 28, 30, 33-40 
ADAMs that appear to be (primarily) 
testis-specific are ADAMs: 2-6, 18, 
20, 21, 24-26, 29, 30, 32, 34, 36-40. 
Figure 5.3. Phylogenetic tree of mouse ADAM family 
members. The phylogenetic tree was created from a 
ClustalW alignment of all of the mouse ADAM family 
members (protein sequences).  Analysis of percent sequence 
identities allowed the identification of five subfamilies whose 
members are greater than 30% identical.  Adam11 is a 
member of one of the subfamilies (indicated by a yellow star).  
Finally, the ADAMs that are predicted to be active 
metalloproteases are outlined in green; the primarily testis-
specific ADAMs are shaded blue.
 
Construction of Adam11 expression plasmids, adenovirus and creation of Adam11 
peptide antibodies 
In order to study the characteristics and function of Adam11, multiple expression 
constructs were made and a peptide antibody to the C-terminus of Adam11A was created 
(see Methods for details).  This peptide was predicted to be unique to Adam11 by a 
BLAST to the mouse genome.  The Adam11A antibody was tested in rat hepatoma McA-
RH7777 cells transfected with a Flag tagged Adam11A expression construct (Adam11A-
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Flag) and a GFP tagged Adam11A construct (Adam11A-GFP).  The antibody recognized 
a pro-form of Adam11 at approximately 100kDa and a processed form at approximately 
75kDa (Figure 5.4A); these bands were not recognized if the antibodies were incubated 
with the peptides used to make the antibodies (data not shown).  These sizes are 
approximately 15kDa larger than the in silico predictions of 80kDa for the pro-form and 
65kDa for the processed form.  This could be due to N-glycosylation.  In addition to the 
expression constructs, an adenovirus expressing the Adam11 ORF under the control of a 
constitutively active CMV promoter was made.  When infected into multiple cell lines, 
this adenovirus induced expression of Adam11A in cells, an example in HEK293 cells is 
shown in Figure 5.4B. 
α-Adam11A
1:  McAR7777 +  Flag empty
2:  McAR7777 + Adam11-Flag
3:  McAR7777 + EGFP empty
4:  McAR7777 + Adam11-GFP
5:  COS1 + Flag empty
6:  COS1 + Adam11-Flag
Figure 5.4.  Characterization of Adam11 peptide antibody, expression constructs and 
adenovirus.  (A) A peptide antibody to the Adam11A isoform were created using a peptide 
corresponding to the Adam11A C-terminal end.  McA-RH7777 (1,2,3,4) and COS1 (5,6) cells were 
transfected with Flag empty (1,5), Adam11A-Flag (2,6), EGFP (3) and Adam11A-GFP (4). Cell 
lysates were blotted with the α-Adam11A antibody.  The antibody recognized a pro-form of Adam11 
at approximately 100kDa and a processed form at approximately 75kDa  (B) An adenovirus 
overexpressing Adam11A (Adam11-Ad) was created; this adenovirus led to the production of the pro 
and processed forms of Adam11 as shown by a Western blot in McA-RH7777 cells.
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Adam11 is localized to the cell surface 
 ADAM family members are mostly predicted to be cell surface proteins with the 
metalloprotease, disintegrin, cysteine-rich and EGF-like domains on the outside of the 
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cell and the C-terminus on the inside.  In order to determine if Adam11 was similar to 
other Adam family members, subcellular localization studies were performed with two 
different Adam11 constructs.  First, Adam11-GFP was transfected into HEK293 cells 
(Figure 5.5A).  Second, Adam11-Flag was transfected in rat hepatoma McA-RH7777 
cells, incubated with an anti-Flag monoclonal antibody and stained with a FITC-
conjugated secondary antibody (Figure 5.5B).  In both experiments, transfected Adam11 
was expressed predominantly at the cell surface.  
HEK293 cells + Adam11A-GFP
Adam11-GFP (green)
Hoescht dye for DNA (blue)
McA-RH7777 cells + Adam11A-Flag
Anti-Flag 1°Ab + FITC 2°Ab (green)
Hoescht dye for DNA (blue)
A B
Figure 5.5. Adam11 was localized predominantly to the cell surface when transfected into cells. 
(A) HEK293 cells were transfected with Adam11A tagged at the C-terminal end with GFP (Adam11A-
GFP) and stained with the DNA dye Hoescht (blue).  (B) McA-RH7777 cells were transfected with 
Adam11A tagged at the C-terminal end with Flag (Adam11A-Flag), fixed, and stained with the anti-
Flag antibody M2 followed by a secondary FITC antibody (green) and Hoescht dye (blue).  Images 
were acquired using epifluorescence microscopy. Approximately 50 cells were examined and images 
shown are representative of the pattern seen in all cells examined.
 
Adam11 tissue expression in vivo 
In order to determine the tissues that express Adam11, non-quantitative RT-PCR 
and Northern blotting was performed.  Based on the results from the 5’ and 3’ RACE 
experiments, it was predicted that Adam11A was a 5kb transcript and Adam11B a 4.5kb 
transcript.  For RT-PCR, cDNA was made from brain, heart, kidney, liver, small intestine 
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and spleen from low and high cholesterol fed mice, and the PCR primers for Adam11A 
and B as described above were used.  In heart, kidney, liver, small intestine and spleen, 
the predominant band corresponded to Adam11A, and Adam11B could only be amplified 
with the forced exon-spanning primer (Figure 5.6A).  In contrast, a highly abundant band 
corresponding to Adam11B was amplified by both primer sets in brain cDNA.  Since RT-
PCR is extremely sensitive and can amplify products from very low amounts of template, 
a multiple tissue Northern (MTN) blot from Clontech was also incubated with a probe 
made from the 3’utr region of Adam11 specific for Transcript A.  Adam11A was shown 
to be expressed most highly in the liver and heart, and to a lower level in testis, kidney, 
and brain (Figure 5.6B).   
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Figure 5.6.  Tissue distribution of Adam11 
mRNA.  (A) C57Bl/6 mice were fed a 0.0% 
cholesterol (Low C) or 0.5% cholesterol (High 
C) diet and multiple tissues were isolated.  
Primers A and B as depicted in Figure 5.1 were 
used on the indicated tissues. The Adam11B 
transcript was amplified from brain; whereas the 
Adam11A transcript was amplified from the 
other tissues.  (B)  A probe within the Adam11A 
specific 3’untranslated region and to a portion 
of the Actin open reading frame were used to 
probe a Clontech multiple tissue Northern blot.  
Adam11 was expressed in heart, brain, liver, 
kidney and testis.    
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Adam11 is regulated by dietary cholesterol and LXR agonists at the RNA level 
The original observation that led to the cloning of Adam11 was that the mRNA 
was up-regulated by dietary cholesterol feeding in mouse liver as assayed by microarray 
and Q-PCR analysis.  This observation was confirmed by Northern blotting of liver 
mRNA from male and female mice (Figure 5.7A) with the Adam11A 3’utr probe and a 
probe to a portion of the Adam11 ORF.  As shown in Chapter 3, the control SREBP-2 
target gene of the cholesterol biosynthetic pathway, Sqle, was also down-regulated in 
these samples.  To investigate whether Adam11 was regulated by dietary cholesterol in 
other tissues, a Northern blot of mRNA from brain, heart, kidney, liver, small intestine, 
and spleen was probed.  In this experiment, Adam11 was expressed mainly in liver, with 
lower levels in brain and heart.  Interestingly, Adam11 mRNA was up-regulated by 
dietary cholesterol only in the liver (Figure 5.7B).  The control LXR target gene, Abcg5, 
was expressed and up-regulated by dietary cholesterol in the liver. 
A
Actin
Sqle
HL HL
Male Female HL HL HL HL HL HL
brain heart kidney liver sm int spleen
Actin
Adam11
B
Adam11A 
3’utr
Abcg5
Adam11 
ORF
Figure 5.7. Adam11 mRNA was regulated by sterol levels.  (A) Northern blot of liver RNA pooled 
from male and female C57Bl/6 mice fed a 0.0% cholesterol diet (L) or a 0.5% cholesterol diet (n = 5 mice 
per group).  Blots were probed for a portion of the Adam11 open reading frame (ORF), the Adam11A 
specific 3’untranslated region (3’utr), squalene epoxidase (Sqle) and actin.  (B) Northern blot of RNA 
from multiple tissues pooled from male C57Bl/6 mice fed a 0.0% cholesterol diet (L) or a 0.5% 
cholesterol diet (H) (n = 5 mice per group).  Blots were probed for the Adam11A 3’utr, Abcg5, and actin.  
Adam11 mRNA was only up-regulated by dietary cholesterol in liver.    
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As described in Chapter 2, up-regulation of gene expression by dietary cholesterol 
can be mediated by the LXR transcription factors.  In order to assay regulation of gene 
expression by LXR, the LXR agonist TO901317 was used in mice.  It was shown in 
Chapter 2 that Adam11 mRNA was up-regulated by the LXR agonist in the livers of mice 
by microarray and Q-PCR analysis.  In order to confirm these results, a Northern blot of 
mRNA from heart, kidney, liver and small intestine of LXR agonist treated mice was 
probed.  As shown in Figure 5.8A, Adam11 mRNA was up-regulated by the LXR agonist 
only in liver.  The control LXR target gene, Abcg5, was up-regulated by the LXR agonist 
in liver and small intestine.  To study these effects in a cell culture system, mouse liver 
hepatoma cells, Hepa1-6, were treated with 25-hydroxycholesterol plus cholesterol 
(25OHC+C), the LXR oxysterol ligand 22(R)-hydroxycholesterol (22ROC), the synthetic 
LXR agonist TO901317, and 22ROC plus TO901317.  The SREBP target gene, Hmgcr, 
was down-regulated by the sterols 25OHC+C and 22ROC and not regulated by the LXR 
agonist TO901317 (Figure 5.8B).  In contrast, Adam11 was up-regulated by the sterols 
25OHC+C, the oxysterol LXR ligand 22ROC and the LXR agonist.   
 Another cell type where gene regulation by LXR has been shown to be important 
is the macrophage.  However, it was determined that Adam11 was not expressed in the 
macrophage cell line, RAW, and in isolated peritoneal macrophages (a gift of Ira Tabas 
and Raymond Soccio), even if treated with sterols or LXR ligands (data not shown). 
LXRs bind to sites called LXR regulatory elements (LXREs) in the promoters of 
genes; these sites are hormone response elements of the DR-4 type (direct repeat 
separated by 4 nucleotides) and can be located in proximal promoters, distal enhancer 
elements, and introns (Edwards et al., 2002).  Conserved regions of the mouse and human 
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Adam11 genes were identified using the program VISTA (Loots et al., 2002), and these 
regions were searched for potential LXREs.  One potential LXRE, 
C[G/C]GGGTgacaGCCGGT in human/mouse, was found in intron one of the Adam11 
gene; however, future studies will be needed to identify the true regulatory elements 
responsible for Adam11 regulation by LXR. 
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Figure 5.8.  Up-regulation of Adam11 by LXR ligands.  (A) Northern blot of RNA from multiple 
tissues pooled from male C57Bl/6 mice treated with 5% sesame oil in ethanol vehicle (V) or vehicle 
plus 10mg/kg of the LXR agonist TO901317 (T) for 30 hours (n = 5 mice per group).  Northern blots 
probed for Adam11, the LXR target gene Abcg5 and Actin.  Adam11 was up-regulated by TO901317 
only in the liver.   (B) Hepa1-6 cells were treated with ethanol (vehicle), 1µg/ml 25-hydroxycholesterol 
and 10µg/ml cholesterol (25OHC+C), 1µg/ml 22(R)-hydroxycholesterol (22ROC), 10µM TO901317 
(TO) or 22(R)-hydroxycholesterol plus TO901317 (22ROC/TO) (3 wells for each treatment).  mRNA 
levels of Hmgcr and Adam11 were determined by Q-PCR, normalized to cylcophilin and the value for 
vehicle set equal to one.  Adam11 was up-regulated by sterols and LXR agonists in Hepa1-6 cells.
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Adam11 functional studies in vitro 
 In order to attempt to understand the function of Adam11, overexpression of 
Adam11 by transient transfection or adenoviral transduction was used in cell culture.  
Various measures of cholesterol metabolism were assayed.  As Adam11 was regulated by 
LXR specifically in the liver, it was hypothesized that Adam11 functions in RCT in the 
liver.  One part of RCT in the liver is the movement of sterols from the plasma into the  
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Figure 5.9. Overexpression of Adam11 had no effect on cholesterol uptake or efflux.  (A) McA-
RH7777 cells were transfected with empty vector (pcDNA), Adam11, or LDLR and incubated in the 
presence of DiI-LDL at 37°C for two hours.  While the positive control LDLR increased DiI-LDL 
uptake, Adam11 had no effect on uptake. Fluorescence was normalized to total protein and values for 
pcDNA set equal to one. (B) McA-RH7777 cells were transfected with empty vector (pcDNA), 
Adam11, or SRBI and incubated in the presence of DiI-HDL at 37°C for two hours.  While the positive 
control SRBI increased DiI-HDL uptake, Adam11 had no effect on uptake. (C) McA-RH7777 cells 
were transfected with Flag empty (green) or Adam11-Flag (blue) and treated with radiolabelled
cholesterol and the indicated acceptors (HDL, apoAI, and serum). Media was collected at the indicated 
time points and radioactivity in the serum was measured.  Adam11 had no effect on the efflux of 
cholesterol in DMEM or to any accpetor.  
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liver and into the bile; since Adam11 is a cell surface protein, it is possible it could 
function in this part of RCT.  Therefore, cholesterol movement across membranes was 
measured.  First, uptake of DiI-labeled LDL and HDL was measured in McA-RH7777 
cells transfected with Adam11A untagged expression construct (Adam11A-pcDNA) or 
infected with Adam11A expressing adenovirus (Adam11A-Ad).  Overexpression of 
Adam11A had no effect on the uptake of DiI-LDL or DiI-HDL in McARH-7777 cells 
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(Figure 5.9A, B).  As a control, transfection of LDLR increased uptake of DiI-LDL and 
transfection of SRBI increased uptake of HDL.  These results were confirmed in studies 
done in collaboration with Denise Drazul-Schrader and George Rothblat where uptake of 
LDL and HDL labeled with 3H-cholesterol ester and 14C-free cholesterol was measured in 
rat hepatoma Fu5AH cells and monkey kidney COS7 cells (data not shown).  In other 
studies done in collaboration with the Rothblat laboratory, cholesterol efflux to HDL, 
apoAI and serum was measured in McA-RH7777 cells transfected with Adam11A-Flag.  
Adam11A did not have an effect on cholesterol efflux to any acceptor (Figure 5.9C), or 
to no acceptor in DMEM (data not shown). 
 Another possible role of LXR target genes could be in the regulation of LXR 
activity itself.  As a measure of LXR activity, a construct expressing the luciferase gene 
under the control of a LXR promoter (LXRE-luc) was used.  This construct was co-
transfected in HEK293 or COS1 cells with other constructs.  As shown in Figure 5.10A, 
Adam11A increased the LXR activity in COS1 cells by 3-fold.  As a control, the LXR 
ligand TO901317 increased LXR activity by nearly 15-fold; furthermore, the intracellular 
cholesterol transporter StAR also increased LXR activity by 4-fold whereas the 
phospholipid transporter PLTP did not have an affect on LXR activity.  This experiment 
indicated that Adam11 may be able to increase the availability of oxysterol LXR ligands.  
One way Adam11 could do this is by altering the cholesterol content of cells; however, 
the free cholesterol and cholesterol ester content was unaltered in McA-RH7777 and 
COS1 cells infected with Adam11A-Ad (Figure 5.10B). 
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Figure 5.10.  Adam11 increased LXR activity but did not change the whole cell cholesterol content.  
(A) COS1 cells were co-transfected with a reporter construct containing a LXR binding site driving a 
luciferase reporter (LXRE-luc), expression constructs for LXRα and RXRα, and the indicated constructs. 
Luciferase activity was measured, normalized to β-gal, and the value for empty set equal to one.  As a 
control, adding 10µM TO901317 (TO) increased LXR activity.  The cholesterol transporter StAR
increased LXR activity; whereas the phospholipid transporter PLTP did not.  Adam11 also increased 
LXR activity.  *p<0.01; **p<0.001.  (B) McA-RH7777 cells or COS1 cells were infected with Ad empty 
(Empty) or Adam11A-Ad (Adam11).  Total cholesterol (TC) and free cholesterol (FC) were measured by 
gas chromatography, and cholesterol ester (CE) was calculated from the difference between TC and FC.  
Adam11 did not affect cholesterol content.
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 The generation of oxysterol ligands not only activates LXRs, but also decreases 
SREBP cleavage and hence activity, leading to decreased lipogenesis.  This may cause a 
decrease in apoB-containing VLDL production (Davis and Hui, 2001).  Therefore, the 
effect of Adam11A overexpression on apoB secretion was investigated in McA-RH7777 
cells.  McA-RH7777 cells were pulsed for 2 hours with 35S-Met/Cys and apoB 
immunoprecipitated from cells and medium.  Overexpression of Adam11A caused a 2-
fold reduction in the amount of apoB48 and apoB100 secreted into the medium (Figure 
5.11A).  To extend this experiment, cells were pulsed with 35S-Met/Cys for 15 minutes 
and chased for 90 and 180 minutes.  As shown in Figure 5.11B, the amount of apoB48 
secreted into the media remained the same at 90 and 180 minutes in both Ad empty and 
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Adam11A-Ad; however, there was approximately 40% less apoB48 at both timepoints in 
Adam11A-Ad treated cells.  The amount of apoB100 secreted into the medium of Ad 
empty cells increased from 90 to 180 minutes.  In contrast, there was a similar amount of 
apoB100 secreted into the medium of Adam11A-Ad cells at 90 minutes, but the amount 
secreted did not increase at 180 minutes in Adam11A-Ad cells, leading to a 65% 
reduction in apoB100 levels in the medium of Adam11A-Ad cells at 180 minutes. 
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Figure 5.11. Adam11 overexpression decreased apoB secretion.  (A) McA-RH7777 cells were 
infected with Ad empty or Adam11A-Ad, pulsed with 35S-Met/Cys for two hours and apoB 
immunoprecipitated from cells and medium.  Overexpression of Adam11 decreased the amount of 
apoB48 and apoB100 in the medium.  (B) McA-RH7777 cells were infected with Ad empty or 
Adam11A-Ad, pulsed with 35S-Met/Cys for 15 minutes, chased for 90 and 180 minutes, and apoB 
immunoprecipitated from medium.  There was less apoB48 in the medium of Adam11 overexpressing 
cells at both time points and a blunted increase in apoB100 secreted into the medium.  
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 If Adam11 decreases apoB secretion due to its effect on the generation of 
oxysterol ligands, it may be predicted that Adam11 would decrease SREBP activity.  
Interestingly, preliminary studies indicated that Adam11A overexpression in McA-
RH7777 cells led to a decrease in activity of a luciferase construct under the control of a 
SREx3 containing promoter (data not shown). 
 Another way in which apoB secretion can be affected is by altering cholesterol 
ester production by ACAT.  Therefore, ACAT activity was assayed by a surrogate 
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measure of whole cell cholesterol esterification.  Adam11A overexpression did not affect 
the amount of 14C-labelled oleate incorporation into cholesterol esters or triglycerides 
(data not shown), consistent with the absence of an effect of Adam11 overexpression on 
whole cell cholesterol ester content.   
 
Adam11 functional studies in vivo 
 The results of the in vitro experiments with Adam11 indicate that Adam11 may 
play a role in the availability of oxysterol ligands and/or in apoB secretion.  To determine 
if Adam11 overexpression may play a role in cholesterol metabolism in vivo, C57Bl/6 
mice were injected with the Adam11A expressing adenovirus (Adam11A-Ad).  There 
was no effect of Adam11 overexpression on plasma total, HDL or non-HDL cholesterol 
levels.  Furthermore, there was no effect of Adam11 overexpression on gallbladder bile 
cholesterol, bile acid or phospholipids content.   
 
CHAPTER SUMMARY 
 This chapter describes the initial work on Adam11, the gene corresponding to one 
of the regulated ESTs in the microarray study described in Chapter 2.  Adam11 was a 
previously known member of the ADAM family of cell surface proteins and had been 
cloned from brain.  We cloned a novel isoform of Adam11 from mouse liver and showed 
that this isoform predominates in most tissues.  Adam11 was shown to be a highly 
conserved member of a subfamily of ADAM proteins containing Adam22 and Adam23.   
Adam11 was shown to be localized to the cell surface.  Adam11A was most highly 
expressed in the liver of mice, with expression also in the heart, brain, testis and kidney.  
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Adam11 mRNA levels were up-regulated by cellular sterols levels putatively via the 
LXR transcription factors; this effect was specific to the liver.  Finally, Adam11 
overexpression increased LXR activity and decreased apoB secretion, indicating a 
potential role for Adam11 in one or both of these processes. 
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CHAPTER 6:  DISCUSSION AND FUTURE DIRECTIONS 
 This thesis has described the use of microarray technology to identify novel genes 
in cholesterol metabolism and the characterization and functional analysis of two of these 
genes, Pcsk9 and Adam11.  Microarray analysis of liver RNA from mice fed a high 
versus a low cholesterol diet and subsequent confirmatory experiments in SREBP 
transgenic mice and LXR agonist mice identified three putative SREBP targets and three 
putative LXR targets.  One of the SREBP targets was cloned, found to be a member of 
the subtilisin protease family, and named Pcsk9.  Pcsk9 was shown to be predominantly 
expressed in the TGN of liver cells.  In vivo overexpression and in vitro overexpression 
and knockdown studies established a role for Pcsk9 in regulating LDLR levels and hence 
LDL cholesterol levels via the induction of LDLR degradation.  One of the LXR targets, 
Adam11, was shown to be a cell surface protein in many tissues including the liver; 
however, a definite functional role has not yet been established. 
 
The use of microarray technology to identify novel genes in cholesterol metabolism 
 Chapter 2 described our model for examining the effects of dietary cholesterol on 
liver gene expression.  Results from three microarray experiments were combined to 
identify 80 probe sets representing 69 unique genes that were regulated by a one-week 
high cholesterol diet (Maxwell et al., 2003).  Of the 36,893 probe sets on the Affymetrix 
MGU74v2 set, approximately 8,900 hybridized to liver RNA (24%) (data not shown).  
Thus less than one percent of the probe sets revealed consistent regulation by dietary 
cholesterol. The expression changes of 15 of the 69 genes regulated by dietary cholesterol 
were examined by Q-PCR analysis and confirmed for 12 genes.  The expression of this 
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subset of genes was further examined in a time course of cholesterol feeding and in 
SREBP transgenic mice by Q-PCR.  In addition, the expression of all of the genes was 
further examined by Affymetrix microarray analysis in mice treated with the LXR 
agonist, TO901317.  The combined analysis yielded three novel putative SREBP target 
genes (Pcsk9, Camk1d and Fabp5) and thirteen novel putative LXR target genes, 
including three (Adam11, Api6, and Fbxo3) that were further confirmed by Q-PCR 
analysis. 
 
The strengths of the microarray study to identify novel genes in cholesterol 
metabolism 
 Our study was successful in identifying novel cholesterol regulated genes in part 
because the model was based on a physiological paradigm, namely cholesterol feeding of 
the intact animal, used in combination with genetically modified mouse models and 
pharmacological activation.  Previous studies in mice to identify novel SREBP and LXR 
target genes mainly involved using SREBP transgenic mice, LXR knockout mice, and 
LXR agonists to study regulation of “candidate genes”, i.e. genes in which a role in 
cholesterol or fatty acid metabolism was already implicated from other work.  Other 
studies used cell culture lines treated with sterols and investigation of the promoters of 
similarly predicted targets.  The validity of our model is supported by other microarray 
studies in SREBP transgenic mice and LXR agonist treated mice.   Horton (Horton et al., 
2003) used Affymetrix microarrays to study liver gene expression in SREBP-1a 
transgenic, SREBP-2 transgenic and SCAP knockout mice and identified 61 known and 
novel SREBP targets that were increased in either SREBP-1a, SREBP-2 or both 
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transgenics and decreased in SCAP knockouts.  The latter was an elegant way of filtering 
out true SREBP targets, which would be decreased by the decreased nuclear SREBPs in 
SCAP knockouts, from genes secondarily affected by long-term overexpression of 
SREBPs.  Approximately half of the down-regulated genes that were not previously 
known SREBP targets identified in our study were among the 61 genes identified by 
Horton.  Of the three confirmed novel SREBP targets in our study (Pcsk9, Fabp5 and 
Camk1d) only Pcsk9 was identified by Horton as well; upon examination of the 
supporting data, however, Fabp5 and Camk1d were increased in SREBP-1a transgenics 
and decreased in SCAP knockouts, but these genes did not make the fold cut-offs for 
inclusion.  Stulnig (Stulnig et al., 2002) used Affymetrix microarrays to study liver gene 
expression in wild-type and LXRαβ knockout mice treated with an LXR agonist and 
identified 319 genes that were regulated by the agonist in wild-type but not in knockout 
mice.  Eight of the thirteen potential LXR targets identified in this study were also 
identified by Stulning, including two of the confirmed genes, Adam11 and Api6.   
 A second strength of our microarray study was performing three independent 
experiments, especially the third experiment which examined responses of four mice per 
condition to assess the individual variation and perform statistical analysis of significant 
differences between groups.  Many microarray analyses rely on a single experiment using 
one microarray per condition.  In the current study, compared to the 48 decreased and 32 
increased probe sets listed for the combined analysis, had we taken only the first 
experiment and used one A chip per condition (0.5% vs. 0.0% cholesterol), the 
Microarray Suite software would have listed 82 decreased and 150 increased probe sets.  
Of the 82 listed as decreased only 18 were on the final list and of the 150 listed as 
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increased only 12 were on the final list.  It is difficult to assess the sensitivity and 
specificity for regulated genes identified by microarray analysis for most studies in the 
literature.  In the current study, in spite of the conservative nature in which genes were 
selected, three of 15 genes tested by Q-PCR were not confirmed. 
 
The disadvantages of the microarray study 
 Many studies of regulated gene expression have used cell culture systems or 
genetically altered mice, and the use of an in vivo feeding model clearly is more complex 
and subject to greater variability.  The use of an inbred mouse strain and strictly 
controlled environmental conditions minimized this concern to the extent possible in a 
complex living organism.  However, there were still additional genes identified in our 
study that were not identified in the Horton and Stulnig studies and this could be a result 
of the increased variability in a physiological system of cholesterol feeding.  Second, 
C57BL/6 mice do not respond to cholesterol feeding with an increase in plasma 
cholesterol levels.  However, we showed in the current study that dietary cholesterol 
increased liver total, free and esterified cholesterol, thus validating our approach for this 
tissue.  Other laboratory animals, such as the rabbit do increase plasma cholesterol levels 
after high-cholesterol diets (Camejo et al., 1973); however, the extensive genomic, 
genetic and molecular techniques used in the mouse are not available, making a similar 
study impossible in the rabbit.  Finally, the stringency of the qualifying criteria and the 
use of a physiological perturbation in our study probably resulted in false negatives.  
Obviously, many more genes were identified by using genetically engineered mice or 
pharmacological activation (Stulnig et al., 2002; Horton et al., 2003).  As an example, 
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Hmgcr and 7-dehydrocholesterol reductase, two known SREBP target genes (Sakakura et 
al., 2001), were not significantly regulated even though they trended towards being 
decreased by cholesterol feeding as they showed extensive array signal variability 
between mice.  As another example, mevalonate kinase and diphosphomevalonate 
decarboxylase, also SREBP target genes (Sakakura et al., 2001), had very low signal 
values, presumably due to poor probe set design, and thus were not considered.  
 
Insights into the potential functions of identified genes 
 Genes down-regulated by cholesterol feeding via the SREBPs to date have been 
involved in cholesterol or fatty acid metabolism.  Integration of information derived from 
the cholesterol feeding time course study and the SREBP-1a and SREBP-2 transgenic 
experiments allow us to make predictions about the function of some of the novel genes 
we have identified that were down-regulated by dietary cholesterol (Table 6.1).  In the 
time course of cholesterol feeding, genes involved in cholesterol biosynthesis, Hmgcr, 
Hmgcs, and Sqle, were immediately down-regulated at day one of feeding and remained 
down-regulated through day seven of feeding.  Furthermore, these genes were also up-
regulated in both SREBP-1a and SREBP-2 transgenic mice.  One of the newly identified 
genes, Pcsk9, also followed this pattern in the time-course and SREBP transgenic studies; 
therefore we predicted that it would be involved in cholesterol metabolism, either in 
cholesterol biosynthesis or cholesterol uptake via the LDLR (see below).  In contrast, a 
gene involved in fatty acid metabolism, Acly, was slowly down-regulated over the seven 
days in the cholesterol feeding time course.  Furthermore, this gene was up-regulated in 
SREBP-1a but not SREBP-2 mice.  The other two identified genes, Camk1d and Fabp5, 
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also followed this pattern; therefore we predict that these genes are involved in fatty acid 
metabolism.  Of note, LXR agonists should increase SREBP-1 target genes via the 
transcriptional activation of SREBP-1c (Repa et al., 2000a); in fact, Fabp5 was up-
regulated in livers of LXR agonist treated animals in the microarray study.  However, 
contrary to predictions, Pcsk9 was also moderately up-regulated by the LXR agonist; 
whereas, Camk1d was not regulated by the LXR agonist.  The significance of these 
findings is unknown. 
Table 6.1. Patterns of regulation for genes down-regulated by dietary cholesterol feeding 
 Dietary 
cholesterol 
DC Time  
course 
SREBP-1a 
Transgenic 
SREBP-2 
Transgenic 
Cholesterologenic genes 
(Hmgcr, Hmgcs, Sqle, Pcsk9) È FastÈ Ç Ç 
Lipogenic genes 
(Acly, Camk1d, Fabp5) È SlowÈ Ç NC 
Genes in pink were identified in the present study.  DC: dietary cholesterol; NC: no change. 
 
 Integration of information derived from the cholesterol feeding time course study 
and the LXR agonist experiments also allow us to make predictions about the function of 
some of the novel genes we have identified that were up-regulated by dietary cholesterol.  
In the time course of cholesterol feeding, the reverse cholesterol transport gene, Abcg5, 
was up-regulated after one day of cholesterol feeding and through day seven of feeding.  
Furthermore, this gene was up-regulated by the LXR agonist.  Adam11, Api6, and Fbxo3 
followed this same pattern; therefore we predict that these genes may also be important in 
reverse cholesterol transport or in other LXR regulated pathways in the liver.  In contrast, 
the acute phase reactant Saa3 was not induced until a later time point in the time course 
and was not induced by LXR agonists and likely represents a secondary response to the 
high cholesterol diet, such as an inflammatory response. 
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Pcsk9 is a member of the subtilisin serine protease family that regulates LDLR 
function and LDL cholesterol levels 
 Chapters 3 and 4 described the cloning, characterization and functional analysis of 
Pcsk9, one the genes identified in the microarray study in Chapter 2.  Pcsk9, a member of 
the subtilisin serine protease family, was shown to be synthesized and processed in the 
ER, transported to the TGN where it existed as the processed form, and finally secreted 
into the medium in cell culture.  In mice, Pcsk9 was mainly expressed in the liver where 
it was down-regulated by cholesterol levels.  Overexpression of Pcsk9 in mice and in vivo 
was shown to decrease LDLR protein levels by a post-transcriptional mechanism.  
Further investigation revealed that overexpression of Pcsk9 led to the degradation of the 
LDLR in a post-ER compartment, probably in the Golgi or TGN.   
 
Cloning of Pcsk9 
 The data presented in Chapter 3 on the cloning and characterization of Pcsk9 are 
in excellent agreement with most of the available literature on Pcsk9.  In addition to the 
cloning of Pcsk9 in our laboratory, Pcsk9 was also cloned by Nabil Seidah’s laboratory 
using a bioinformatics approach (Seidah et al., 2003).  Seidah BLASTed short conserved 
segments of the catalytic subunit of the subtilisin protease family member S1P against the 
patent division of GenBank and found a cDNA that had been identified in a screen for 
genes regulated by serum starvation induced apoptosis in primary neural cultures.  This 
gene had been named Neural apoptosis regulated convertase 1 (Narc-1).  Using this 
sequence information, Seidah then cloned the full length Narc-1 cDNA from human 
HepG2 cells and mouse liver; human and mouse Narc-1 are identical to the human and 
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mouse Pcsk9 cDNAs cloned in this study.  Similar domain structure and sequence 
elements have been described in other studies (Naureckiene et al., 2003; Seidah et al., 
2003), including the signal peptide, the catalytic domain with a D,H,S, catalytic triad and 
an oxyanion hole, the putative P-domain with a RGD motif, and the N-glycosylation site.  
The identity of the putative P-domain as a true P-domain has been questioned, 
particularly because Pcsk9 truncation mutants lacking the putative domain fold correctly, 
although processing is less efficient (Naureckiene et al., 2003; Benjannet et al., 2004).  
Using tunicamycin treatment and site-directed mutagenesis, Seidah demonstrated that 
Pcsk9 is in fact glycosylated on the predicted site (Seidah et al., 2003).  Finally, 
phylogenetic analyses in two other studies confirmed our designation of Pcsk9 as a 
member of the proteinase K subfamily of subtilisin serine proteases (Naureckiene et al., 
2003; Seidah et al., 2003).   
 We demonstrated that mouse Pcsk9 was expressed in cells as an approximately 
79kDa pro-form and processed to an approximately 62kDa processed form which was 
secreted into the media of McA-RH7777 and Fu5AH cells both endogenously and when 
overexpressed by transient transfection or infection.  Similar results were seen when rat 
Pcsk9 was overexpressed as a myc tagged form in COS-7 cells (Naureckiene et al., 
2003), when human Pcsk9 was overexpressed as a V5 tagged form in CHO cells and 
HEK293 cells (Seidah et al., 2003; Benjannet et al., 2004), and when human Pcsk9 was 
overexpressed as a Flag tagged form by adenovirus in HepG2 cells or transfection in 
CHO cells (Park et al., 2004).  Importantly, in the latter three studies, where it was tested, 
Pcsk9 was shown to be secreted into the medium of cells, similar to our results.  The 
processing of Pcsk9 has been demonstrated to occur at FAQ↓SIP, a conserved site in 
 155
mouse, rat and human Pcsk9 (Naureckiene et al., 2003; Benjannet et al., 2004); 
furthermore, mass spectroscopy has confirmed that the pro-form of human Pcsk9 is 
75kDa and the processed form is 61kDa (Benjannet et al., 2004).  Similar to our studies 
with mouse Pcsk9, others have found that mutation of the serine residue of the catalytic 
triad to alanine in rat or human Pcsk9 results in the absence of pro-form cleavage 
(Naureckiene et al., 2003; Seidah et al., 2003), indicating that Pcsk9 processing occurs by 
self-cleavage.  Using a myc-tagged catalytic triad mutant and a GFP tagged wild-type 
construct, Naureckiene elegantly demonstrated that Pcsk9 self-cleavage occurs 
intramolecularly (Naureckiene et al., 2003), similar to other mammalian subtilases 
(Bergeron et al., 2000).   
 
Subcellular Localization of Pcsk9 
 Using fluorescence microscopy and subcellular fractionation, we demonstrated 
that the pro-form of Pcsk9 was localized to the ER and the processed form was localized 
to the TGN.  Seidah also found that the pro-form of Pcsk9 was endoglycosidase-H 
sensitive, indicating that it localizes to the ER; however the localization of the processed 
form was not reported (Seidah et al., 2003).  Our subcellular localization results are in 
discordance with a recent report (Sun et al., 2005) which used a McA-RH7777 cell line 
stably expressing myc-tagged human Pcsk9 to demonstrate that Pcsk9 colocalized by 
immunofluorescence with an ER marker (PDI) and not with a Golgi marker (GM-130).  
This group proposed that prodomain cleavage of Pcsk9 does not result in transport to the 
Golgi and that Pcsk9 may function in the ER.  However, while the cell line used by this 
group produced both the pro-form and processed forms of Pcsk9 as demonstrated by 
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whole cell western blot, it did not secrete processed Pcsk9 into the medium.  Since 
transiently transfected Pcsk9 in our laboratory and transiently or stably overexpressed 
Pcsk9 in two other laboratories leads to secretion of processed Pcsk9 (see above) and 
endogenous Pcsk9 in both McA-RH7777 cells and Fu5AH cells is secreted (Chapter 3), 
we propose that the stable cell line reported by this group does not reflect the true 
behavior of normal Pcsk9.  Furthermore, the processed forms of all other subtilisins are 
localized to the TGN or secretory granules (see Chapter 1).  Hence it is unlikely that 
endogenous, normally functioning Pcsk9 is localized only in the ER. 
 
Pcsk9 Expression Patterns 
 We demonstrated by Northern blotting that Pcsk9 was mainly expressed in mouse 
liver and small intestine; similarly, Seidah found that Pcsk9 was most abundantly 
expressed in rat liver, jejunum and ileum (but not in duodenum) (Seidah et al., 2003).  
They also found low Pcsk9 expression in the spleen, kidney, thymus and testis.  We only 
found additional expression in the kidney by Northern blotting; however we also found 
expression in the spleen by RT-PCR, but thymus and testis were not tested.  By Northern 
blotting, neither Seidah nor we found expression of Pcsk9 in the brain; however Seidah 
found expression of Pcsk9 in the cerebellar granular layer and rostral extension of the 
olfactory peduncle by in situ hybridization.  This restricted brain expression is probably 
the reason a band cannot be found by Northern blotting of whole brain RNA.   
 We originally identified Pcsk9 due to its down-regulation by dietary cholesterol in 
mouse liver and up-regulation in SREBP-1a and SREBP-2 transgenic mice.  Furthermore, 
we have shown that mouse and rat Pcsk9 was regulated by cellular sterol levels at the 
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protein level in McA-RH7777, Fu5AH and Hepa1-6 cells.  This has been confirmed in 
vitro for human Pcsk9 at the mRNA level in HepG2 cells (Dubuc et al., 2004).  As 
discussed above, Horton also found that Pcsk9 mRNA was up-regulated in SREBP-1a 
and SREBP-2 transgenic mice (Horton et al., 2003).  They demonstrated that this is likely 
to be a direct effect because Pcsk9 was also down-regulated in SCAP knockout mice; 
without SCAP, the SREBPs are not escorted to the Golgi for processing, a prerequisite 
for nuclear localization and transcriptional activation.  SREBPs bind to SRE sites in the 
promoters of target genes.  We identified two potential SRE sites in the Pcsk9 promoter; 
the more proximal site has been proposed to be the functional SRE in the rat Pcsk9 
promoter although detailed promoter analysis was not performed (Dubuc et al., 2004).  
SREBP target genes are predicted to be up-regulated by treatment of cells or whole 
animals with statins, drugs which decrease cellular sterol levels (and hence activate 
SREBPs) by turning off cholesterol biosynthesis due to inhibition of the rate limiting 
enzyme, Hmgcr.  In fact, we showed that Pcsk9 protein levels were up-regulated by statin 
treatment in McA-RH7777 and Hepa1-6 cells.  This has been confirmed at the mRNA 
level in HepG2 cells (Dubuc et al., 2004) and in vivo at the mRNA level in mice (Rashid 
et al., 2005).  Finally, we demonstrated that mouse Pcsk9 is up-regulated by the LXR 
agonist TO901317 at the mRNA level in mice and at the protein level in vitro; whereas 
the LXR agonist 22(R)-hydroxycholesterol decreased Pcsk9 protein expression as may be 
expected due to oxysterol mediated suppression of SREBP-2 processing (Wang et al., 
1994).  Duboc stated that human Pcsk9 was not regulated by LXRs; however, they only 
used 22(R)-hydroxycholesterol.  The physiological relevance of Pcsk9 regulation by 
LXRs is still unknown.   
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Mutations in the Pcsk9 gene are associated with the third locus for autosomal 
dominant hypercholesterolemia 
 These initial studies by our laboratory and others indicated an important potential 
role for Pcsk9 in cholesterol metabolism, and support for this hypothesis came in June, 
2003 by the demonstration that missense mutations in Pcsk9 were associated with 
Hchola3, a form of autosomal dominant hypercholesterolemia (ADH) in families without 
linkage to the LDLR or apoB loci (see Chapter 1 and Table 1.1).  This was first 
demonstrated by Abifadel (Abifadel et al., 2003), who redefined the locus interval in 
previously described French Hchola3 families (Varret et al., 1999) with additional 
markers and found it to be more distal (between 74-86cM) to that originally defined and 
in better agreement with mapping data of Utah and Mexican Hchola3 families (Hunt et 
al., 2000; Canizales-Quinteros et al., 2003).  After sequencing the exons of 8 of the 41 
known genes in the critical interval, they found a serine to arginine substitution in Pcsk9 
at amino acid position 127 (S127R) in two families and a phenylalanine to leucine 
substitution at position 216 (F216L) in another family (Figure 6.1).  These substitutions 
were not found in 200 control chromosomes.  Timms (Timms et al., 2004) narrowed the 
locus in a Utah Hchola3 kindred with additional markers to between 76-82cM.  They 
identified the haplotype of the allele transmitting ADH, which was also found in another 
kindred not transmitting ADH.  Mutation screening comparing exons of all genes in this 
interval found only one variant between these kindreds, which was an aspartic acid to 
tyrosine substitution in Pcsk9 at amino acid position 374 (D374Y) (Figure 6.1).  This 
substitution was not found in 338 control chromosomes.  Interestingly, if the mapping 
data from the literature are combined, the critical interval for Hchola3 is only 3.8Mb, 
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between 51.57 and 55.38 Mb on human chromosome 1.  This interval contains Pcsk9 at 
54.88Mb as well as 24 other known genes and 27 predicted genes (Ensembl database 
version 25).   
 After the initial studies were published, Leren (Leren, 2004) described Norwegian 
individuals with a clinical diagnosis of familial hypercholesterolemia who did not have 
LDLR or apoB mutations.  Two of these patients had the D374Y mutation in Pcsk9, 
which segregated with the disease in their families.  Leren also identified a patient 
heterozygous for both D374Y and an asparagine to lysine substitution in Pcsk9 at amino 
acid position 157 (N157K) (Figure 6.1).  However, the segregation of these mutations 
with ADH in the patient’s family was not reported and it is not known whether these 
mutations are on the same or different Pcsk9 alleles.   Recently, the D374Y mutation has 
been described in three additional ADH families from England who have particularly 
severe hypercholesterolemia; heterozygotes mean LDL cholesterol was 550mg/dl (range 
352-743mg/dl, NL<130mg/dl)  (Sun et al., 2005).  Finally, two other missense mutations 
in Pcsk9 have been identified, namely arginine to serine at position 218 (R218S) and 
arginine to tryptophan at position 237 (R237W) (Benjannet et al., 2004), but segregation 
with ADH in families was not reported.  In summary, six missense mutations in Pcsk9 
have been associated with ADH (Figure 6.1). 
 Variants in Pcsk9 have also been shown to affect cholesterol levels in the general 
population.  Multiple polymorphisms in the exons and flanking introns of Pcsk9 have 
been described in Japanese (Shioji et al., 2004)  and American Caucasian (Chen et al., 
2005) individuals.  Of the 21 polymorphisms identified in the Japanese population, two 
polymorphisms, isoleucine to valine at position 474 (I474V) and intron 1/C(-161)T, 
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significantly affected total and LDL cholesterol levels when comparing homozygotes for 
the major allele with heterozygotes and homozygotes for the minor allele.  Of the 12 
polymorphisms identified in the American Caucasian population, one polymorphism, 
glutamic acid to glycine at position 670 (E670G), was significantly associated with LDL 
cholesterol levels when comparing homozygotes for the minor allele with either 
heterozygotes or homozygotes for the major allele.    
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Figure 6.1. Genetic variants in Pcsk9 and effects on LDL cholesterol levels.  The known variants in 
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In all, it appears that missense mutations in Pcsk9 are associated with high total and LDL 
cholesterol levels in the general population and in families with hypercholesterolemia 
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(Figure 6.1).  While it is still formerly possible that other mutations in the chromosome 1 
Hchola3 critical region could be the pathogenetic mutations causing 
hypercholesterolemia, the cumulative genetic evidence has provided substantial support 
for a role for Pcsk9 in regulating LDL cholesterol levels.   
 
Overexpression of Pcsk9 in mice results in a LDLR knockout phenotype 
 In order to study the function of Pcsk9 in cholesterol metabolism, we took an in 
vivo overexpression approach and injected an adenovirus constitutively expressing 
murine Pcsk9 (Pcsk9-Ad) into C57BL/6 male mice (Maxwell and Breslow, 2004), as 
described in Chapter 4.  Injection of Pcsk9-Ad in mice resulted in an increase in total 
cholesterol due to a specific increase in LDL cholesterol; there was also a small increase 
in VLDL cholesterol.  Furthermore, Pcsk9-Ad injected mice had normal hepatic 
cholesterol levels and gallbladder bile composition.  This phenotype is identical to the 
phenotype of LDLR knockout animals (Ishibashi et al., 1993; Osono et al., 1995).  In 
fact, injections into LDLR knockout mice revealed that the Pcsk9 induced increase in 
LDL cholesterol was dependent on the LDLR.  Finally, wild type mice injected with 
Pcsk9 had a near absence of liver LDLR protein with normal levels of mRNA, indicating 
that Pcsk9 induced a post-transcriptional decrease in LDLR protein levels leading to a 
LDLR knockout phenotype. 
 That overexpression of Pcsk9 decreases LDLR protein levels and leads to 
increased total and LDL cholesterol levels in mice has been extensively confirmed by 
other laboratories using adenoviral mediated overexpression of human Pcsk9 (Benjannet 
et al., 2004; Park et al., 2004; Lalanne et al., 2005).  Lalanne further confirmed that the 
 162
defect in Pcsk9 overexpressing animals was in LDL clearance by following the fate of 
radiolabeled LDL (Lalanne et al., 2005).  In addition, Park found that adenoviral 
mediated overexpression of Pcsk9 in mice did not affect levels of SREBP-1 or SREBP-2 
precursor or nuclear forms, nor did it affect the mRNA levels of SREBP target genes 
Hmgcs, Hmgcr, Sqle, Acac, and fatty acid synthase, consistent with the lack of effect on 
LDLR mRNA levels.  Finally, while LDL/IDL apoB100 was increased in Pcsk9-Ad 
treated animals, as expected from the LDL increase, other proteins involved in liver 
cholesterol metabolism, including ARH, LRP1, SRBI, and HDL apoAI, apoAII and 
apoE, were unchanged (Park et al., 2004; Lalanne et al., 2005). 
 The effect of Pcsk9 on LDLR function has been recapitulated in vitro in our 
laboratory and by others.  We showed that overexpression of Pcsk9 in McA-RH7777 and 
HepG2 cells either by transient transfection or adenoviral infection led to a decrease in 
LDLR protein levels and DiI-LDL binding and uptake.  Similar results have been seen by 
transient transfection in human hepatoma Huh7 cells (Lalanne et al., 2005) and in HepG2 
stable cell lines (Benjannet et al., 2004; Park et al., 2004).  Strangely, Sun found that 
McA-RH7777 cells stably expressing Pcsk9 had normal levels of LDLR protein (Sun et 
al., 2005); however, as discussed above, these cells appeared to have a defect in Pcsk9 
trafficking as processed Pcsk9 was retained in the ER and not secreted in this cell line.   
 
Overexpression of Pcsk9 leads to the degradation of the LDLR in a post-ER 
compartment 
 Since overexpression of Pcsk9 in vivo led to a decrease in LDLR protein levels by 
a post-transcriptional mechanism, we used the in vitro HepG2 system to study the 
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mechanism of these effects (Maxwell et al., 2005).  Overexpression of Pcsk9 did not have 
an effect on the incorporation of 35S -Met/Cys into the LDLR or on the conversion of the 
precursor to mature form of the LDLR, indicating that Pcsk9 does not affect LDLR 
synthesis or maturation.  In contrast, pulse chase studies demonstrated that Pcsk9 had a 
major effect on accelerating the degradation of the mature LDLR, and that this effect 
required an active Pcsk9 catalytic domain.  Use of various inhibitors demonstrated that 
the Pcsk9 induced degradation of the mature LDLR did not require the proteasome, 
occurred in a post-ER, pH dependent compartment, and did not require endocytosis. 
The studies demonstrating that the Pcsk9 induced degradation of the LDLR 
required the catalytic activity of Pcsk9 have been confirmed in other studies.  
Overexpression of human Pcsk9 mutated at the histidine catalytic site residue also has no 
effect on LDLR protein levels in HepG2 cells (Benjannet et al., 2004), and injection of 
human Pcsk9 mutated at the serine catalytic site residue has no effect on LDLR protein 
levels in mice (Park et al., 2004).  Given that Pcsk9 is not processed to the catalytically 
active form until the TGN, it is likely that Pcsk9 acts to degrade the LDLR in this 
compartment or more distally.  We showed that Pcsk9 could still degrade an 
internalization defective mutant LDLR, and Park demonstrated that injection of Pcsk9 
into ARH knockout mice still led to a decrease in LDLR protein levels (Park et al., 2004), 
indicating that ARH/clathrin-mediated endocytosis is not required for Pcsk9 induced 
degradation of the LDLR, unless another unknown adaptor protein is used.  These data 
indicate that Pcsk9 is not playing a role in the constitutive degradation of the LDLR that 
occurs at the end of the LDLR lifetime in the endocytic recycling compartment.  
Furthermore, these results and our data in BFA treated cells localize the Pcsk9 site of 
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action to the Golgi, TGN, distal secretory vesicles or the cell surface.  Finally, our data 
with fractions of the secretory pathway suggest that Pcsk9 initiates LDLR degradation in 
the TGN.   
 Secretory and membrane proteins can be targeted for degradation at multiple 
points along the secretory pathway and at the cell surface as a mechanism of protein 
quality control (QC) and in the post-translational regulation of expression (Trombetta and 
Parodi, 2003) (Figure 6.2).  Secretory and membrane proteins are synthesized in the ER 
and undergo maturation in the ER and Golgi with the assistance of generalized and 
private chaperones that function in folding, glycosylation and formation of proper 
quarternary structure.  Along the synthetic pathway, a protein may be marked as failing 
QC if it is not properly folded due to mutation, does not complex with binding partners, 
fails to bind ligand, or lacks a post-translational modification.  In addition, normal 
proteins may be marked as failing QC, often in response to some metabolic signal.  
Regardless of the reason, some proteins marked as failing QC in the ER and some 
proteins which are retrieved from the cis Golgi are targeted for ER-associated 
degradation (ERAD) (Bonifacino and Weissman, 1998; Trombetta and Parodi, 2003).  
ERAD involves the retrotranslocation of the protein across the ER membrane, followed 
by polyubiquitination and subsequent degradation by the proteasome.  Our data do not 
support a Pcsk9 induced degradation of the LDLR by ERAD because degradation was 
prevented in BFA treated cells and was not sensitive to proteasome inhibitors.  Thus, 
LDLR degradation induced by Pcsk9 is different from that reported for class 2 LDLR 
mutants, which undergo proteasomal degradation (Li et al., 2004b).  In the same study, 
wild-type LDLR was not affected by proteasome inhibitors.   
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Some proteins marked as failing QC are not targeted for ERAD and instead travel 
into the Golgi; furthermore, it is now becoming clear that other proteins destined for the 
plasma membrane may be diverted at the TGN under conditions where they are not 
needed at the cell surface (Figure 6.2) (Trombetta and Parodi, 2003; Babst, 2005).  In the 
latter pathway, a group of proteins called Golgi-associated γ-adaptin homologs, Arf-
binding (GGAs) bind mono-ubiquitinated proteins at the TGN cytoplasmic face and 
target them to endosomes in a clathrin-dependent pathway (Babst, 2005).  These 
endosomes are joined by those derived from the plasma membrane by a similar 
mechanism involving mono-ubiquination and clathrin-mediated endocytosis.  
Invagination of the ubiquinated cargo in the endosomes by the endosome sorting complex 
required for transport (ESCRT) proteins leads to the formation of multivesicular bodies 
(MVBs).  Finally, these MVBs fuse with lysosomes to degrade the targeted proteins 
derived from the TGN and the cell surface.  The yeast membrane protein general amino 
acid permease 1 (Gap1) has been shown to be targeted to the TGN-MVB-lysosome 
pathway under conditions when it is not needed at the cell surface (Babst, 2005).  This is 
an attractive pathway by which Pcsk9 may induce LDLR degradation for the following 
reasons.  First, we have localized the Pcsk9 induced degradation between the ER and the 
plasma membrane, most likely in the TGN due to results with BFA treated cells, 
subcellular fractionation, internalization defective LDLR mutants and by the 
demonstration that the LDLR degraded by Pcsk9 is in the 160kDa form, indicating that it 
has Golgi specific modifications.  Furthermore, proteasome inhibitors have no effect but 
ammonium chloride does affect the Pcsk9 induced degradation of the LDLR supporting a 
potential role for the lysosome versus the proteasome.  The lysosome contains proteases 
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of mostly the cysteine class, but also aspartic acid, metalloprotease and serine proteases 
(Turk et al., 2001; Pillay et al., 2002).  Our data with E64d, pepstatin and 
phosphoramidon indicate that the Pcsk9 induced degradation of the LDLR does not 
depend on cysteine, aspartic acid and metallo-proteases and does not provide support for 
lysosomal degradation.  However, not all lysosomal proteases may be inhibited in our 
experiments, and it is still possible that the responsible proteases are found in lysosomes.  
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The process of protein degradation from the secretory pathway and the cell 
surface is further complicated by the fact that some proteins at the cell surface and the 
Golgi are targeted to lysosomes via non-ubiquitin and/or non-clathrin dependent 
pathways (Arvan et al., 2002; Babst, 2005).  While alternative pathways are possible, we 
propose that Pcsk9, under conditions where the LDLR is not needed for cholesterol 
uptake, cleaves the LDLR or another protein bound to the LDLR in the TGN as a signal 
leading to transport of the LDLR into the MVB and eventually the lysosome for 
degradation (Figure 6.2).  This pathway may depend on ubiquitination of the LDLR, 
interaction with a GGA protein and clathrin-mediated budding from the TGN surface; 
however, the ARH protein would not be involved.  
 
Why do SREBPs turn on both the LDLR and Pcsk9?   
 It has been questioned why both the LDLR and its degrader, Pcsk9, would be 
activated by the same transcription factor, SREBP.  A purely speculative hypothesis is as 
follows.  When cellular sterol levels are low, the SREBPs are transported to the Golgi for 
processing and move to the nucleus to turn on many genes, including Hmgcr to increase 
cholesterol biosynthesis and the LDLR to increase cholesterol uptake.  When these 
processes result in excess cellular sterols (which is cytotoxic), one way to turn off 
cholesterol biosynthesis and uptake is to prevent transcription of Hmgcr and LDLR by 
preventing SREBP processing.  However, it is predicted that this process would be slow 
and it would not decrease the levels of Hmgcr and LDLR that are already present in the 
cell, and at a long half-life (for the LDLR); thus potentially resulting in cytotoxic 
accumulation of sterols.  Therefore, the cell could have a system ready, i.e.  
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transcriptionally activated by the same pathway, to decrease cholesterol biosynthesis and 
uptake without the need for further transcription. It is already known that the cell has 
such a mechanism to reduce cholesterol biosynthesis, namely sterol mediated degradation 
of Hmgcr by the proteasome, a process that requires the SREBP target Insig-1 (Horton et 
al., 2003; Sever et al., 2003).  Therefore, it seems perfectly reasonable that the cell would 
also have a mechanism, possibly sterol mediated, for degradation of the LDLR (Figure 
6.3).  Interestingly, the TGN-MVB-lysosome pathway proposed above to be the 
mechanism of Pcsk9-induced degradation of the LDLR has been proposed to be a way 
for cells to degrade newly synthesized plasma membrane proteins under conditions where 
transcription-based regulation is too slow to affect changes in the amounts of the protein 
at the cell surface (Babst, 2004)  
 
Degradation of the LDLR as a mode of regulation of LDLR levels 
 Regulation of LDLR levels has been mostly studied at a transcriptional level; 
however, evidence exists that the LDLR is also subjected to regulation at the level of 
mRNA stability (Wilson et al., 1998; Nakahara et al., 2002; Kong et al., 2004), 
translation (Huang et al., 1997), protein degradation, and limited proteolysis.  Regulation 
at the level of protein degradation has been suggested in the Zucker fatty rat (Liao et al., 
1997a), and in rats treated with endotoxin (Liao et al., 1996), glucagon (Rudling and 
Angelin, 1993), histamine (Liao et al., 1997b), and coffee diterpenes (Rustan et al., 1997; 
de Roos and Katan, 1999); however, the exact mechanisms are unknown.  Pulse labeling 
of human fibroblasts indicated that the half-life of LDLRs was greatly decreased by 
cycloheximide, suggesting protein mediated LDLR degradation (Casciola et al., 1988); 
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however, the site and mechanism of degradation was not determined.  Furthermore, it is 
known that certain cell lines, such as the J774 macrophage cell line, have increased 
degradation rates of the LDLR (Yoshimura et al., 1988; Shite et al., 1990a).  
Interestingly, the increased degradation in J774 cells was shown not to be affected by the 
cysteine protease inhibitors leupeptin and E64, but slowed by BFA treatment and 
incubation at 18ºC (Shite et al., 1990a).  These results are similar to our data on the Pcsk9 
induced degradation of the LDLR.  However, the mechanisms must be at least partially 
different in that ammonium chloride did not affect the increased degradation in J774 cells 
(Shite et al., 1990a) and we do not have evidence for Pcsk9 expression in macrophages. 
 There is also evidence for degradative type regulation of the LDLR at the level of 
limited proteolysis.  First, Begg (Begg et al., 2004) demonstrated that phorbol ester 
treatment of HepG2 cells increased LDLR degradation rate by inducing the release of a 
soluble LDLR.  It does not appear, however, that Pcsk9 is acting by this mechanism as no 
evidence for a soluble LDLR was found in the media of control or Pcsk9 overexpressing 
cells.  Second, Kraemer (Kraemer et al., 1996) demonstrated that treatment with the 
cAMP inducing agents isoproterenol and forskolin decreased LDLR levels in adipose 
cells concomitant with the appearance of a 90-95kDa proteolytic product in the plasma 
membrane.  While we have not investigated plasma membrane fractions specifically, we 
have also not found evidence of a proteolytic LDLR cleavage product in Pcsk9 
overexpressing cells, although this still remains a possibility.   
 The existence of LDLR mutants with accelerated degradation also supports the 
notion of regulation at the level of protein degradation.  These mutant LDLRs show 
either normal or only slightly slowed processing of precursor to mature forms and greatly 
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accelerated degradation rates in the absence or presence of ligand, leading to decreased 
LDLR function and hypercholesterolemia.  These mutations include missense mutations 
(Fourie et al., 1988; Leitersdorf et al., 1989; Miyake et al., 1992; Rubinsztein et al., 
1992), a small deletion (van der Westhuyzen et al., 1991), and a small duplication 
(Bertolini et al., 1994) all in the EGF precursor homology domain, indicating that this 
domain may be important for LDLR degradation.  Of note, deletion of the entire EGF 
precursor homology domain only causes an increased degradation of the LDLR in the 
presence of ligand (Davis et al., 1987), indicating that the role of the EGF precursor 
homology domain is complex.  It is possible that analysis of the accelerated degradation 
mutants may aid in the elucidation of the Pcsk9 pathway, including the identification of 
other important members. 
 
How Pcsk9 may result in hypercholesterolemia in humans – the LDLR hypothesis 
 One of the most critical outstanding questions in the Pcsk9 field is how missense 
mutations in Pcsk9 lead to ADH.  In general, autosomal dominant diseases result when 
the presence of one abnormal copy of a gene is sufficient to produce disease.  Thus, loss-
of-function mutations will cause a dominant disease if the amount of gene product is 
critical; these could be nonsense mutations (e.g. LDLR nonsense mutations that cause 
ADH) or missense mutations (e.g. LDLR and apoB missense mutations that cause ADH).  
Dominant diseases can also be caused by gain of function mutations; these can also be 
missense mutations if the mutation increases protein activity in a situation where the 
amount of gene product is critical, causes the acquisition of a novel function, causes 
improper spatial or temporal expression of the protein, or induces overexpression of the 
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gene.  Finally, dominant diseases can be caused by missense mutations that result in a 
dominant negative phenotype when one bad copy poisons a multimeric complex and 
prevents it from acting. 
Overexpression of Pcsk9 results in the same phenotype as missense mutations, 
namely elevated LDL cholesterol due to low LDLRs.  One hypothesis is that a loss of 
function mutation and overexpression of Pcsk9 result in the same phenotype, as is seen 
with LRP1 and RAP.  In RAP knockouts, hepatic LRP1 protein is diminished and shows 
decreased physiological function (Willnow et al., 1995; Willnow et al., 1996); and 
adenoviral mediated RAP overexpression also results in decreased physiological function 
of LRP1 (Willnow et al., 1994).  Another hypothesis is that Pcsk9 missense mutations are 
gain of function mutations resulting in increased protein activity or increased protein 
expression.  This hypothesis predicts that a knockout or loss of function mutation in 
Pcsk9 would cause the opposite phenotype, namely elevated LDLR levels due to 
decreased LDLR degradation, as overexpression.  This hypothesis is suggested by our 
siRNA results and those of Lalanne (Lalanne et al., 2005) in which siRNA mediated 
knockdown of Pcsk9 in human HepG2 or Huh7 cells resulted in elevated LDLR protein 
levels.  The most convincing support for this hypothesis has come from the recent 
publication of Pcsk9 knockout mice (Rashid et al., 2005).  Pcsk9 knockout mice have a 
50% reduction in plasma total cholesterol due to a near absence of LDL cholesterol and a 
30% reduction in HDL cholesterol. This phenotype is likely due to the the 3-fold increase 
in liver LDLR protein levels and 5-fold increase in the clearance of injected radiolabeled 
LDL.  Results with one of our Pcsk9 siRNAs in human cells indicated that knockdown of 
Pcsk9 increased LDLR synthesis and LDLR mRNA levels, bringing up the concern that 
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knockdown and overexpression of Pcsk9 resulted in the opposite endpoint by different, 
not opposite, mechanisms.  However, the Pcsk9 knockouts have no change in LDLR 
mRNA levels or SREBP nuclear to cytoplasmic ratio, thus supporting the hypothesis that 
Pcsk9 knockdown increases LDLR levels by preventing LDLR degradation not by 
increasing synthesis.  Furthermore, our contradictory results may be siRNA dependent as 
one Pcsk9 siRNA did not increase LDLR mRNA levels but still increased LDLR protein 
levels.  Obviously, more experiments with the Pcsk9 knockout mice and Pcsk9 siRNA in 
cell culture are needed to work out the mechanism. 
It is also formally possible that overexpression of Pcsk9 and missense mutations 
in Pcsk9 result in the same phenotype due to a difference in the function of Pcsk9 in mice 
and humans.  However, recent results suggest that Pcsk9 may function to similarly 
regulate LDLR levels in both mice and humans.  Cohen (Cohen et al., 2005) showed that 
two loss-of-function mutations in Pcsk9, Y142X and C679X, were associated with an 
approximately 40% decrease in LDL cholesterol levels in two populations of African 
Americans (Dallas, Texas and Chicago, Illinois).  These mutations appeared to be 
surprisingly common, as 2% of the individuals in both of these populations carried a 
nonsense mutation in Pcsk9.  These mutations also appeared to segregate as autosomal 
dominant traits in families.   
The available results show that knockout and nonsense mutations in Pcsk9 result 
in high LDLR protein levels and low LDL cholesterol levels; whereas, overexpression 
and missense mutations in Pcsk9 result in low LDLR protein levels and high LDL 
cholesterol levels.  Unfortunately, studies using overexpression of the natural Pcsk9 
mutants in cell culture and in mice to decipher the mechanism of the missense mutations 
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has led to confusing results.  In one line of experiments, when the Pcsk9 S127R and 
F216L mutations were overexpressed in stable HepG2 cell lines (Benjannet et al., 2004), 
HepG2 cells infected with virus, or mice infected with virus (Park et al., 2004), the 
decrease in LDLR levels observed was similar to that seen with wild-type Pcsk9.  
However, it is most likely that any increase in activity of the mutants is masked by the 
level of overexpression.  In a more perplexing line of experiments, Benjannet expressed 
some of the known human Pcsk9 mutations in HEK293 cells to examine prodomain 
cleavage as a readout for Pcsk9 activity.  They found that the D374Y mutant had 
abolished cleavage, the S127R mutant had decreased cleavage, and the F216L, R218S, 
and R237W mutants had normal cleavage.  While the presence of normal cleavage of the 
latter three mutants is compatible with the mutation increasing Pcsk9 activity, it does not 
immediately make sense how the D374Y or S127R mutation could increase Pcsk9 
activity if cleavage is not taking place.  These ideas will be discussed further in the 
section describing two models for Pcsk9 action. 
 
How Pcsk9 may result in hypercholesterolemia in humans – the apoB hypothesis 
 Increased LDL cholesterol levels can result from decreased uptake of LDL by the 
LDLR or by increased production of apoB-containing VLDL and subsequent metabolism 
into LDL in the circulation.  While a controversy still exists, it is becoming clear that at 
least wild-type Pcsk9 does not play a significant role in apoB secretion.  First, injection 
of mouse or human wild-type Pcsk9 adenovirus did not increase LDL levels in LDLR 
knockout mice after four days in our study, after 3 days (Park et al., 2004), and after 4,5,7 
or 9 days (Lalanne et al., 2005).  While a fourth study did find an increase in LDL levels 
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after 7 days of adenoviral mediated overexpression of Pcsk9 in LDLR knockout mice 
(Benjannet et al., 2004), these contradictory results may be explained by the extremely 
high titer of virus used as between 2 and 6 fold higher numbers of virus particles were 
used in this study compared with the others.  Studies with Pcsk9-Ad infected wild-type 
mice showed no significant accumulation of apoB in the plasma of mice injected with 
tyloxapol to inhibit triglyceride hydrolysis and allow accumulation of newly synthesized 
VLDL (Lalanne et al., 2005).  Furthermore, hepatocytes isolated from Pcsk9-Ad infected 
mice (Park et al., 2004), Huh7 cells transfected with Pcsk9 (Lalanne et al., 2005), and 
HepG2 cells infected with Pcsk9-Ad (our studies) did not show a significant increase in 
apoB secretion in pulse-labeling studies.  Finally, hepatocytes from Pcsk9 knockout 
animals (Rashid et al., 2005) and siRNA mediated Pcsk9 knockdown in HepG2 cells (our 
studies) and Huh7 cells (Lalanne et al., 2005) did not have significantly decreased apoB 
secretion.  It is important to note, that while none of these studies showed significant 
effects, there were slight increases or decreases in apoB levels, possibly reflecting the 
direct effect of the absence or presence of LDLRs on apoB secretion rates, as LDLR 
presence in the secretory pathway induces presecretory degradation of apoB in the ER 
(Twisk et al., 2000; Gillian-Daniel et al., 2002). 
 While these results do not support a direct role for wild-type Pcsk9 in the control 
of apoB secretion, results from patients carrying the S127R mutation must be taken into 
account.  In vivo kinetic labeling studies from two human patients with the S127R 
mutation showed a 1.5-fold decrease in LDL fractional catabolic rate (compared to 2.5-
fold for FH heterozygotes) and a 3-fold increase in VLDL total production rates 
(compared to 1.5-fold for FH heterozygotes) indicating an effect of the Pcsk9 S127R 
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mutation on apoB production that is different from the effect of having half the normal 
amount of LDLR (Ouguerram et al., 2004).  Furthermore, patients with the S127R 
mutation have been shown to have an increase in apoB in VLDL fractions; whereas FH 
heterozygotes do not (Lalanne et al., 2005).  These results indicate that the S127R 
mutation of Pcsk9 may represent a gain-of-function resulting in new activity in 
controlling apoB secretion in addition to affecting LDLR levels.  Alternatively, the 
increase in apoB secretion in Pcsk9 mutants could simply be due to the absence of the 
LDLR as LDLR-defective FH patients have been shown to have increased apoB 
production rate (Millar et al., 2005). 
 
Models of Pcsk9 action 
 The available data on Pcsk9 may be summarized into two potential models of 
Pcsk9 action.  Model #1 is apoB-independent, and Model #2 is apoB-dependent.  Both 
models propose that the natural function of Pcsk9 is to degrade the LDLR in a rapid 
manner when cellular sterol levels are high.  In low sterol conditions or upon early 
SREBP activation, Pcsk9 and the LDLR are synthesized within the ER, and Pcsk9 is in 
an inactive precursor conformation due to the binding of its pro-domain to its catalytic 
site.  Transfer of Pcsk9 to the Golgi allows cleavage of the pro-domain; however, Pcsk9 
remains inactive due to pro-domain binding and steric hindrance of its catalytic site; in 
this situation, the LDLR traffics to the cell surface (Figure 6.4A).  In high sterol 
conditions or perhaps in response to some other stimulus, a secondary event in the Golgi 
removes the pro-domain from the Pcsk9 catalytic site, allowing direct cleavage of the 
LDLR or some other protein and activation of LDLR degradation (Figure 6.4B).  In this 
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model, a knockout of Pcsk9 would allow the LDLR to escape degradation in all 
circumstances, leading to an increase in LDLR levels (Figure 6.4C).  In contrast, 
overexpression of Pcsk9 would allow so many molecules of Pcsk9 to be made, that a 
certain proportion would inappropriately escape from pro-domain inhibition and activate 
LDLR degradation (Figure 6.4D).  Similarly, one could use this model to explain the 
F216L, R218S, and R237W mutations.  These mutations could allow normal pro-domain 
cleavage, but could somehow prevent pro-domain binding to the catalytic site, thus 
allowing unregulated activation of Pcsk9 and inappropriate activation of LDLR 
degradation (Figure 6.4E).  If the D374Y and S127R mutations do truly prevent pro-
domain cleavage, one could also explain these mutations using this model if these 
mutations were proposed to elicit pro-domain binding to another site on the Pcsk9 
molecule, preventing pro-domain cleavage but not inhibiting the Pcsk9 catalytic site, 
allowing inappropriate activation of LDLR degradation (Figure 6.4F).   
 Model #2 also proposes that the natural role of Pcsk9 is to degrade the LDLR in 
the Golgi; however, it adds that Pcsk9 may have a second role in either directly 
increasing apoB secretion or indirectly increasing apoB secretion by decreasing LDLR 
levels within the ER.  This role is not or only moderately apparent under normal, 
overexpressed, and knockout conditions because Pcsk9 is usually rapidly trafficked from 
the ER to the Golgi.  However, if the S127R and D374Y mutations induced inappropriate 
retention of Pcsk9 within the ER, this role may become more apparent, leading to 
decreased LDLR levels and increased apoB secretion.   
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 The fledging field of Pcsk9 biology promises to hold much excitement for the 
future (Maxwell and Breslow, 2005).  It also demonstrates the power of modern biology 
to combine large scale genomic, bioinformatic, and genetic techniques in a variety of 
model systems and in humans to identify important new biological pathways.  However, 
much remains to be learned regarding Pcsk9, both in its role in cholesterol metabolism in 
the liver and in its potential roles in other tissues.  One of the more exciting prospects in 
the Pcsk9 field is the prediction that an inhibitor of Pcsk9 could decrease LDLR 
degradation, increase LDL uptake by the liver, and lower plasma LDL cholesterol levels.  
Furthermore, it is predicted that such an inhibitor would be synergistic with statins, as the 
rise in LDLR levels predicted by statin treatment may be dampened by Pcsk9 (Figure 
6.5).  Evidence from mice already supports this hypothesis as statin treatment in normal 
mice actually decreased LDLR protein levels despite an increase in SREBPs; whereas 
statin treatment in Pcsk9 knockout mice increased LDLR levels above that seen in 
control statin treated Pcsk9 knockouts (Rashid et al., 2005).  Furthermore, LDL clearance 
was unchanged in statin treated wild-type mice, increased in Pcsk9 knockout mice, and 
even further increased in statin treated Pcsk9 knockout mice.  
statin Cholesterolbiosynthesis
Drug
TargetSREBP
LDLR
Pcsk9
Figure 6.5.  Proposed synergistic action of statins and a Pcsk9 inhibitor.  Statins inhibit the action 
of HMG CoA reductase, the rate limiting step of cholesterol biosynthesis, thus decreasing cellular sterol 
levels.  This activates SREBP-mediated transcription of both the LDLR and Pcsk9.   If Pcsk9 degrades 
the LDLR under these circumstances, the increase in Pcsk9 may limit the statin induced increase in the 
LDLR.  Therefore, a Pcsk9 inhibitor may allow a maximal increase in LDLR levels to be achieved, 
providing increased lowering of plasma LDL cholesterol. 
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Adam11 is a catalytically inactive, somatically expressed ADAM family member  
 Chapter 5 described the characterization and initial functional analysis of mouse 
Adam11, one the genes identified in the microarray study in Chapter 2.  A novel isoform 
of Adam11, named Adam11A, was cloned from mouse liver and shown to encode a 
different C-terminal tail as the previously cloned Adam11, which we named Adam11B. 
Both isoforms are predicted to encode catalytically inactive members of the a disintegrin 
and metalloprotease family.  Adam11A was shown to be expressed at the cell surface.  In 
mice, Adam11A was shown to be expressed in many tissues; however it was regulated by 
dietary cholesterol and LXR activation only in the liver.  Finally, we described initial 
attempts to determine the function of Adam11. 
 
Cloning of Adam11 identifies a novel Adam11 isoform 
 Adam11 was originally cloned from a human brain cDNA library in 1993 in a 
search for genes within a breast cancer susceptibility locus on human chromosome 
17q21, called BRCA1 (Emi et al., 1993).  Adam11 was found to be disrupted by somatic 
rearrangement in two sporadic breast cancers; however, Adam11 was not found to be the 
responsible gene in the BRCA1 locus, as the Brca1 gene was cloned a year later.  
Regardless, another human Adam11 cDNA (Katagiri et al., 1995) and mouse Adam11 
cDNA (Sagane et al., 1999) were subsequently cloned from brain cDNA libraries.  When 
we set out to clone mouse Adam11 from liver to study its properties and function, we 
used primers corresponding to these Adam11 sequences.  These efforts determined that a 
cDNA corresponding to the previously cloned Adam11 sequence could only be cloned 
from mouse brain cDNA.  Instead, a cDNA encoding a novel Adam11 isoform was 
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amplified from all other tissues tested, including the liver.  These two cDNAs differ at 
their C-terminal ends; the first 12 amino acids of the C-terminal tails are identical, then 
Adam11A has 9 more amino acids whereas Adam11B has 4 different amino acids.  Since 
the only cDNAs cloned from human (all from brain) correspond to Adam11B, it is still 
unclear if the Adam11A isoform exists in humans.  However, there are ESTs from human 
tissue libraries in the sequence database which could only correspond to Adam11A, thus 
it is likely that this isoform is also expressed in human tissues. 
 
Tissue expression of Adam11 
 All of the published studies examining tissue expression of Adam11 used a cDNA 
corresponding to the brain Adam11B isoform.  While sequences from this cDNA should 
also recognize the Adam11A isoform, hybridization efficiency may be lower due to the 
sequence divergence of the Adam11A 3’end.  Therefore, it is difficult to compare the 
expression patterns of Adam11 reported in the literature to that determined in Chapter 5.  
In the literature, Adam11 has been reported to be expressed by Northern blotting most 
highly in the adult brain in humans, mice and rats (Katagiri et al., 1995; Sagane et al., 
1998; Sagane et al., 1999; Karkkainen et al., 2000).  Expression in other tissues was 
different in various studies; two studies reported expression only in the brain (Sagane et 
al., 1998; Karkkainen et al., 2000); whereas three other studies reported expression in 
other tissues such as heart, liver, kidney and testis (Katagiri et al., 1995; Sagane et al., 
1999; Rybnikova et al., 2002).  In our study, we found that mouse Adam11A was 
expressed most abundantly in the heart and liver, with lower expression in the brain, 
kidney, and testis by Northern blotting.  These differences can be interpreted with the 
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cloning results to mean that Adam11B is expressed mostly in the brain; whereas 
Adam11A is expressed in other tissues.  It is also important to note that we have not 
found expression of  either Adam11 isoform in macrophages; similarly Adam11 was 
found not to be expressed in human blood monocytes in another study (Namba et al., 
2001).   
 A complete description of Adam11 expression in the mouse was reported by 
Rybnikova (Rybnikova et al., 2002).  They showed that in the adult mouse, Adam11 was 
expressed in peripheral nervous system ganglia, neural cells in the retina, the stratum 
spinosum in the skin, spermatogenic cells in the testis, and in the kidney.  Furthermore, 
they extensively described expression of Adam11 in neurons within the developing and 
adult central nervous system.  Finally, as applicable to the current study, they showed that 
Adam11 expression within the liver was restricted to hepatocytes, with the highest levels 
of expression near portal triads at the peripheral parts of hepatic lobules and lower 
expression near the central vein at the center of hepatic lobules.  Adam11 was not 
expressed in the developing liver. 
 
Regulation of Adam11 expression 
 We have found that Adam11 expression is highly regulated by cellular sterol 
levels and the LXR ligands 22(R)-hydoxycholesterol and TO901317, specifically in the 
mouse liver.  It has been found that another LXR target gene, Abca1, is induced by 
retinoic acid in addition to LXR ligands (Costet et al., 2000).  Interestingly, in a 
microarray study, Adam11 was found among 57 genes that were up-regulated by 
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treatment of human embryonal carcinoma cells with retinoic acid (Freemantle et al., 
2002).   
 The farnesoid X receptor (FXR) is naturally activated by bile acids and up-
regulates genes involved in lowering bile acid levels.  It has recently been shown that 
TO901317, while a more potent activator of LXR, is also an activator of FXR (Houck et 
al., 2004).  Therefore, it is possible that the up-regulation of Adam11 by TO901317 could 
be mediated by FXR, and that the dietary cholesterol up-regulation of Adam11 could be 
due to the generation of bile acids in the liver.  However, feeding rats a 2% cholesterol 
diet for 7 days up-regulates the LXR target genes Abca1 and Cyp7a1 but not the FXR 
target genes SHP and BSEP (Xu et al., 2004).  We have shown that Adam11 is up-
regulated by dietary cholesterol feeding after one day of feeding; therefore, it is unlikely 
that Adam11 is a FXR target gene. 
 
Possible Functions of Adam11 in the brain 
 Few studies have been published regarding Adam11, and all published studies 
focused solely on the cloning and expression patterns of Adam11; therefore any 
hypotheses on Adam11 function have been purely speculative.  Given the extensive work 
on Adam11 expression patterns in the embryonic and adult central nervous system and 
the thought that Adam11 and its subfamily members, Adam22 and Adam23, are brain-
specific, most initial roles hypothesized for Adam11 have been “neuro-centric”.  Since 
Adam11 is predicted to be catalytically inactive but to retain the potential integrin 
binding loop, roles proposed for Adam11 have involved either integrin dependent or 
independent adhesion.  For example, Xenopus Adam11 (MDC11a), expressed in neural 
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crest cells, was proposed to be involved in cell-cell or cell-matrix interactions during 
neural crest cell migration (Cai et al., 1998).  Furthermore, Adam11 has been proposed to 
play a role in any one of many integrin functions in the adult or developing brain, such as 
neuronal plasticity in the adult brain, or neuronal migration, differentiation, and synapse 
formation in the developing brain (Rybnikova et al., 2002).   
 Two other studies besides our own identified Adam11 by large scale genomic or 
proteomic approaches.  As stated above, Adam11 was found to be up-regulated by 
retinoic acid in human embryonal carcinoma cells (Freemantle et al., 2002).  This result 
was interpreted to mean that Adam11 plays a role in retinoic acid induced differentiation 
of embryonal cells to a neuronal lineage, a possibility since Adam11 is expressed in 
neurons in the developing mouse embryo (Rybnikova et al., 2002).  In another study 
employing a proteomics approach, Adam11 was found to be expressed in mouse 
embryonic fibroblasts (MEFs) only after irradiation (Xie et al., 2004).  The purpose of 
this study was to identify genes that are expressed by irradiation inactivated MEFs that 
are used as feeder cells for human embryonic stem (ES) cells.  Therefore, the authors 
proposed that Adam11 could be involved in maintaining human embryonic stem cells in 
an undifferentiated state by binding to an integrin on the ES cell surface.   
 Sagane reported that they had produced Adam11 knockout mice (Sagane et al., 
1999).  However, while it was stated that no abnormalities were detected, nothing else 
was described and nothing has been published since.  Knockouts of the Adam11 
subfamily members Adam22 and Adam23 have severe ataxia and postnatal death 
(Mitchell et al., 2001; Sagane et al., 2005); in Adam22 this is due to defective Schwann 
cell myelination in the peripheral nervous system.  Given the high sequence homology of 
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Adam11, Adam22, and Adam23 and the absence of an obvious CNS phenotype in any of 
the knockouts, it is therefore very likely that they have redundant functions in the CNS.  
However, Adam22 and Adam23 have only been shown to be expressed in neural tissues 
in the literature, and neither Adam22 nor Adam23 were expressed in the liver under any 
condition in our microarray studies.  Therefore, it is possible that Adam11 has a non-
redundant role in non-neural tissues such as the liver. 
 
Possible functions of Adam11 in the liver 
 The process of RCT involves removal of cholesterol from peripheral tissues, via 
cholesterol efflux by macrophages, to plasma lipoproteins and delivery back to the liver 
for efflux into the bile and eventual elimination in the intestine (Repa and Mangelsdorf, 
2002).  Many of the proteins involved in RCT are targets of the LXR transcription 
factors.  Since we showed that Adam11 was up-regulated by cholesterol putatively via 
the LXR transcription factors, we propose that Adam11 may play a role in RCT.  Since 
Adam11 was not expressed in the macrophage or the small intestine and as a cell 
membrane protein it is not predicted to be secreted into the plasma compartment, we 
predict that Adam11 may play a role in RCT specifically in the liver.  The liver’s role in 
RCT is via the movement of cholesterol across the plasma membrane into cells for 
conversion into bile acids or efflux into bile.  The protein SRBI plays a role in selective 
cholesterol uptake into the liver from HDL (Krieger, 2001), and the proteins Abcg5 and 
Abcg8 play a role in cholesterol removal into the bile (Yu et al., 2003).  Since Adam11 is 
localized to the cell surface, Adam11 may have an accessory role for SRBI or the 
Abcg5/8 complex or it may play an independent role.  Therefore, we first assayed 
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whether Adam11 affected either cholesterol efflux or uptake into cells; however we 
found no effect of Adam11 overexpression on LDL or HDL uptake or efflux of 
cholesterol to various acceptors.  While these experiments indicate that Adam11 is not 
sufficient to induce cholesterol movement across membranes, it is still possible Adam11 
plays a role in regulating these processes (Figure 6.6). 
 It has been shown that treatment of THP-1 macrophage-like cells or peritoneal 
macrophages with LXR ligands such as TO901317, 22(R)-hydroxycholesterol, and 
24(S),25-epoxycholesterol up-regulate LXRα mRNA in an autoregulatory loop (Whitney 
et al., 2001).  This indicates that another role of LXR is to amplify its own signaling.  
However, LXR ligands do not up-regulate LXRα in hepatocytes (Whitney et al., 2001), 
indicating that if LXR signaling is amplified in liver, it must occur by another 
mechanism.  Interestingly, we found that overexpression of Adam11 in HEK293 cells or 
COS1 cells increased the activity of a LXR reporter construct but did not increase cellular 
cholesterol content.  It is possible, then, that Adam11 is induced by LXRs in order to 
directly increase the availability of oxysterols or to lead to LXR activation by another 
signaling pathway, thus amplifying LXR signaling (Figure 6.6).  If the role of Adam11 is 
to increase the availability of oxysterol ligands, this may be the explanation of the 
decrease in apoB secretion that we found with Adam11 overexpression in McA-RH7777 
cells.  Specifically, if Adam11 generates oxysterols, these could repress SREBP 
activation and decrease lipogenesis, which in turn may decrease apoB secretion (Kang 
and Davis, 2000).   
 Alternatively, Adam11 may play a separate and more direct role in regulating 
apoB secretion (Figure 6.6).  ApoB secretion in VLDL will only occur in the presence of 
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sufficient phospholipids, cholesterol, cholesterol esters and triglyceride and with 
sufficient activity of MTP (Avramoglu and Adeli, 2004).  Alteration of any of these 
factors will affect the amount of apoB secreted.  First, secretion of apoB is regulated at a 
translational level in conjunction with MTP neutral lipid transfer, although the molecular 
mechanism is unknown.  Furthermore, apoB secretion is regulated at a co- and post-
translational level by ER associated degradation, post-ER presecretory proteolysis, and 
reuptake (Fisher et al., 2001).  Therefore, Adam11 could regulate apoB secretion by a 
large number of mechanisms and further work with Adam11 knockdown or knockouts 
will be necessary to decipher a role for Adam11 in apoB secretion.  Interestingly, it has 
been proposed that VLDL secretion occurs in periportal hepatocytes; whereas Cyp7a1 
mediated bile acid synthesis occurs in pericentral hepatocytes (Kang and Davis, 2000).  
Adam11 has been shown to be more highly expressed in periportal hepatocytes 
(Rybnikova et al., 2002). 
 Two other major roles of LXR target genes in the liver are in inducing lipogenesis 
via up-regulation of SREBP-1c and in inducing bile acid synthesis via up-regulation of 
Cyp7a1 (Edwards et al., 2002).  LXRs also appear to be involved in the repression of 
pathways such as gluconeogenesis and inflammatory pathways (Steffensen and 
Gustafsson, 2004).  Adam11 could play a role in one of these processes; however, we 
currently do not have data supporting this. 
 Finally, maintenance of the vast array of liver functions is dependent on 
interactions between the various liver cell types (hepatocytes, Kupffer cells, and 
endothelial cells), between cells of the same type, and between cells and the extracellular 
matrix (Selden et al., 1999).  These interactions are important for the maintenance of  
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Figure 6.6. Possible functions of Adam11 in the liver.  (A) Since Adam11 is up-regulated by LXR and 
many LXR targets are involved in RCT, Adam11 may play a role in RCT in the liver.  Adam11 may act 
as a cofactor for SRBI mediated cholesterol uptake on the sinusoidal membranes, or Adam11 may act as 
a cofactor for Abcg5/8 mediated cholesterol efflux on the canalicular membranes.  (B) Adam11 was 
shown to increase LXR activity; thus Adam11 may play a role in increasing oxysterol concentrations and 
amplifying LXR signaling.  This increase in oxysterols may secondarily lead to decreased apoB 
secretion.  (C) Adam11 was shown to decrease apoB secretion; therefore, Adam11 may have a direct 
impact on apoB translation or apoB degradation.  (D) Since Adam family members bind integrins and 
extracellular matrix, Adam11 may function in the maintenance of cell shape or cell-cell interactions when 
membrane cholesterol levels are high.  
 
individual hepatocyte cuboidal shape and maintenance of the specialized liver 
organization into cords of cells interacting with incoming portal blood and outgoing 
venous blood and bile.  Furthermore, evidence exists that these interactions can have vast 
consequences on liver cell function by the alteration of gene expression via signaling 
pathways.  ADAM proteins are uniquely positioned to play an important role in this 
process as they can interact with extracellular matrix proteins directly or via integrins and 
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heparin sulfate proteoglycans and can interact with other cells via integrins or other 
proteins (White, 2003).  Since the cholesterol to phospholipid ratio in membranes is 
critically important in maintaining cell shape and thus cell function, it is therefore 
possible that Adam11 is induced by high cholesterol diets to maintain proper liver cell 
adhesion, morphology, and function via interaction with other cells and/or the 
extracellular matrix (Figure 6.6).  Such a role may only be apparent in studies of intact 
animals since many of the functions of liver cells are lost in cell culture owing to the lack 
of important cell-cell and cell-matrix interactions (Selden et al., 1999) 
 
  
Future Directions for the Pcsk9 Project 
 
What are the substrates for Pcsk9?   A crucial question that remains unanswered is the 
identity of the substrate(s) for Pcsk9.  Two lines of experimentation could be used to 
investigate this question: 1) direct proteomic approaches to identify substrates; 2) 
definition of the Pcsk9 consensus cleavage site followed by bioinformatics search for 
potential substrates and in vitro confirmation. 
Direct identification of Pcsk9 substrates:  The most direct approach would be to use 
proteomic techniques to identify Pcsk9 substrates.  One way to do this would be to create 
stable cell lines overexpressing Pcsk9, a siRNA hairpin to Pcsk9, and the appropriate 
vector control.  Lysates from these cell lines or from Pcsk9 knockout and littermate 
control mice would be subjected to two dimensional gel electrophoresis and differentially 
expressed spots would be identified by matrix assisted laser desorption ionization time of 
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flight (MALDI-TOF) and/or tandem mass spectroscopy (MS/MS).  Another way to 
identify Pcsk9 substrates would be to use inactive catalytic domain capture techniques 
which are based on the principle that when an inactive protease binds its substrate, it will 
remain bound and not cleaved, allowing identification (Lopez-Otin and Overall, 2002).  
Here, the Pcsk9S402A catalytic mutant would be used as bait in a yeast two-hybrid 
screen.  Alternatively, the mutant could be immobilized on a column or solid matrix, liver 
protein lysates added and allowed to bind, and eluted substrates identified by MALDI-
TOF or MS/MS.    
Definition of the Pcsk9 consensus cleavage site:  Using recombinant rat Pcsk9 and 
fluorogenic substrates, Pcsk9 was shown to be unable to cleave at canonical bacterial 
subtilisin sites (GGL), mammalian furin sites (RVRR), or tripeptidyl peptidase II sites 
(AAF) (Naureckiene et al., 2003), indicating the Pcsk9 consensus cleavage site is not the 
same as other subtilases.  Clues to the consensus could come from the Pcsk9 self-
cleavage site, which has been shown to occur at VFAQ↓SIP (Naureckiene et al., 2003; 
Benjannet et al., 2004).  However, a limited mutagenesis study of these residues has 
shown that many substitutions are allowable (Benjannet et al., 2004).   In single 
mutagenesis, only the P4 Val and P3’ Pro were critical for self-cleavage; however, SIP 
could be replaced with GTS; thus, these results preclude the establishment of a strong 
consensus. It may be still be possible to identify a Pcsk9 consensus cleavage using large 
scale protease profiling tools and computer analysis.  For example, recombinant Pcsk9 
purified from a bacterial expression system could be applied to protease peptide 
microarrays, such as those from JPT Peptide Technologies.  This company has two 
microarrays, one containing 768 peptides corresponding to annotated protease substrate 
 191
cleavage sites, and one containing 1536 peptides, each of four random amino acids.  
Identification of the peptides cleaved by Pcsk9 and alignment using computer algorithms 
would be a less time-consuming way than mutagenesis studies to identify a possible 
consensus cleavage site.  Once such a site was defined, BLAST searches would be used 
to identify known and hypothetical proteins containing this site. 
 
What are other proteins involved in the Pcsk9 pathway?  A yeast two-hybrid screen 
with the Pcsk9 catalytic mutant (described above) or wild-type Pcsk9 may not only 
identify substrates but also other proteins that bind to Pcsk9 and are possibly involved in 
the Pcsk9 induced LDLR degradation pathway.  However, since these techniques often 
produce false positives, a genetic technique may be more applicable.  Park has shown that 
a CHO cell line stably expressing Pcsk9 does not lead to a decrease in LDLR protein 
(Park et al., 2004).  This may be due to improper trafficking of Pcsk9, as proposed for the 
McA-RH7777 cell lines used by Sun (Sun et al., 2005), alternatively, it may be that CHO 
cells lack one or more proteins necessary for Pcsk9 action.  To identify possible proteins, 
CHO cells expressing Pcsk9 would be plated in multi-well plates and transfected with 
pools of clones from a mouse liver cDNA expression library and rapidly assayed by DiI-
LDL binding.  Pools which restored Pcsk9 ability to decrease DiI-LDL binding would be 
analyzed for the individual clone(s) which restored Pcsk9 ability to decrease LDLR 
protein levels by Western blotting.   
 
Does Pcsk9 directly bind and cleave the LDLR?  As described, no evidence has yet been 
found for a LDLR cleavage product; furthermore, we do not have evidence that Pcsk9 co-
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immunoprecipitates with the LDLR.  The latter experiments were performed using 
overexpressed Pcsk9 which co-immunoprecipitates with the LDLR monoclonal antibody 
and a nonspecific monoclonal antibody (data not shown).  Therefore, these experiments 
should be repeated using liver extracts and probing for endogenous proteins.  The above 
techniques to identify Pcsk9 substrates and binding partners may also identify the LDLR, 
particularly the use of the catalytic mutant.   
 
Does Pcsk9 induce LDLR degradation by targeting it to the GGA-dependent TGN-
MVB-lysosome pathway?  I proposed that Pcsk9 may target the LDLR for degradation 
via the newly described TGN-MVB-lysosome pathway.   Yeast Gap1 is targeted for this 
pathway by mono-ubiquitination and binding to the yeast GGA proteins (Gga1 and 
Gga2).  In preliminary experiments, we did not find evidence for ubiquitination of the 
LDLR by immunoprecipitation of the LDLR in cells expressing Ad empty or Pcsk9-Ad 
followed by ubiquitin western blot.  However, this western blot was technically imperfect 
and should be repeated with better techniques to identify mono-ubiquitination; for 
example it has been shown by comparison to ubiquitin chain ladders, that certain 
antibodies recognize monoubiquitinated complexes whereas others recognize 
polyubiquitinated complexes (Haglund et al., 2003).  Alternatively, targeting to the MVB 
by GGAs may not require ubiquitination.  Therefore, another possible line of experiments 
would be to determine whether Pcsk9 can induce LDLR degradation in cells where the 
mammalian GGA proteins (GGA1, GGA2, and GGA3) are knocked down by siRNA; 
plasmids encoding siRNAs for the GGAs have been published (Ghosh et al., 2003).   
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 Another way to investigate the cellular pathway by which Pcsk9 induces LDLR 
degradation would be to extend the immunofluorescence studies described in Chapter4.  
In these experiments, it would be most useful to microinject LDLR-YFP and Pcsk9-CFP 
into nuclei and use immunofluorescence time-lapse video microscopy to follow the fate 
of the LDLR through synthesis and trafficking in the secretory pathway.  These studies 
could be extended with colocalization studies using lysosome markers and 
coimmunofluorescence with proteins such as the GGAs to hopefully follow the fate of 
LDLR-YFP from the TGN into the lysosomes. 
 
Does Pcsk9 lead to sumoylation of the LDLR?  Another mechanism of post-translational 
modification of proteins is via addition of ubiquitin-like proteins such as SUMO (Watts, 
2004; Hay, 2005).  Although sumoylation has been mostly found as a mechanism of 
affecting nuclear protein activity, studies demonstrate that sumoylation decreases the 
transmembrane receptor GLUT1 protein levels and activity, with no change in mRNA 
levels (Giorgino et al., 2000). Sumoylation is regulated by SUMO specific proteases.  
Interestingly, when the Pcsk9 self-cleavage site VFAQSIP is BLASTed to the NCBI 
protein database, only 4 known proteins are identified that contain the necessary Val and 
Pro, the met proto-oncogene (VFAQSKP), Epstein-Barr virus induced gene 2 
(VFAQTLP), long chain acyl-CoA synthase 6 (VFAQNRP) and SUMO specific protease 
6, Senp6 (VFLQAIP).  Therefore, it is possible that Senp6 usually prevents sumoylation 
of the LDLR and inactivation of the protease by Pcsk9 leads to sumoylation and eventual 
degradation of the LDLR.  In order to study this pathway, it will first be necessary to 
immunoprecipitate the LDLR from Pcsk9 overexpressing cells and blot with a SUMO 
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antibody.  If Pcsk9 induces the sumoylation of the LDLR, experiments could be done to 
determine if the sumo conjugating enzyme, Ubc9, increases LDLR degradation and if 
overexpression of Senp6 or another Senp decreases LDLR degradation. 
 
Is Pcsk9 responsible for the rapid degradation seen in certain LDLR mutants?  The 
following mutations have been shown to result in rapid degradation of the LDLR by 
biosynthetic analysis:  V408M (Leitersdorf et al., 1989), D412H (Miyake et al., 1992), 
P664L (Rubinsztein et al., 1992), and deletion exons 7-8 (van der Westhuyzen et al., 
1991).  In order to study these mutations, they could be introduced into a LDLR-YFP 
tagged plasmid to allow the ability to distinguish the mutant from endogenous wild-type 
LDLR, and used to make stable HepG2 cell lines.  Next, siRNA mediated knockdown 
would be used to determine if Pcsk9 is necessary for the LDLR mutant phenotype, i.e. is 
rapid degradation of the LDLR prevented in the absence of Pcsk9.  If it is for any of the 
mutants, the cell line would be mutagenized to search for mutations in Pcsk9 or other 
proteins that prevent the rapid LDLR degradation.  These studies will help to define 
important residues in Pcsk9 or possibly even other partners necessary for LDLR 
degradation.  Also, these cell lines could be used to co-express constructs encoding the 
natural human Pcsk9 mutants to determine if the mutants prevent rapid LDLR 
degradation. 
 
What is the effect of Pcsk9 knockdown in a model organism with human-like 
lipoprotein profiles?  While the Pcsk9 mouse knockout provides evidence that an 
absence of Pcsk9 leads to increased LDLRs and decreased LDL, the mouse is not the 
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ideal organism to study this question as mice have very low LDL levels to begin with.  
Therefore, it would be very interesting to determine the effect of Pcsk9 knockdown in the 
guinea pig which has a human-like lipoprotein profile with higher LDL levels.  Since the 
extensive genetic techniques are not available in the guinea pig to construct a traditional 
knockout, this could be accomplished by injecting an adenovirus expressing a Pcsk9 
siRNA hairpin.  These animals could then be used to study LDLR mRNA and protein 
levels and LDL kinetic parameters.   
 
High throughput screening for Pcsk9 inhibitors:  A screen for Pcsk9 inhibitors has been 
envisioned which would use rat or human hepatoma cells overexpressing Pcsk9 either by 
infection or in a stable cell line and plated into 384-well plates.  These cells would be 
treated with DiI-LDL at 4ºC to allow binding to cells and read using a microplate 
fluorescence reader.  The High Throughput Screening core facility’s 20,000 compound 
library from Chemical Diversity would be screened for the ability to increase DiI-LDL 
binding to the cells.  To try to identify Pcsk9-specific inhibitors versus general LDLR 
pathway activators, the positive compounds would be re-screened for a lack of an effect 
in Pcsk9 knocked out cells.  Initial attempts to set up this screen have been hindered by 
the lack of adherence of the hepatoma cells to the 384-well plate during the washes 
necessary for the experiment; however, it is likely that these technical difficulties may be 
overcome.  
 
Do differences in mouse and human Pcsk9 partially account for the differences in 
LDL levels between mice and humans?  Humans have over 5 times higher LDL 
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cholesterol levels than mice.  The studies here and by others have shown that high Pcsk9 
activity induces high LDL cholesterol levels; therefore, it is possible that humans may 
have higher LDL levels at least in part due to higher Pcsk9 activity.  Increased activity 
could result from number of mechanisms, including transcriptional or translational 
regulation; in addition, intrinsic differences in the protein could be responsible.  Mouse 
and human Pcsk9 have multiple differences in protein structure, as delineated in Chapter 
3.  One way to test the latter hypothesis would be to create a human Pcsk9 transgenic on 
a mouse Pcsk9 knockout background and select for lines that express human Pcsk9 
protein at similar levels to that seen in wild-type mice.  If the hypothesis is correct, the 
humanized lipoprotein profile of this mouse would also be an interesting mouse model 
for use in many areas of cholesterol metabolism.   
 
Do Pcsk9 polymorphisms affect responsiveness to high cholesterol diets in humans?  
The original impetus for using microarray analysis of dietary cholesterol fed mice versus 
simply SREBP transgenic mice to identify novel genes in cholesterol metabolism was 
driven by the desire to find genes which may explain differences in responsiveness of 
LDL cholesterol levels to high cholesterol diets in humans.  Since Pcsk9 mRNA 
expression is repressed by a high cholesterol diet, presumably leading to reduced LDLR 
degradation and increased LDL uptake, it is possible that polymorphisms in Pcsk9 may 
affect responsiveness to diet.  In this hypothesis, people who increase LDL cholesterol 
levels in response to high cholesterol diets may have Pcsk9 polymorphisms that lead to 
the absence of sterol repression of Pcsk9, high Pcsk9 levels, LDLR degradation and 
decreased LDL uptake.  On the other hand, people who do not increase LDL cholesterol 
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levels after a high cholesterol diet may have Pcsk9 polymorphisms that lead to increased 
sterol repression of Pcsk9, decreased LDLR degradation and increased LDL uptake.   
 
Future Directions for the Adam11 Project 
 
Does Adam11 have polarized cell surface expression in the liver?  Hepatocytes are 
polarized with a basolateral side facing the liver sinusoids and the blood and an apical 
side facing the bile canaliculi and the bile.  In the context of cholesterol movement for 
reverse cholesterol transport, it would be predicted that if Adam11 affected cholesterol 
uptake into the liver from the blood, it would be expressed on the basolateral surface of 
hepatocytes.  However, if Adam11 affected cholesterol efflux into the bile it would be 
expressed on the apical surface.  Therefore, the cell surface expression of Adam11 in 
polarized hepatocyte cell lines or intact liver should be investigated to determine if 
Adam11 has polarized expression. 
 
What is the effect of Adam11 siRNA mediated knockdown in cell culture on apoB 
secretion?  We have found that mouse hepatoma Hepa1-6 cells express Adam11 and that 
Adam11 mRNA and protein levels (data not shown) are regulated by LXR agonists in 
these cells.  Therefore, the Hepa1-6 cell line could be used to investigate the effect of 
siRNA-mediated knockdown of Adam11.  For any experiments along these lines, cells 
treated with Adam11 siRNA should be examined under normal conditions, and under 
sterol-treated and LXR agonist-treated conditions.  Since Adam11 overexpression led to 
decreased apoB levels, apoB secretion rates should be investigated in cells treated with 
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Adam11 siRNA.  If Adam11 siRNA leads to increased apoB secretion, then the cells 
could be examined for apoB mRNA levels and MTP mRNA and protein levels.  If these 
are normal, it is likely that the effect is due to decreased degradation of apoB and the 
various pathways, ERAD, PERPP or reuptake should be examined. 
 
What is the effect of Adam11 siRNA mediated knockdown in cell culture on LXR 
activity?   
In addition, cells treated with Adam11 siRNA should be examined for measures of LXR 
activity, namely LXR protein levels, activity of the LXRE-luciferase reporter, and mRNA 
levels of LXR target genes such as Cyp7a1 and Abcg5.   It would be predicted from the 
preliminary experiments that siRNA-mediated knockdown of Adam11 would result in 
decreased LXRE-luciferase activity and decreased levels of target genes.  Furthermore, 
Adam11 overexpressing and knockdown cells should be examined for concentrations of 
key LXR regulating oxysterols such as 24,25(S)-epoxycholesterol; however this is 
technically challenging.  It is possible that a collaboration could be established with Dr. 
Thomas Spencer who has developed a method to measure oxysterol levels by high 
performance liquid chromatography analysis of ∆4-3-ketone derivatives (Zhang et al., 
2001b). 
 
Does Adam11 affect liver cell morphology and function?  In order to determine if the 
role of Adam11 is in maintaining liver cell morphology and function, particularly in high 
cholesterol conditions, traditional hepatoma cell lines would likely be inappropriate due 
to the loss of normal liver cell morphology that is seen with these cell lines.  It is known 
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that culture of primary hepatocytes on a complex matrix (called Engelbreth Holm Swarm 
mouse sarcoma-derived matrix) preserves cell shape and function (Selden et al., 1999).  
First, it should be determined if Adam11 is expressed in cells cultured in this way.  If it 
is, cells treated with Adam11 siRNA in low and high sterol conditions could be examined 
for cell shape, measures of cell death, and basic liver type functions such as the secretion 
of albumin.   
 
What proteins interact with Adam11?  A general question that may shed light on the 
above and other potential functions of Adam11 is to determine what proteins interact 
with the extracellular domain of Adam11 and what proteins interact with its two C-
terminal tails.  If the absence of Adam11 affects basic liver cell functions, it may be 
possible that this effect is mediated by the binding of the Adam11 extracellular domain to 
another protein such as an integrin.  One approach to identify such proteins could be to 
bind Adam11 tagged with an Fc domain to protein A columns, add whole cell lysates to 
trap potential binding partners, elute complexes and identify proteins by MALDI-TOF or 
MS/MS.  A stable cell line expressing Adam11-Fc which is secreted into the medium of 
these cells has already been created and could be used as a source of protein.  On the 
other hand, any function of Adam11 could be mediated by binding of its C-terminal tail 
to proteins within the cell.  An approach to identify these proteins would be to create 
GST-fusions with the two different Adam11 C-termini, isolate complexes on a GST 
column and identify proteins by MALDI-TOF or MS/MS.  Finally, another approach 
could be to use the DUALmembrane yeast two-hybrid from DUALsystems.  In this 
approach, Adam11A and Adam11B would be tagged with the C-terminal half of 
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ubiquitin (Cub) and the LexAVP16 transcription factor.  A liver cDNA library would be 
tagged with a mutated N-terminal half of ubiquitin (NubG).  Co-expression of the 
Adam11 construct, the library, and LexAVP16 reporter constructs in yeast cells results in 
reporter activity only when Adam11 is bound to a library protein, allowing close 
proximity of Cub and NubG and reconstitution of an ubiquitin that is recognized by a 
specific protease.  In this way, transmembrane proteins which bind the Adam11 
extracellular domain or C-terminal domain and membrane associated proteins that bind 
that Adam11 C-terminal domain could be identified. 
 
What is the phenotype of an Adam11 knockout?  Sagane has reported that Adam11 
knockouts have no obvious phenotype; however, it may be that the appropriate 
phenotypes were not investigated, or the phenotype of Adam11 knockouts may not be 
apparent unless the animals are challenged with a high cholesterol diet.  It may be 
possible to obtain the Adam11 full knockouts from the Sagane laboratory; furthermore, 
Marc Waase is in the process of developing liver-specific Adam11 knockouts.   These 
knockouts will be critical in determining Adam11 function.  Initial experiments should 
involve measurement of plasma and hepatic cholesterol levels, plasma apoB levels, liver 
mRNA levels of LXR target genes, gallbladder bile composition, liver function tests 
(GGT, alkaline phosphatase, AST, ALT, albumin), and examination of liver histology in 
mice on a low cholesterol diet and challenged with a high cholesterol diet.  The 
phenotype of the knockouts for these parameters will determine further lines of 
experimentation.   
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Concluding Thoughts 
 Adam11 is a cell surface protein up-regulated by cholesterol putatively via the 
LXRs and preliminary studies indicate a role for Adam11 in apoB metabolism or LXR 
activation, although multiple other roles for Adam11 are still possible.  Adam11 was the 
most highly up-regulated gene on the cholesterol microarrays, indicating the potential for 
it to have an important role in cholesterol homeostasis.  The preliminary studies presented 
here pave the way for examination of this potentially exciting gene.    
 Pcsk9 is a serine protease of the secretory pathway that plays a role in the post-
transcriptional regulation of the LDLR and hence LDL cholesterol levels.  The thirty-one 
years of research on the LDLR have shown it to be a critically important gene in the 
maintenance of LDL cholesterol levels, and elegant studies have delineated the 
importance of transcriptional regulation of the LDLR.  Transcriptional down-regulation 
of the LDLR by cholesterol levels as a by-product of inhibiting cholesterol biosynthesis 
is the basis for the use of the statin drugs.  Throughout the years, many groups have 
shown evidence for post-transcriptional regulation of the LDLR.  The studies presented 
here in conjunction with the exciting work from other laboratories on Pcsk9 and its role 
in hypercholesterolemia in humans demonstrate that regulation of the LDLR at the level 
of degradation may be just as important as regulation at the level of transcription.  
Furthermore, these studies indicate that pharmacological inhibition of Pcsk9 may provide 
a direct way of regulating LDLR levels, LDL uptake and LDL cholesterol levels.  While 
the field is extremely young, I hope that the extension of these and other early studies on 
Pcsk9 may one day lead to the development of a drug used to treat hypercholesterolemia.     
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CHAPTER 7:  MATERIALS AND METHODS 
 
Cell culture: All cell culture reagents were obtained from Invitrogen.  Lipoprotein 
deficient serum (LPDS) was made by ultracentrifugation by standard techniques.  McA-
RH7777 cells (CRL-1601), HepG2 (HB-8065), and Hepa1-6 (CRL-1830) were obtained 
from the American Type Culture Collection; Fu5AH and COS7 cells were a generous gift 
of George Rothblat (Children’s Hospital of Philadelphia, Philadelphia, PA); CHOK1, 
HEK293, and COS1 cells were from laboratory stocks.  McA-RH7777 cells were 
maintained in DMEM supplemented with 20% horse serum, 5% fetal bovine serum 
(FBS) and 1% penicillin-streptomycin (Pen-Strep).   Fu5AH cells were maintained in 
EMEM supplemented with 5% calf serum and 0.5% gentamycin.  All other cells were 
maintained in DMEM supplemented with 10% FBS and 1% Pen-Strep.  HepG2 and 
McA-RH7777 cells were grown on collagen coated plates.  For studies of sterol 
regulation of RNA and protein expression in cell culture, cells in triplicate wells per 
condition were treated in DMEM supplemented with 10% LPDS and 10µg/ml 
cholesterol, 1µg/ml 25-hydroxycholesterol, 1µg/ml mevinolin/lovastatin, 1µg/ml 22(R)-
hydroxycholesterol, or 10µM TO901317 (Sigma).   
 
Animal Studies:  All animal protocols were approved by The Rockefeller University 
Animal Care and Use Committee.  Wild type C57BL/6 mice, SREBP-1a transgenic mice, 
SREBP-2 transgenic mice, and LDLR knockout mice on the C57BL/6 background 
(B6.129S7-Ldlr tm1Her) were obtained from the Jackson Laboratory (stock numbers 
00664, 002840, 003311, and 002207, respectively).  Animals were housed in a humidity- 
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and temperature-controlled room with 12-h dark/12-h light cycle at the Laboratory 
Animal Research Center at The Rockefeller University and fed standard chow unless 
indicated.   
 For dietary studies, six-week old C57BL/6 male and female mice were fed a semi-
synthetic modified AIN76a diet containing 10% kcal as fat and 0.0% cholesterol 
(Clinton/Cybulsky Rodent Diet-Research Diets D12102N (Lichtman et al., 1999) for one 
week.  The mice were then split into two groups and fed either the 0.0% cholesterol diet 
or the same diet supplemented with 0.5% (wt/wt) cholesterol (Research Diets 
D00083101, cholesterol is added as a powder prior to pelleting) for one week prior to 
sacrifice.  For the time course studies, twenty male and twenty female six-week old mice 
were fed the 0.0% cholesterol diet for one week; four mice were sacrificed at the one 
week time point and the remaining mice were switched to a 0.5% cholesterol diet.  Four 
mice were sacrificed at days 1, 2, 4 and 7 of feeding.  For the LXR agonist study, seven-
week old male C57BL/6 mice were placed on the 0.0% cholesterol diet for one week and 
then gavaged with vehicle alone (5% ethanol, 95% sesame oil) or with vehicle plus 
10mg/kg TO901317.  This treatment was repeated after 24 hours and mice sacrificed on 
the same day.  Transgenic mice expressing truncated nuclear forms of human SREBP-1a 
or SREBP-2, backcross generations to C57BL/6 N6/N7 and N2/N3, respectively, were 
used.  Mice were genotyped by Rachel Adams and Raymond Soccio by PCR from tail tip 
DNA, see (Soccio et al., 2005) for sequences.  Transgenic and littermate control mice of 
both sexes were fed standard rodent chow from birth to 8 weeks.  They were then 
switched to a 65% protein, 10% carbohydrate diet (Purina TestDiet 8092) for two weeks 
to induce maximal transgene expression, since the SREBP transgenes were under the 
 204
control of the PEPCK promoter.  For adenovirus injections, ten-week old male C57Bl/6 
or LDLR knockout animals were anesthetized with Nembutal and injected via the tail 
vein or retro-orbital plexus with 1x108 pfu, 5x108 pfu, 1x109 pfu, or 3x109 pfu of 
adenovirus in PBS per mouse in initial studies; 1x109pfu was used for all subsequent 
studies.  Mice were sacrificied four days after injection.  
 At the end of all mouse experiments, food was removed from the cage at 9 AM 
and the mice were fasted for five hours, sedated with ketamine/xylazine, and sacrificed.  
Blood was collected by left ventricular puncture, and harvested tissue pieces were frozen 
in liquid nitrogen and stored at –80˚C or stored in RNAlater (Ambion) according to 
manufacturer instructions. 
 
Mouse Plasma, Liver, and Gallbladder Bile Analysis:  Blood was collected by left 
ventricular puncture and plasma isolated by centrifugation.  To separate HDL and non-
HDL plasma fractions, plasma was mixed 1:1 with KBr at a density of 1.12g/ml and 
centrifuged at 40,000rpm for 18 hours.  To obtain lipoprotein profiles, plasma was 
subjected to fast protein liquid chromatography (FPLC).  Cholesterol and triglycerides in 
total plasma and fractions was measured by enzymatic assay (Sigma or Roche).  Liver 
tissue was excised and immediately frozen in liquid nitrogen.  Liver total, free and 
esterified cholesterol (mg/g liver) were measured by gas chromatography with 
coprostanol as an internal standard as described (Sehayek et al., 1998a).  Gallbladder bile 
was isolated and analyzed for cholesterol, phospholipids and bile acids by enzymatic 
assay (Sigma and Roche).   
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Sample preparation for gene expression analysis:  Tissues in RNAlater were 
homogenized in TRIzol reagent (Invitrogen).  Total RNA from tissues was isolated 
according to manufacturer instructions and subjected to RNeasy cleanup (Qiagen), and 
RNA from cells was isolated using Qiagen RNeasy for microarray, Q-PCR, Northern 
blotting, and RT-PCR.  For microarrays, 20µg of total liver RNA was reverse transcribed 
using Superscript II (Invitrogen) and a poly-dT primer containing the T7 RNA 
polymerase binding site (Genset Corporation).  Second strand cDNA was then made 
using E.coli DNA polymerase, E.coli DNA Ligase and T4 DNA polymerase (Invitrogen).  
Double stranded cDNA was purified on Phase-Lock gel columns (Eppendorf), ethanol 
precipitated, and resuspended in water.  cRNA was synthesized from the cDNA using 
biotin labeled ribonucleotides and T7 RNA polymerase (Enzo Bioarray/Affymetrix) and 
purified on Qiagen RNeasy columns.  cRNA was then fragmented for 30 min at 95˚C in a 
solution of 40mM Tris-acetate pH8.1, 100mM potassium acetate, and 30mM magnesium 
acetate.  For Q-PCR and RT-PCR analysis, total RNA was treated with Dnase I 
(Ambion), and 5µg was reverse transcribed using Superscript II and a mixture of oligo-
dT and random hexamer primers (Amersham Pharmacia Biosciences).  For Nothern 
blotting, poly-A RNA was isolated from total RNA using oligo-dT-cellulose columns 
(Amersham Pharmacia Biotech). 
 
Affymetrix oligonucleotide microarrays:  Three microarray experiments were performed 
using cholesterol-fed and control mice according to the protocol above.  Six male mice 
were used for experiment 1 (n=3 on each diet) and ten male and ten female mice (n=5 on 
each diet) were used for experiment 2.  In these experiments, mice were housed together 
 206
in cages.  Equal amounts of liver RNA samples from mice within a sex and feeding group 
were pooled together and split into duplicate samples for cDNA and cRNA synthesis and 
application to the microarrays.  In experiment 3, eight male and eight female mice (n=4 
on each diet) were housed in separate metabolic cages to prevent coprophagia and 
competition for food, and liver RNA from each mouse was processed for an individual 
microarray.  For all three experiments, fragmented cRNA samples were combined with 
hybridization controls (Affymetrix), herring sperm DNA (Promega), and acetylated BSA 
(Invitrogen) and hybridized to microarrays for 16 hours at 45˚C.  Each sample was 
hybridized to the Affymetrix Test3 microarray and checked for quality before hybridizing 
to the MGU74v2 microarray set (three chips: A, B, and C).  This set contains greater than 
36,000 probe sets corresponding to greater than 23,000 Unigene clusters (for information, 
see www.affymetrix.com).  Washing, staining, and scanning of the microarrays was 
preformed by Richard Pearson and Greg Khitrov of the Gene Array Core Facility at 
Rockefeller University according to standard protocols (Affymetrix).   All chips were 
analyzed for noise and background values at acceptable levels, consistency between 
chips, proper behavior of spiked controls, and signal ratios of 5’ to 3’ sequences from 
housekeeping genes approximately equal to one.   
 
Data analysis of Affymetrix microarrays:  The raw data from the microarrays was 
analyzed using the Microarray Suite Software version 5.0 (MAS5.0, Affymetrix), and 
each array was subjected to absolute analysis.  The signal values for all arrays were 
scaled using a scaling factor (SF) derived from the formula:  SF x mean signal = 250.  
For experiments 1 and 2, there were duplicate arrays for each diet, so four pair-wise 
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comparisons were performed between feeding groups within a sex.  In both experiments, 
genes with a signal on at least one condition greater than 250 and average fold for the 
pair-wise comparisons greater than |1.6| were included in the preliminary analysis.  Since 
experiment 3 had four mice per group, this allowed examination of biological variation in 
gene expression.  The standard deviations of the log2[signal value] for every gene and 
subsets of genes with signal values greater than 250 were computed and the median 
calculated to produce a value (σ) as an estimate of global variance in signal values 
between samples.  Next, a power calculation for eight samples was performed using a 
false positive rate α =0.001 and a false negative rate β=0.05 to determine the fold 
difference (δ) that was distinguishable for the estimated variance.    The formula used 
was: Total # samples in 2 groups = 4 x [(z,α +z,β) / (δ / σ)] 2.  By this calculation, it was 
determined that our data could detect a fold difference of |1.6|, for genes with signal 
values greater than 250.  Next, the experiment 3 signals derived from the MAS5.0 
absolute analysis were subjected to an ANOVA statistical analysis software package 
(Pavlidis and Noble, 2001).  Genes in experiment 3 were determined to be significantly 
regulated by dietary cholesterol if the signals in at least one group were greater than 250, 
the fold greater than |1.6|, and the ANOVA p-value<0.001.  Genes were also kept in the 
final analysis if in experiment 3 their ANOVA p-value was between 0.01-0.001 and they 
also met the criteria specified above for the preliminary analysis in experiments 1 or 2.   
 Information regarding each probe set identified in the combined statistical and 
MAS analysis was downloaded from www.affymetrix.com; this information included the 
gene name shown in Tables 2.2 and 2.3, other information such as accession number and 
Unigene cluster can be obtained by searching with the probe set identifier.  In cases 
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where the probe set was not assigned to a gene by Affymetrix, the sequence was used to 
query the mouse genome (www.ensembl.org or www.celera.com) to identify a putative 
gene; this information is in parentheses next to the Affymetrix name in Tables 2.2 and 23.   
 
Real Time Quantitative RT-PCR (Q-PCR):  Q-PCR was performed as described (Soccio 
et al., 2002) with slight modifications.  Briefly, first strand cDNA was synthesized as 
above and 5µl of diluted cDNA was used as template in 20µl reactions.  Dilutions of 
cDNA were based on original RNA concentration in the first strand synthesis reaction 
and made such that the final concentration corresponded to 2 ng/µl of original RNA.  
Each sample was amplified in duplicate for the genes of interest and a housekeeping 
gene, cyclophilin A or Hprt for mouse and cyclophilin B for human, on an Applied 
Biosystem 7700 or 7900 Sequence Detection System using the quencher dye TAMRA as 
a passive reference.  Sequences of forward and reverse primers and Q-PCR probes are 
shown in Table 7.1 (all tables are at the end of Chapter 7).  The threshold was set in the 
linear range of normalized fluorescence, and a threshold cycle (Ct) was measured in each 
well; data was analyzed as in (Soccio et al., 2002).  In all cases, Q-PCR primers and 
probes were chosen in regions of the gene at a different location from that of the 
Affymetrix probe set; furthermore, primers and probes were chosen that spanned exon 
boundaries.   
 
Northern Blotting and non-quantitative RT-PCR:  RT-PCR was performed for cloning, 
to obtain Northern probes and for direct analysis of tissue expression.  In all cases, first 
strand cDNA was used as a template for PCR amplification using standard reagents and 
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primers listed in Table 7.2.  For Northern blotting, poly-A RNA was size fractionated on 
either formaldehyde or glyoxal/DMSO (Ambion) containing agarose gels.  RNA was 
transferred to nitrocellulose membranes (Ambion) and UV crosslinked.  Multiple tissue 
Northern blots were purchased from Clontech.  The β-actin template was from Ambion.  
Primers for amplifying Northern probe templates of genes of interest are in Table 7.2, and 
probes were labeled with 32P-ATP using the Strip-EZ Kit or DECAprime kit (Ambion).  
Probes were hybridized to membranes in either UltraHyb (Ambion) or ExpressHyb 
(Clontech) and exposed to film or a phosphoimager screen for quantification using 
ImagePro or ImageQuant software, respectively. 
 
Cloning, 5’RACE and 3’RACE:  At the time these studies were performed, Pcsk9, 
Camk1d and the novel Adam11A isoform had not been cloned.  The Affymetrix probe 
set sequence was used to query the mouse genome, and putative coding sequences were 
identified by in silico analysis.  In addition, Adam11B and human Pcsk9 were cloned.  
Full length ORFs were cloned using RT-PCR from C57Bl/6 mouse liver for Pcsk9, 
Camk1d and Adam11 and from HepG2 cells for human Pcsk9; primers are listed in Table 
7.2.  PCR reagents were Super Taq Plus polymerase (Ambion) for mouse Pcsk9, 
Advantage cDNA polymerase (Clontech) for Camk1d, and Advantage-GC2 polymerase 
(Clontech) for human Pcsk9 and Adam11.  Thermal cycling was on a Perkin-Elmer 9700.  
To identify sequence polymorphisms for mouse Pcsk9, the full length ORF was also 
cloned from CASA/Rk mouse liver using the same PCR conditions.  The 5’ends of 
Camk1d, mouse Pcsk9, human Pcsk9 and Adam11 genes were identified by 5’ RACE 
(Ambion).  For 5’RACE, cDNA was amplified from liver and an adaptor was ligated to 
 210
the 5’ends of all cDNAs.  Next, nested PCR was performed with primers to the adaptor 
and primers specific to sequences in the gene of interest (Table 7.2).  The 3’end of 
Adam11A was determined by 3’RACE (Ambion) and the 3’end of Pcsk9 and Camk1d 
was deduced by identification of a poly-A signal (ATTAAA) in the genome sequence in 
agreement with transcript size on Northern blotting.  All PCR products were TA cloned 
with pCR-2.1-TOPO (Invitrogen) and sequence-verified.  Sequences have been deposited 
in GenBank, Accession numbers: AY273821 for mouse Pcsk9 and AY273822 for 
Camk1d. 
 
Development of expression constructs and adenoviruses:  Expression constructs were 
created for mouse Adam11, mouse Pcsk9 and human Pcsk9 using the primers in Table 
7.3 and amplification from either mouse liver cDNA or TA clones (above).  A mouse 
LDLR expression construct was created using the primers in Table 7.3 and IMAGE clone 
5704871/MGC:62289 (Research Genetics/Invitrogen).  The mouse Pcsk9 catalytic 
mutant, Pcsk9S402A, was made by site directed mutagenesis using the Quick Change Kit 
(Stratagene) and primers in Table 7.2.  All constructs were sequence verified.  The SRBI 
expression construct was a generous gift of David Silver (Columbia University, New 
York, NY), and the human LDLR-YFP, LDLR-GFP, LDLRA18-YFP, and LDLRA18-
GFP constructs were a generous gift of Geri Krietzer (Weill Medical College of Cornell 
University, New York, NY).  To make adenoviruses, the open reading frames for mouse 
Pcsk9, mouse Pcsk9S402A, and mouse Adam11A were transferred from pcDNA3 
expression constructs into the pAd5-CMV-NpA shuttling vector.  Recombinant 
adenoviral particles containing the ORFs under the control of a constitutive CMV 
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promoter were created by Viraquest.  These viruses are referred to as Pcsk9-Ad, 
Pcsk9S402A-Ad, and Adam11-Ad. Two control adenovirus, Ad empty and lacZ-Ad, 
were obtained from Viraquest 
 
Transfection and adenoviral mediated overexpression in cell culture:  For experiments 
using cell types other than HepG2, cells were plated at 5x104 cells/24-well; 1x105 
cells/12-well; or 2x105 cells/6-well 24 hours prior to transfection with Lipofectamine 
Plus (Invitrogen) according to the manufacturer’s directions or infection with adenovirus 
at a multiplicity of infection of 3000.  HepG2 cells were plated at 1.25x105 cells/12-well 
or 2.5x105 cells/6-well twelve hours prior to transfection with Fugene (Roche) according 
to the manufacturer’s directions or infection with adenovirus at a multiplicity of infection 
of 3000.  Most experiments were performed 36 hours after transfection or infection.  For 
experiments on the effects of Pcsk9 overexpression in HepG2 cells (western blotting, cell 
surface biotinylation, LDLR metabolic labeling studies, LDLR endocytosis assay), the 
medium was changed to DMEM containing 10% LPDS 24 hours after infection, the cells 
re-infected at the same titer and used twelve hours later.  
 
Antibodies:  For Western blotting, rabbit anti-human LDLR (Research Diagnostics) was 
used at 1:250; mouse anti-human Transferrin receptor (Zymed) at 1:500; mouse 
monoclonal to synthetic gamma-tubulin (Sigma) at 1:10,000; rabbit anti-canine calnexin 
(Stressgen) at 1:2,000; mouse anti-rat TGN38 (Affinity Bioreagents) at 1:500; mouse 
monoclonal M2 to synthetic Flag (Sigma) at 1:2000.  Antibodies to the mouse LDLR 
cytoplasmic tail (Ab #3143) were a generous gift of Joachim Herz (Southwestern 
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Medical School, Dallas, TX) and were used at 1:1,000 for Western blotting and 1:500 for 
immunoprecipitation.  Antibodies to the rat LDLR LBD repeats 4-5 were a generous gift 
of Frederic Kraemer (Stanford University Medical Center, Palo Alto, CA) and were used 
at 1:500 for immunoprecipitation. Mouse anti-human LDLR (Clone IgG-C7) bioreactor 
supernatant was prepared from ATCC hybridoma CRL-1691 by the Monoclonal 
Antibody Core Facility of the Rockefeller University and used for immunoprecipitations.  
Antibodies to mouse apoB were a generous gift of Edward Fisher (New York University, 
New York, NY) and were used at 1:200 for immunoprecipitation.  For 
immunofluorescence, anti-Flag M2 (Sigma) was used at 1:200.  Secondary antibodies for 
Western blotting, goat anti-rabbit HRP and goat anti-mouse HRP (Calbiochem), were 
used at 1:10,000.   
 
Creation of Pcsk9 and Adam11 Peptide Antibodies:  To create antibodies specific for 
Pcsk9, the mouse Pcsk9 primary amino acid sequence was analyzed with Protean 
Software (DNAStar) to identify regions with high antigenic index.  The amino acid 
sequences of two positions, amino acids 500-520 and 583-603 of the C57BL/6 mouse 
form of Pcsk9 were chosen.  These sequences and the sequence of the Adam11A and 
Adam11B specific C-terminal tail were submitted to Bethyl, where corresponding 
peptides were made and used to immunize two rabbits each.  The resulting affinity 
purified antibodies were tested extensively in cells overexpressing Pcsk9 or Adam11 by 
transient transfection or infection.  Antibodies were used at the following dilutions: anti-
Pcsk9-500, 1:5,000; anti-Pcsk9-583, 1:5,000; and anti-Adam11A, 1:10,000. 
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Western Blotting:  Proteins were isolated from cells or mouse liver by homogenization in 
Ripa buffer (50mM Tris, pH7.4, 150mM NaCl, 1mM EDTA, 0.1% SDS, 1% Triton X-
100, 1% deoxycholate) containing Complete Mini protease inhibitor cocktail (Roche).  
Crude extracts were centrifuged at 16,000xg for 10 minutes to pellet cellular debris and 
nuclei.  Media was collected from cell culture and, unless indicated, was spun at 
16,000xg for 10 minutes.  Protein concentration was measured by the BCA assay 
(Pierce), and equal amounts of protein per lane (between 10-40µg depending on 
experiment) were electrophoresed using reducing SDS-PAGE gels (unless indicated).  
Proteins were transferred to nitrocellulose membranes and Western blotting performed.  
Band intensities were measured using Image Pro Plus.   
 
Fluorescence Microscopy:  HepG2 or McA-RH7777 cells (1-2x105 cells) on poly-D-
Lysine or collagen coated coverslips, respectively, and transfected with constructs of 
interest tagged with a fluorescent protein (GFP, YFP, or CFP) 24 hours later. After 
another 24 hours, coverslips were mounted using Vectashield mounting medium with or 
without DAPI (Vector Laboratories).  For immunofluorescence, HEK293 cells (2.5x104) 
were plated on mini-well microscope slides and transfected with Adam11-Flag 24 hours 
later.  After another 24 hours, slides were incubated in PBST plus 3% normal rabbit 
serum and 1:50 dilution of anti-Flag M2 antibody for one hour.  After three washes, 
slides were incubated in PBST and 1:200 dilution of rabbit anti-mouse Alexa Fluor-488 
(Molecular Probes) for 30 minutes.  Slides were washed and mounted using Vectashield 
mounting medium with DAPI.  For colocalization studies, cells were treated with a 
1:1000 dilution of BODIPY-TR-C5-ceramide or ER-Tracker-Red (Molecular Probes) and 
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mounted on slides using 30% glycerol.  For DiI-LDL binding studies, cells were treated 
as below and mounted on slides with Vectashield.  Cells were visualized using confocal 
microscopy with the help of Alison North of the Bio-Imaging Resource Center of the 
Rockefeller University or by epifluorescence microscopy.  Between 50 and 100 cells 
were examined for each experiment and images shown are representative of the results.   
 
Subcellular Fractionation:  Subcellular fractionation was performed exactly as 
described (Gusarova et al., 2003).  Briefly, HepG2 cells (~1x106) were homogenized by 
passing 10 times each through a 25-gauge and 30-gauge needle and layered on top of a 
seven-step sucrose gradient.  The collected fractions were analyzed using a refractometer 
to ensure that a density gradient had been achieved.  The fractions were then analyzed for 
the ER marker calnexin and the TGN marker TGN38 by Western blotting as below.  
Golgi fractions were identified using an assay of α-mannosidase activity.  For this assay, 
4µl of each fraction was added to 72µl of Reagent II (1.25X PBS, 0.125% TritonX-100, 
1.25mM 4-methylumbelliferyl α-D-mannopyranoside, pH7.4) and 14µl of Reagent III 
(0.25M sucrose, 10mM Hepes pH7.4, 0.5mM DTT, protease inhibitors) and incubated at 
37ºC for 30 minutes.  Stop reagent (180µl of 0.5M glycine, 0.5M NaCO3) was added and 
fluorescence read at excitation 355, emission 460 using a fluorescent microplate reader.  
Fractions were then analyzed for Pcsk9 by western blotting and LDLR by 
immunoprecipitation followed by western blotting.  4-methylumbelliferyl α-D-
mannopyranoside was from Sigma. 
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DiI-LDL and DiI-HDL Binding and Uptake Studies:  Protocols were adapted from 
those of the George Rothblat laboratory and published methods (Goldstein et al., 1983).  
Cells were washed two times in ice-cold PBS and then treated with 10µg/ml DiI-LDL 
without or with 200µg/ml unlabelled LDL in medium containing 10% lipoprotein 
deficient serum for 1-2 hours at 4°C for binding or various times at 37ºC for uptake.  
Cells were incubated with 10µg/ml DiI-HDL in medium containing 10% lipoprotein 
deficient serum for 2 hours at 37ºC for uptake.  Cells were then washed three times in 
rapid succession in TBS + 2mg/ml BSA, one time in TBS+BSA for 2 min, and finally 
two times in TBS.  For fluorescence, cells were visualized as described above.  For 
microplate assays, cell lysates from triplicate wells were made in Ripa buffer and cell 
associated fluorescence was measured in a microplate reader; the fluorescence measured 
from untreated cells was subtracted from all measurements of treated cells.  DiI-LDL or 
DiI-HDL background subtracted fluorescence was then corrected for cellular protein or 
fluorescence from Hoechst DNA staining.  Specific binding or uptake was calculated by 
subtracting the average normalized DiI-LDL fluorescence in the presence of excess 
unlabelled LDL from the average fluorescence in its absence.  Human LDL labeled with 
1,1'-dioctadecyl-3,3,3',3'-tetramethyl-indocarbocyanine perchlorate (DiI-LDL) was from 
Biomedical Technologies.  Unlabelled human LDL was obtained from Calbiochem and 
Hoechst-33342 DNA stain was from Molecular Probes.   
 
Metabolic labeling and LDLR immunoprecipitations:  For metabolic labeling, cells 
were starved in DMEM without L-methionine and L-cysteine (DMEM*), pulse labeled 
with DMEM* containing 200µCi/well of EXPRE 35S Protein Labeling Mix (NEN Life 
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Sciences), and chased with DMEM* containing 1.5mg/ml L-methionine and 0.5mg/ml L-
cysteine.  Two to three wells per condition were assayed.  LDLR immunoprecipitations 
with IgG-C7 were performed as described (Tolleshaug et al., 1982).  Specifically, 
preformed LDLR immune complexes were made by incubating 6µg/well of IgG-C7 with 
96µg/well of goat anti-mouse IgG in Buffer E (50mM Tris-HCl pH8, 200mM NaCl, 
1mM EDTA, 0.5% Igepal) for 30 minutes at room temperature and then 36 hours at 4°C.  
The supernatant above the complexes was removed and the complexes washed in Buffer 
E two times before resuspension in 100µl/well of Buffer E.  LDLR immunoprecipitations 
with other antibodies were performed using antibody complexed with 0.5% protein A-
sepharose in NET buffer (150mM NaCl, 5mM EDTA, 50mM Tris pH7.5, 1% Triton X-
100, 0.1% SDS, protease inhibitor cocktail).  At the end of the metabolic study, cells 
were washed with PBS and lysed in LDLR Lysis Buffer (10mM HEPES pH7.4, 200mM 
NaCl, 2mM CaCl2, 2.5mM MgCl2, 1% Triton X-100 with protease inhibitor cocktail).  
Cell lysates were spun at 16,000xg at 4ºC for 30 minutes.  The supernatant was combined 
with the preformed LDLR immune complexes above and rocked for one hour at 4ºC.  
The immunoprecipitations were then layered on top of a five-step sucrose gradient as 
described (Tolleshaug et al., 1982).  Gradients were centrifuged at 30,000xg at 4ºC for 30 
minutes in a SW55Ti Beckman rotor in an ultracentrifuge.  The pellet was washed in 
LDLR Lysis Buffer and finally resuspended in loading buffer (8M urea, 200mM DTT, 
10% glycerol, 5% 2-mercaptoethanol, 2.35% SDS, and 75mM Tris-HCl pH6.8).  
Samples were electrophoresed in 4-12% Tris-glycine gels after normalization to 
trichloroacetic acid insoluble counts.  Gels were fixed in 25% methanol-10% acetic acid, 
washed in distilled water, treated with Autofluor (National Diagnostics), dried and 
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exposed to film or a phosphoimager screen.  Band intensities were measured using 
ImagePro or ImageQuant software, respectively.  Goat anti-mouse IgG and Protein A 
Sepharose CL-4B were from Pierce or Jackson Immunochemicals and Amersham 
Biosciences, respectively. 
 
Metabolic studies with inhibitors:  HepG2 cells were infected, starved and pulsed as 
above.  Cells were then chased in the presence of inhibitors at the following 
concentrations:  ALLN (100µM), ammonium chloride (10mM), chloroquine (75µM), 
E64d (10µM), lactacystin (10µM), MG132 (20µM), Pefabloc (0.1mg/ml) pepstatin 
(50µg/ml), phosphoramidon (100µM), brefeldin A (5µg/ml), nocodazole (20µg/ml), and 
monensin (0.5µM).  Two to three wells per condition were assayed.  To show that the 
inhibitors were active, lysates from the experiments were mixed at 1:50 dilution in assay 
buffer (2.5mM HEPES pH7.5, 0.5mM EDTA, 0.05% Igepal, 0.001% SDS) with or 
without 50µM substrate.  The substrate Suc-LLVY-AMC was used to assay proteasome 
activity, and the substrate Z-RR-AMC was used to assay cysteine protease activity.  The 
reactions were incubated at 37ºC for one hour and then fluorescence due to the cleavage 
of the substrate was read in a microplate reader.  MG132, lactacystin, ALLN, Suc-
LLVY-AMC, and Z-RR-AMC were from Calbiochem.  Ammonium chloride, 
chloroquine, E64d, brefeldin A and nocodazole were from Sigma.  Pefabloc, pepstatin, 
and phosphoramidon were from Roche. 
 
Cell surface biotinylation and endocytosis assay:  For studies of cell surface protein 
levels, cells in duplicate wells per condition were incubated in PBS containing 0.5mg/ml 
 218
EZ-Link Sulfo-NHS-LC-Biotin (Pierce) at 4°C for one hour.  The reaction was quenched 
in 100mM glycine in PBS and the cells washed five times in ice cold Tris-buffered saline.  
Cells were lysed in LDLR Lysis Buffer (above) and immunoprecipitated for the LDLR.  
For endocytosis assays, cells were treated with monensin (20µM) for various times 
before undergoing cell surface biotinylation as described (Michaely et al., 2004). Cell 
lysates were electrophoresed and biotinylated proteins visualized with avidin-HRP 
(Pierce).   
 
apoB secretion analysis:  Analysis of apoB secretion was performed in collaboration 
with Meihui Pan and Edward Fisher (New York University, New York, NY).  Cells in 
triplicate wells per condition were metabolically labeled as for LDLR analysis above, cell 
lysates collected in cell lysis buffer (Pan et al., 2004), and media collected.  Lysates and 
media were immunoprecipitated for apoB using protein A complexes as described above.  
Samples were electrophoresed in 4% Tris-glycine gels after normalization to 
trichloroacetic acid insoluble counts, and gels processed as above. 
 
siRNA experiments:  siRNAs were obtained from Dharmacon and the sequences are as 
in Table 7.4.  For controls, the siControl nonspecific siRNA was obtained from 
Dharmacon and the apoM and GFP siRNAs were a generous gift of Markus Stoffel 
(Rockefeller University, New York, NY).  HepG2 cells were plated at a density of 
1.5x105 cells in 6-well dishes and McA-RH7777 and Hepa1-6 cells were plated at a 
density of 5x104 cells in 12-well dishes 24 hours prior to transfection.  Two to three wells 
per siRNA were assayed.  HepG2 cells were transfected with 200pmol of siRNA and 9µl 
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of Oligofectamine (Invitrogen); McA-RH7777 and Hepa1-6 cells were transfected with 
100pmol of siRNA and 4.5µl of Oligofectamine and assayed 24-36 hours later.  
 
Analysis of cholesterol efflux:  Cholesterol efflux studies were performed in 
collaboration with Denise Drazul-Schrader and George Rothblat (Children’s Hospital of 
Philadelphia, Philadelphia, PA).  Cells were incubated in 3H-cholesterol overnight, 
0.2%BSA was added for 2 hours, and an aliquot of cells was isolated for a time zero 
count.  Cholesterol acceptors were added for various lengths of time, the media removed, 
filtered, and counted.  The percent release of lipid was calculated as (cpm in medium per 
cpm time zero) x100. 
 
Analysis of LXR activity and cellular cholesterol content:  LXR reporter activity was 
measured by co-transfecting cells with the construct of interest, a LXRE-luciferase 
construct and a β-galactosidase construct for normalization, exactly as described (Soccio 
et al., 2005).  Cholesterol content was measured by Denise Drazul-Schrader and George 
Rothblat using gas chromatography.   
 
Data analysis and statistics:  For all quantitative experiments except the microarray 
study, data was analyzed in Microsoft Excel, and the two-tailed type 2 Student’s t-test 
was used to compare control and experimental groups.  Changes were considered 
significant above a p value of 0.05.  Data was graphed in GraphPad Prism. 
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Table 7.1. Sequences of primers and probes used for Q-PCR 
 
Housekeeping Genes 
Cyclophilin A, X52803 
For GGCCGATGACGAGCCC   
Rev TGTCTTTGGAACTTTGTCTGCAA 
probe TGGGCCGCGTCTCCTTCGA 
  
Cyclophilin B, *human*, NM_000942 
For GGAGATGGCACAGGAGGAAA 
Rev CCCGTAGTGCTTCAGTTTGAAGT 
probe AGCATCTACGGTGAGCGCTTCCCC 
  
Hprt, AH003453 
For GCAAACTTTGCTTTCCCTGG 
Rev TTCGAGAGGTCCTTTTCACCA 
probe ACAGCCCCAAAATGGTTAAGGTTGCAA 
  
SREBP and LXR target genes 
Acac , BI250197 
For CAGTCTACATCCGCTTGGCTG 
Rev CAGCTCCTTCCGCTCAGTG 
probe CGATTGGGCACCCCAGAGCTAAGC 
  
Acly, BC005533 
For CACCCCGCTGCTCGACT  
Rev TCAGGATAAGATTTGGCTTCTTGG 
probe TGCCCTGGAAGTGGAGAAGATTACCACC 
  
Hmgcs, AA673053 
For CTCTGTCTATGGTTCCCTGGCT  
Rev TCCAATCCTCTTCCCTGCC 
probe TGTCCTGGCACAGTACTCACCTCAGCA 
  
Hmgcr, M62766 
For GGGAGCATAGGCGGCT  
Rev TGCGATGTAGATAGCAGTGACA 
probe CAACGCCCACGCAGCAACA 
  
LDLR, X64414 
For GGATGGCTATACCTACCCCTCA  
Rev CGGCTCTCCCGGCTG 
probe TCAGCCTGGAGGACGATGTGGCA 
  
LDLR, *human*, NM_000527 
For GGCAGTGTGACCGGGAATAT 
Rev GTTGGGTCCCTCGCAGAGT 
probe ACATGAGCGATGAAGTTGGCTGCGTTAAT 
  
Sqle, D42048 
For GGAAGAGCCTCATCTCCAGTAAAG 
Rev TGTGGTGCATCCTTCATAAGGA 
probe CTCCGTTTCTTCCCACTTCGTTGGC 
  
Abcg5, NM_031884 
For TGGGATGTTCGGCAAGCT 
Rev CGCATAATCACTGCCTGCTTATT 
probe TGTCCTGCTGAGGCGAGTAACAAGAAACTTAA 
 
 
 
 
 
Novel cholesterol regulated genes 
Adam11, NM_009613 
For TCAAGCCAGTGTCCCCCTAA 
Rev TACAGCGGCCTCCATAGCA 
probe AAGCTGGACGGTTACTACTGTGATCATGAGCA 
  
Api6, NM_009690 
For TTTTGACTGCTCACATGAAGAAGAT 
Rev CGCACATCCTCTGGAATGAA 
Probe ACAGTGTGAGAACCCAGACAGTGACCTCCT 
  
Camk1d, AY273822 
For AATGGAGACAAGCGTTTAAC 
Rev GGCTGCTGCCAAGCTGG 
probe ACGGCAGTCGTGAGACATATGCGGAG 
  
Fabp5, AJ223066 
For CGACAGCTGATGGCAGAAAA 
Rev CCCATTGCTGGTGCTGG 
Probe TGCACCTTCCAAGACGGTGCCCT 
  
Fbxo3, NM_020593 
For TCGCTGTTCATACCGGATCC 
Rev TGCCATACTTCCCAGCAACC 
probe CAACGGGCAAAAGTTAGTGGTGCCG 
  
Laptm5, NM_010686 
For CCTGTCCCTTCAAATCATGGA 
Rev AGTACGCTGGCAATTCGATGT 
probe TGCCTGCTCACACTGCTGGGCT 
  
Pcsk9, AY273821 
For TTGCAGCAGCTGGGAACTT 
Rev CCGACTGTGATGACCTCTGGA 
probe ACGACGCCTGCCTCTACTCCCCAG 
  
Pcsk9, *human*, NM_174936 
For GGTACCGGGCGGATGAATA 
Rev TTTCCCGGTGGTCACTCTGTA 
probe AGCCCCCCGACGGAGGCA 
  
Rgs16, U94828 
For CCGATCAGCCACCAAACTG 
Rev GCTTCGCTGCGGATGTACTC 
probe CGTCCAGGGCTCACCACATCTTTGA 
  
Saa3, NM_011315 
For GAAGCCTTCCATTGCCATCA 
Rev TCATGAACTGGACCCATCTTTG 
probe TCTTTGCATCTTGATCCTGGGAGTTGACA 
  
StarD4, BY677271 
For TGCCGTGGTTTGCGG 
Rev AGGCAGGAACATGGCTTCTCTA 
probe CTCTGCTCCTACCCTGTCAGCTCCATGA 
  
Uxt , NM_013840 
For TGCTGCGGTACGAGACCTTT 
Rev TCGATGATCCAGCACCTTTTG 
probe TCAGTGACGTACTGCAGCGAGACTT 
All primers and probes are to mouse genes unless indicated.  Gene names and Genbank accession numbers are indicated.   
All probes are labeled at the 5’end with 6’FAM (6-carboxyfluorescein) and at the 3’end with TAMRA (N,N,N',N'-
tetramethyl-6-carboxyrhodamine). 
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Table 7.2. Primers used for Northern probes, cloning, 5’RACE, and 3’RACE 
Primers for Northern probes  5’RACE Primers 
Adam11, NM_009613, ORF   Adam11, NM_009613 
For CTGAACGTGGAGGGGACAGAGCGTGG  Outer TGAGTCGAAGGCCGGGATGACGA 
Rev GCGGCCCCTCCGGACCTTCC  Inner CCAACTGTGGCTTTCGGACCTCT 
     
Adam11A, novel, A specific 3’utr   Camk1d, AY273822 
For GACCCGACCCAGCAGGGGGCAGTGT  Outer CTCCTCGTCTTGACTGTAGTATAA 
Rev TGAGGCTGGGCTCTGAGGGTGAGCC  Inner CCATTCTGTGGAGATAGTATACG 
     
Camk1d, AY273822  Pcsk9, AY273821 
For ATCACCTCTACCTGGTCATGCAACTTGTG  Outer CAACAGGTCACTGCTCATCTTCAC 
Rev TCACTTGCTTCCAGTGTGCCCTGTTGT  Inner CAATCTGTAGCCTCTGGGTCTCCT 
     
Fabp5, AJ223066  Pcsk9, *human*, NM_174936 
For ATGGCCAGCCTTAAGGATCT   Outer AGAGGAGTCCTCCTCGATGTAGTC 
Rev TCATTGCACCTTCTCATAGACCCG  Inner GACATGCAGGATCTTGGTGAGGTA 
     
Pcsk9, AY273821, ORF   Primers for Cloning full length ORF 
For GCCGGTGGGTATAGCCGCATCCTCA  Adam11A, novel 
Rev CTCAATCCAATCACCACGACGCCTCC  For ATGAGGCGGCTGCGGCGCTGG 
   Rev TCACACTGCCCCCTGCTGGGTC 
Pcsk9, novel, 3’utr     
For CTCAGTTCTCAGGCCTTAGGGTGTATTTG  Adam11B, NM_009613 
Rev CTGATCTGTGGGACTGGGGCTAAGG  For ATGAGGCGGCTGCGGCGCTGG 
   Rev TTAGGCCCCTCCGGACCTTCC 
Sqle, D42048    
For GCGGGGATGTCACCCTGGCCAACAA  Camk1d, AY273822 
Rev CATCCGCAACAACGGTGAGCGGGGCGT  For GGGCTAATTATGCAGGTTTTCAGG 
   Rev ATGCAGGGTGGGTGGGGTTTCT 
Mutagenesis Primers    
Pcsk9S402A mutant  Pcsk9, AY273821 
For TCACAGAGTGGGACCGCACAGGCTGCTGCCC  For ATGTCCTTCCCGAGGCCGCGCG 
Rev GGGCAGCAGCCTGTGCGGTCCCACTCTGTGA  Rev TCACTGAACCCAGGAGGCCTTT 
 
 
   
3’RACE Primers  Pcsk9, human, novel 
Adam11, novel  For ATGGGCACCGTCAGCTCCAGG 
Outer ACCTGCCCTGGAAGTGGAGAGC  Rev TCACTGGAGCTCCTGGGAGGC 
Inner GTCCCAGCGGTACCAACATCA    
Primers are for the mouse gene unless indicated.  Primers in 5’Æ 3’ direction. 
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Table 7.3.  Primers used to make expression constructs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primers are for the mouse gene unless indicated.  Primers in 5’Æ 3’ direction. 
 
 
 
 
 
Table 7.4.  Sequences of siRNAs 
Gene Name Sequence Position in hPcsk9 (NM_174936)* 
mouse, rat, human  Pcsk9 mhPs-1 5’UCAUAGGCCUGGAGUUUAU 1085-1102 
mouse, rat, human  Pcsk9 mhPs-3 5’GCCAUCUGCUGCCGGAGCC 2317-2335 
human Pcsk9 hPs-3 5’UCCUAGACACCAGCAUACA 842-860 
human Pcsk9 hPs-5 5’GGAGGACUCCUCUGUCUUU 723-741 
*The Pcsk9 ORF is from 292-2370 in NM_174936.  All siRNAs were preceded by AA at the 5’end. 
 
Adam11A-EGFP 
For XhoI ATCGCTCGAGATGAGGCGGCTGCGGCGCTGG 
Rev EcoRI ATCGGAATTCCCACTGCCCCCTGCTGGGTCGG 
   
Adam11A-Flag 
For EcoRI ATCGGAATTCATGAGGCGGCTGCGGCGCTGG 
Rev XhoI ATCGCTCGAGCACTGCCCCCTGCTGGGTCGGGT 
   
Pcsk9-EGFP 
For EcoRI ATCGGAATTCATGTCCTTCCCGAGGCCGCGCG 
Rev BamHI ATCGGGATCCGCCTGAACCCAGGAGGCCTTTG 
   
Pcsk9-Flag 
For HindIII ATCGAAGCTTATGTCCTTCCCGAGGCCGCGCG 
Rev XhoI ATCGCTCGAGCTGAACCCAGGAGGCCTTTGCT 
   
Pcsk9-pcDNA3 
For HindIII ATCGAAGCTTGTCATGTCCTTCCCGAGGCCGCGCG 
Rev XhoI ATCGCTCGAGTCACTGAACCCAGGAGGCCTTT 
   
Pcsk9-Flag, human 
For HindIII ATCGAAGCTTATGGGCACCGTCAGCTCCAGG 
Rev XhoI ATCGCTCGAGCTGGAGCTCCTGGGAGGCCTG 
   
Pcsk9-pcDNA3, human 
For HindIII ATCGAAGCTTGTCATGGGCACCGTCAGCTCCAGG 
Rev XhoI ATCGCTCGAGTCACTGGAGCTCCTGGGAGGC 
   
LDLR-pcDNA3 
For HindIII ATCGAAGCTTATGAGCACCGCGGATCTG 
Rev XhoI ATCGCTCGAGTCATGCCACATCGTCCTC 
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